












PREPARATION AND CHARACTERIZATION OF 







Doctoral Program in Nanomedicine and Pharmaceutical Innovation 
International Doctoral School 
 
 

















TESIS DE DOCTORADO 
 
PREPARACIÓN Y CARACTERIZACIÓN DE 
NANOPARTÍCULAS DE QUITOSANO CARGADAS 






Programa de Doctorado en Nanomedicina e Innovación Farmacéutica 
Escuela de Doctorado Internacional 
 
 














AUTHORIZATION OF THE THESIS SUPERVISORS 
 
Prof. Noemi Csaba, Professor at the Department of Pharmacology, Pharmacy and 
Pharmaceutical Technology in the University of Santiago de Compostela, Spain 
Dr. Cyrille Grandjean, Chargé de Recherche at CNRS – Unité Fonctionnalité et Ingénierie des 
Protéines (UFIP), UMR 6286, Université de Nantes, France / Assistant Researcher at French 
National Centre for Scientific Research (CNRS), UFIP, UMR 6286, University of Nantes, France 
 
REPORT: 
That the experimental dissertation entitled: “Preparation and characterization of antigen 
loaded chitosan nanoparticles for immunization” presented by Maruthi Prasanna was 
conducted under their supervision at the Department of Pharmacology, Pharmacy and 
Pharmaceutical Technology at the University of Santiago de Compostela and at the Faculty of 
Sciences and Techniques, Unit of Functionality and Proteins Engineering, UMR CNRS 6286 at 
the University of Nantes, France. Being completed, they authorize its presentation, evaluation 
by the assigned jury members, considering that it meets the requirements demanded in 
article 34 of the Regulation of Doctoral Studies of the USC, and that as supervisors of this 
thesis they do not incur in the abstention causes established by the law 40/2015.  
And for the record, they issue and sign the present certificate in Santiago de Compostela and 


















AUTORIZACIÓN DEL DIRECTOR/ TUTOR DE LA TESIS 
 
Prof. Noemí Csaba, profesora del Departamento de Farmacología, Farmacia y Tecnología 
Farmacéutica de la Universidad de Santiago de Compostela, España 
Dr. Cyrille Grandjean, Chargé de Recherche en CNRS / Investigador en el Centro Nacional 
Francés de Investigación Científica (CNRS), UFIP, UMR 6286, Universidad de Nantes, Francia 
 
INFORMA: 
Que la disertación experimental titulada: "Preparación y caracterización de nanopartículas 
de quitosano cargadas de antígeno para inmunización" presentada por Maruthi Prasanna 
se realizó bajo su supervisión en el Departamento de Farmacología, Farmacia y Tecnología 
Farmacéutica de la Universidad de Santiago de Compostela y en la Facultad de Ciencias y 
Técnicas, Unidad de Funcionalidad e Ingeniería de Proteínas, UMR CNRS 6286 en la 
Universidad de Nantes, Francia. Una vez completado, autorizan su presentación, evaluación 
por parte de los miembros del jurado asignados, considerando que cumple con los requisitos 
exigidos en el artículo 34 del Reglamento de Estudios Doctorales de la USC, y que como 
supervisores de esta tesis no incurren en las causas de abstención establecido por la ley 
40/2015. 
Y para que conste, emiten y firman el presente certificado en Santiago de Compostela y 

















        
 
PhD CANDIDATE STATEMENT 




Mr. Maruthi Prasanna 
 
I submit my Doctoral thesis, following the procedure according to the Regulation, stating 
that: 
1) This thesis gathers the results corresponding to my work. 
2) When necessary, explicit mention is given to the collaborations the work may have had. 
3) The present document is the final version submitted for its defense and coincide with the 
document sent in electronic format. 
4) I confirm that this thesis does not incur in any plagiarism of any other authors or documents 
submitted by me for obtaining other degrees. 
 
 















        
 
DECLARACIÓN DEL AUTOR DE LA TESIS 
Preparación y caracterización de nanopartículas de quitosano cargadas de antígeno para 
inmunización 
 
Mr. Maruthi Prasanna 
 
Presento mi tesis, siguiendo el procedimiento adecuado al Reglamento, y declaro que: 
1) La tesis abarca los resultados de la elaboración de mi trabajo. 
2) En su caso, en la tesis se hace referencia a las colaboraciones que tuvo este trabajo. 
3) La tesis es la versión definitiva presentada para su defensa y coincide con la version enviada 
en formato electrónico. 
4) Confirmo que la tesis no incurre en ningún tipo de plagio de otros autores ni de trabajos 
presentados por mí para la obtención de otros títulos. 
 
 














CONFLICT OF INTEREST 
 























































 ‘Let noble thoughts come to us from all sides’ 














My deepest gratitude goes to my supervisors; Dr. Noemi Csaba, Dr. Cyrille Grandjean and Dr. 
Emilie Camberlein. Noemi’s patient guidance, encouragement and advice has been beyond 
enough to see me through this amazing but challenging journey. The great efforts you put at 
improving this manuscript humbles me and I will forever be grateful. 
Cyrille was more than a supervisor and he provided me almost everything I need for scientific 
research by guiding me how to efficiently address many issues logically. I do not have words 
to express my gratitude towards him. 
To my co-supervisor Dr. Emilie Camberlein, thanks for providing technical expertise and 
valuable suggestions. I have been extremely fortunate as a researcher to learn the work of 
bacterial cultures and protein expression from you. 
I would like to extend my special thanks to Dr. Marcos Garcia. I am deeply indebted to him 
for assistance, guidance, and constructive advices he provided during the meetings. 
I would like to thank Prof. Maria Jose for constantly inspiring us with her energy and the talks. 
The suggestions you gave during the seminars and the congress are always valuable.  
I would like to show my greatest gratitude towards Dr. Ruben Varela for introducing me to 
the science of immunology and Cristina Calvino for initially helping me with the dendritic cell 
experiments. 
I would like to thank our collaborators from Lille: Dr. Francois Trottein and Daphnee Soulard 
for their help in animal experimentation. 
I would like to express my thanks to all the members of the Nanoscopy for Nanomedicine lab, 
especially to the Dr. Lorenzo Albertazzi and Dr. Silvia Pujals for kindly hosting me in their 
laboratory in Barcelona, Spain. I also thank Maria Arista Romero for helping me with my 
experiments during my stay. 
I would like to thank members of follow-up thesis committee Prof. Jeremy Brown and Dr. 





I would like to thank Sindhu for helping me with the statistical analysis and proofreading of 
the thesis. Thanks, Sandra for helping me with the Spanish translations. Thanks, Tamara for 
helping me with the documents required for the thesis. 
To my beloved Nanochachos: José, Tamara, Sakthi, Shubaash, Sara, German, Edi, Mireya, 
Sergio, Ana, Irene, Belén, Cecilia, Catarina, Fernando, Lena, Mati, Sofia, Carmen, Lungile, 
Nataliya, Niu, Howl, Sonia, Surasa, Andrea, Vanessa, Bhanu, Iago, Franchesco and Desi. To my 
Hermanos, Carla and Diego, whom I always annoy. Thanks, Diego for helping me with the 
experiments whenever needed. My labmates Sandra, Sheila, Chema, Hector, Saeedeh, Paul 
and Howl were a wonderful company. You guys were incredible. I can never forget the coffee 
breaks, lab dinners, the movies we watched and the sports we played together.  Altogether, 
you guys made my stay at lab a total bliss. Thanks Howl and Lu, you guys received me on the 
first day and help me get familiar with the university. Thank you, Belen and Sonia for being 
very nice to me. Thanks, Sofia and Carla for your wonderful company. Thank you, Belen, Rafa 
and Balbi for providing the technical support during this journey of PhD. Puri helped me in 
solving the issues related to the administration and university registration process, thanks a 
lot.  
I would like to thank the other members of CiMUS: Sulay, Anxo, Vanessa and Lucia. They 
helped me and provided me the guidance to work with the common facilities at CiMUS. 
Thankyou Carmen for helping me with the necessary documentation from the CiMUS. 
Furthermore, I would like to mention people from research teams at the University of Nantes: 
Johann, Amelie, Annie, Fabienne, Charles and Fabrice. Also, I would like to thank my other 
friends from UFIP Iyanar, Mahesh, Aline, Lidiya, Typhaine, Christophe, Yuonnick, Benoit and 
Ennis for your wonderful company. The Friday evening movie time, the food parties, the chess 
games and the coffee breaks are the best moments that I had there. Thank you all for those 
memories. 
I sincerely acknowledge the Erasmus mundus, European doctorate in nanomedicine and 
pharmaceutical innovation (NanoFar) Fellowship for the financial assistance during my PhD. I 
would like to thank Prof. Frank Boury, Marion and related NanoFar members for their 





Special thanks to Jose for his wonderful company to play badminton and table tennis. You 
thought me first Spanish song “no es mi culpa” and the memories of the time we spent at 
your farm will always remain special. 
I would like to thank my Indian friends at Santiago: Bhanu, Sunil, Shubaash and Sakthi. For the 
amazing company and lot of fun that we had together. The evening chats and the food 
exchange parties with them relieved my home sick. The after-work hours we spent cooking, 
playing sports and watching movies will always be remembered. 
I would like to thank my friends Sindhu, Vijay and Narendra for always being there for me. 
Thank you very much Sindhu for the unconditional support and encouragement. Thank you, 
Vijay for constantly boosting my confidence. 
It would not be complete without mentioning my parents and my brother. I cannot forget the 
hardship that my parents took to make me what I am today, specially my mom. My greatest 
strength, my brother, always acted as a backbone and supported me in every decision I took. 
My gratitude towards my uncles and sisters who helped me during my education, I would not 













Table of Contents 
 
 
Abstract/Resumen  ……………………………………………………………………………………………………..  25 
Resumen in extenso  ……………………………………………………………………………………………….….  31 
Introduction: Approaches for design and delivery of subunit pneumococcal vaccines  ….  57 
Background, Hypothesis and Objectives  ……………………………………………………………..….…  99 
Chapter 1: Semisynthetic glycoconjugate based on dual role protein/PsaA as a 
pneumococcal vaccine  ………………………………………………………………………………….…………..  107 
Chapter 2: Chitosan nanoparticles as carriers for the delivery of semisynthetic 
glycoconjugate antigen  …..……………………………………..…………………………………….…………… 143 
Chapter 3: Interaction of glycoconjugate loaded chitosan nanoparticles with human 
dendritic cells  ……………………………………………………………………………………………………………  175 
Overall discussion  ………………………………………………………………………………………….…………  209 
Conclusions  ……………………………………………………………………………………………………….…….  219 
Annex: Super-resolution imaging of nanoparticle uptake by dendritic cells  ………..………  223 
List of Abbreviations  …………………………………………………………………………………..……………  236 



































Existing pneumococcal vaccines are based on capsular polysaccharides from selected 
serotypes and provide no complete protection against pneumonia, and the major concern is 
serotype replacement. Current preventive strategies involve the development of vaccines 
based on common pneumococcal proteins. When used independently or as a carrier in 
glycoconjugate vaccines, protein antigens could induce serotype independent protection. 
While pneumococcal protein-based glycoconjugates have demonstrated their 
immunogenicity and ability to activate humoral immune response, their combination with 
nanotechnological approaches can improve protein stability, provide adjuvancy and enhance 
immune response. In this line, we investigated glycoconjugate-loaded nanoparticles as next-
generation pneumococcal vaccines. 
In this study, we have developed a semisynthetic glycoconjugate (GC) by covalently linking 
the pneumococcal surface adhesin A (PsaA) with a synthetic mimic of the capsular 
polysaccharide from Streptococcus pneumoniae serotype 14 (Pn14TS). The required PsaA was 
obtained from rDNA technology and Pn14TS was chemically synthesized. The prepared GC 
had high yield, high purity and long-term storage stability after freeze drying. Further 
characterization was performed by circular dichroism, which showed that the protein 
maintained its secondary structural confirmation throughout the conjugation process. 
Preliminary immunization studies in mice have shown that the GC was able to induce IgG 
antibodies against both of its protein and tetrasaccharide components. 
Next, we explored chitosan nanoparticles (CNPs) as carriers for the GC. The GC-CNPs were 
prepared using a simple ionic gelation method, resulting in nanoparticles with 150 nm size 
and zeta potential of 30 mV. The GC-CNPs showed 70% encapsulation efficiency, colloidal 
stability in simulated nasal mucosal fluid for 24h and were able to control the antigen release 
more than 24h. In addition, the GC-CNPs could be freeze dried and reconstituted without 
altering their properties. These nanoparticles displayed low levels of toxicity and were 
successfully internalized by dendritic cells. In addition, they were able to induce the 
upregulation of co-stimulatory markers and T cell activation. 
Finally, the immunization studies in the mice reveal that, on S.C immunization the GC-CNPs 
displayed a 100-fold and 10-fold higher anti-PsaA IgG and anti-CP (capsular polysaccharide) 
IgG response respectively over the mice immunized with GC. In summary, the study 












Las vacunas actuales frente el neumococo están constituidas por polisacárido capsular de 
serotipos específicos, lo que no ofrece una protección completa contra la neumonía, siendo 
el problema principal la falta de cobertura serotípica. Las estrategias profilácticas actuales 
comprenden el desarrollo de vacunas basadas en proteínas neumocócicas comunes. Estos 
antígenos proteicos, empleados tanto de manera independiente o como vehículo en vacunas 
glicoconjugadas podrían dar lugar a una protección independiente del serotipo. Aunque los 
glicoconjugados constituidos por proteínas neumocócicas han demostrado ser 
inmunogénicos y capaces de iniciar una respuesta inmune humoral, su uso dentro de una 
perspectiva nanotecnológica puede contribuir a mejorar la estabilidad proteica, proporcionar 
adyuvancia e incrementar su respuesta inmune. En esta línea, hemos investigado el desarrollo 
de nanopartículas glicoconjugadas como la siguiente generación de vacunas neumocócicas. 
En este estudio, se desarrolló un glicoconjugado semisintético (GC) uniendo covalentemente 
la adhesina A de la superficie del neumococo (PsaA) con un imitador sintético del polisacárido 
capsular del serotipo 14 del Streptococcus pneumoniae (Pn14TS). El PsaA se obtuvo a través 
de la tecnología de ADN recombinante y el Pn14TS fue sintetizado químicamente. El GC 
resultante presentó un alto rendimiento, alta pureza y buena estabilidad durante su 
almacenamiento a largo plazo tras un proceso de liofilización. Su caracterización adicional 
mediante técnicas de dicroísmo circular demostró que la proteína mantuvo la conformación 
de su estructura secundaria durante todo el proceso de conjugación. Los estudios 
preliminares de inmunización en ratones demostraron que el GC fue capaz de inducir 
anticuerpos IgG contra sus componentes tanto proteicos como tetrasacáridos. 
Posteriormente, estudiamos el uso de las nanopartículas de quitosano (CNP) como sistemas 
transportadores del GC. Estas GC-CNP se prepararon mediante un método de gelificación 
iónica simple, dando como resultado nanopartículas de 150 nm de tamaño y con un potencial 
zeta de 30 mV. Las GC-CNP presentaron una eficiencia de encapsulación del 70%, estabilidad 
coloidal en fluido simulado de mucosa nasal durante 24h y fueron capaces de controlar la 
liberación de antígeno durante más de 24h. Además, las GC-CNP pudieron liofilizarse y 
reconstituirse sin que conllevara un cambio en sus propiedades. Las nanopartículas 
mostraron bajos niveles de toxicidad y una internalización exitosa por las células dendríticas. 
Además, las nanopartículas fueron capaces de inducir una regulación positiva de marcadores 
coestimuladores y la activación de células T. 
Finalmente, estudios de inmunización en ratones revelaron que, tras su inmunización 
subcutánea, las GC-CNP mostraron una respuesta 100 y 10 veces mayor de niveles de IgG 
anti-PsaA y anti-CP (polisacárido capsular), respectivamente, en comparación los ratones 
inmunizados con GC. En resumen, el estudio demuestra que las nanopartículas de quitosano 
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Resumen en español 
Introducción 
La neumonía constituye la causa principal de muerte entre las enfermedades infecciosas, 
siendo el Streptococcus pneumoniae responsable de la mayoría de las neumonías adquiridas. 
Este patógeno es, además, causante de meningitis bacteriana, sepsis y otitis media, causas de 
morbilidad y mortalidad tanto en niños como en adultos. El Instituto de Medición y Evaluación 
de la Salud (IHME) estima que las infecciones debidas a S. pneumoniae son responsables de 
1,2 millones de muertes al año [1,2]. Se han identificado alrededor de 96 serotipos distintos 
de S. pneumoniae a partir de los polisacáridos que componen la superficie de la cápsula de la 
bacteria [3]. Las vacunas antineumocócicas disponibles se basan en polisacáridos capsulares 
de un serotipo específico, sin embargo, estos polisacáridos varían para cada serotipo 
neumocócico.  
Actualmente, se utilizan dos tipos de vacunas antineumocócicas: una vacuna de polisacárido 
neumocócico 23-valente (PPV23) con una mezcla de polisacáridos de diferentes serotipos 
neumocócicos; y vacunas conjugadas neumocócicas (PCV-7, 10, 13), con polisacáridos 
antigénicos conjugados con proteínas transportadoras, capaces de generar una respuesta 
inmune potente. Aunque la introducción de estas vacunas conjugadas ha reducido la carga 
global de neumonía, las vacunas disponibles protegen solo contra las infecciones causadas 
por un número limitado de serotipos. Hoy en día, las vacunas comercializadas cubren hasta 
el 75-90% de las cepas prevalentes en niños [4]. Sin embargo, las infecciones por los serotipos 
no incluidos en las vacunas han aumentado, produciéndose un reemplazo de cepas virulentas 
[5]. Es necesario llevar a cabo una búsqueda de candidatos a vacunas con capacidad de 




Una estrategia eficiente para mejorar la cobertura y la inmunogenicidad consiste en la 
incorporación de proteínas neumocócicas universales, que estén presentes en todos los 
serotipos. PsaA es una proteína de 37 kDa altamente conservada, presente en los 96 serotipos 
de S. pneumoniae [6], y es miembro de la familia de transportadores ABC dependientes de 
ATP. Además, la PsaA es una proteína de superficie que juega un papel importante en la 
adhesión y colonización de S. pneumoniae [7,8], lo que la convierte en candidata ideal para la 
vacunación [9,10]. La PsaA se unió covalentemente a un tetrasacárido sintético de 
polisacárido capsular Pn14TS, obteniéndose un glicoconjugado (Pn14TS-mPsaA /GC) [11]. El 
Pn14TS es el tetrasacárido más pequeño aislado del polisacárido capsular del serotipo 14 de 
S. pneumoniae, capaz de provocar una respuesta opsonofagocítica [12].  
El principal obstáculo en el desarrollo de una vacuna eficaz y exitosa es el diseño de un sistema 
de liberación de antígenos. La búsqueda de vacunas más seguras ha aumentado la demanda 
de aquellas constituidas por subunidades de componentes bacterianos o virales purificados. 
Sin embargo, la mayoría de estos componentes son débilmente inmunogénicos [13,14]. Por 
este motivo se incorporan o se administran conjuntamente con adyuvantes para 
desencadenar la respuesta inmune. Las células dendríticas (DCs) son las principales células 
presentadoras de antígeno que desempeñan un papel vital en el desarrollo de la inmunidad 
humoral mediada por células [15,16]. Como células presentadoras de antígeno profesionales 
(APC), las DCs actúan como la conexión entre el sistema inmune innato y adaptativo [15,17]. 
Al tener la capacidad de procesar los antígenos capturados, las DCs pueden estimular 
eficazmente las células T. 
En los últimos años se ha estudiado el uso de polímeros biocompatibles y biodegradables 
como adyuvantes y sistemas de liberación de antígenos. Polímeros como el quitosano, 
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alginato, protamina, dextrano, ácido hialurónico o ácido poliláctico-co-glicólico (PLGA) se han 
investigado en busca del desarrollo de vacunas basadas en proteínas/péptidos [18] o 
ADN[19]. Entre ellos, el quitosano continúa mostrando un gran potencial. Es un polímero 
natural biocompatible, biodegradable y mucoadhesivo, considerado como un excelente 
biomaterial para el diseño de sistemas de liberación de antígenos [20]. Es un adyuvante 
potencial para la administración mucosa, debido a sus propiedades mucoadhesivas y su 
capacidad para abrir uniones estrechas, promoviendo el transporte paracelular de antígenos 
[21,22]. Su naturaleza catiónica promueve su interacción con las células epiteliales, 
aumentando el tiempo de residencia. Como adyuvante inmune, se sabe que el quitosano 
mejora la inmunidad humoral y celular [23]. Estas propiedades hacen del quitosano un 
candidato ideal para el desarrollo de nanopartículas para la administración de vacunas.  
El uso de nanopartículas como sistema de liberación ofrece varias ventajas debido a sus 
características fisicoquímicas: tamaño de partícula, carga superficial y propiedades 
inmunoestimuladoras [24,25]. La preparación de nanopartículas de quitosano (CNP) implica 
un método de gelificación iónico simple y sin solventes. Además, permiten formar un depósito 
en el sitio de administración, controlando la liberación del antígeno [26,27]. A pesar de estos 
aspectos positivos, algunas limitaciones como una rápida liberación inicial y una reducida 
estabilidad en medios biológicos constituyen un desafío para su aplicabilidad como sistema 
de liberación de fármacos [28].  
En la presente tesis hemos investigado las nanopartículas basadas en quitosano como un 
posible vehículo para la administración de vacunas [18]. En este estudio, el glicoconjugado se 
encapsuló en las CNP (GC-CNP) y se realizó la caracterización. Se llevó a cabo un estudio 




la nanoencapsulación para incrementar la inmunogenicidad de los glicoconjugados. En 
resumen, esta tesis demuestra el uso potencial de los sistemas de nanopartículas para 
administrar vacunas glicoconjugadas de manera efectiva. 
Objetivo 1: Preparación y caracterización del glicoconjugado semisintético. 
La expresión de PsaA se realizó mediante la tecnología de ADN recombinante en E. Coli. La 
PsaA es una proteína de 37 kDa constituida por 309 residuos de aminoácidos. Esta proteína 
completa presenta un péptido señal en el extremo N-terminal de la región transmembrana. 
La presencia de esta secuencia líder reduce significativamente la expresión de dicha 
proteína[29]. Para evitar esta limitación, se produjo un PsaA maduro (mPsaA o PsaA 21-309) 
que no presentaba esta secuencia peptídica terminal. Se aisló el plásmido pET11a que 
albergaba el gen PsaA junto con una secuencia de polihistidina (HHHHHH) y una proteasa TEV 
(ENLYFQS) en su extremo N-terminal y se replicó en E. coli BL21 (DE3) mediante el método de 
choque térmico. Esta secuencia adicional de polihistidina se introdujo con el fin de facilitar la 
purificación de la proteína. Aunque se puede realizar su expresión y purificación en ausencia 
de esta cola [29], si se emplea, es necesario llevar a cabo su eliminación posterior para 
garantizar la ausencia de interferencia con la respuesta inmune. La proteasa TEV interviene 
en el enlace peptídico Q-S, dejando en su lugar un residuo de serina. Este residuo de serina, 
que asimismo se produce naturalmente en esta posición, lo que significa que la mPsaA nativa 
se recupera después de la digestión con la proteasa TEV. La expresión de mPsaA se confirmó 
mediante SDS-PAGE observándose la banda correspondiente a la proteína con el peso 
molecular esperado (Figura 1, Carril 2). La cola de histidina del HtTEV-mPsaA se eliminó 
usando la proteasa AcTEV ™ y la mPsaA resultante se purificó usando cromatografía de 
afinidad para eliminar la etiqueta de histidina. 




Figura 1: Caracterización de mPsaA. Análisis de la eliminación de la etiqueta de histidina de HtTEV-
mPsaA por SDS-PAGE (A) y por Western blot (B). Carril 1: marcador de proteína; Carril 2: HtTEV-mPsaA; 
Carril 3: proteasa AcTEV ™ utilizada; Carril 4: mPsaA purificada después de la eliminación de la etiqueta 
de polihistidina; Carril 5: eluido después de la purificación de proteína mPsaA en perlas de NiNTA; 
Espectros MALDI-TOF-MS de PsaA antes y después de la eliminación de la etiqueta de histidina (C).  
Los resultados experimentales obtenidos a partir del Western blot mediante el empleo de 
anticuerpos anti-histidina confirmaron la identidad y pureza de HtTEV-mPsaA y la eliminación 
del residuo de polihistidina. Mediante cromatografía de afinidad se observó que la muestra 
correspondiente a la fracción no unida presentó una banda ligeramente por debajo de la 
HtTEV-mPsaA SDS-PAGE, tras ser revelada mediante azul Coomassie, y ausente en el análisis 
de Western blot (Figura 1A y B, Carril 4). También se pueden observar en el eluido, tanto una 
primera banda correspondiente a la proteasa HtTEV como una segunda banda de HtTEV-
mPsaA sin escindir, con muy baja intensidad, tras la purificación en perlas de NiNTA (Figura 
1, Carril 5B). La identidad de ambas formas de PsaA fue confirmada mediante MALDI-TOF 
(Figura 1C). El peso molecular de las dos proteínas difiere en 1751 unidades de masa, lo que 
corresponde a la cola y al residuo terminal de metionina. El peso molecular de mPsaA 
equivalente a una molécula de PsaA que se obtuvo fue de 32.395 Da. La síntesis del 
tetrasacárido antigénico Pn14TS se realizó previamente en el grupo de Ingeniería Molecular 




El mPsaA se conjugó con Pn14TS mediante una reacción de acoplamiento tiol/maleimida. Con 
este objetivo, los grupos amino libres de las lisinas expuestas en la superficie de la proteína 
se derivatizaron por tratamiento con reactivo SATA-NHS (relación 120M). El exceso del 
reactivo fue eliminado mediante diálisis. Posteriormente, el vehículo modificado se conjugó 
con Pn14TS-mal en una relación 1:16M en presencia de exceso de hidrocloruro de 
hidroxilamina con el fin de generar grupos reactivos tiol in situ. El conjugado PsaA-Pn14TS 
resultante se purificó por filtración en gel, se liofilizó y almacenó a -80 °C. De manera similar, 
se preparó un conjugado BSA-Pn14TS como control para evaluar la importancia de PsaA como 
un elemento portador. El análisis de la composición química de los glicoconjugados por el 
método fenol-sulfúrico y el ensayo de Bradford revelaron que las relaciones molares de 
azúcar/proteína de los dos conjugados fueron de 5.4/1. El análisis de dicroísmo circular (CD) 
del conjugado mPsaA-Pn14TS y sus intermedios en comparación con mPsaA reveló que no 
hay cambios en la estructura secundaria de la proteína. El PsaA exhibió picos negativos a 208 
nm y 222 nm en todas las etapas de conjugación y liofilización, lo que demuestra un plegado 
de proteína similar y con un número significativo de hélices alfa y láminas beta de acuerdo 
con la estructura mPsaA determinada [6]. Se observó un patrón de plegado similar tras la 
superposición de los espectros de DC de HtTEV-PsaA, mPsaA y mPsaA-Pn14TS, confirmando 
la estabilidad en la proteína durante el proceso de conjugación (Figura 2). 




Figura 2: La superposición de los espectros CD de la proteína en las diferentes etapas de purificación, 
conjugación y liofilización.  
La conservación de mPsaA y mPsaA-Pn14TS se realizó mediante almacenamiento a -80 °C 
después de su liofilización y también en glicerol al 40%. En ambos casos el mPsaA ha 
mantenido su estructura secundaria incluso después de un almacenamiento de 12 meses a -
80 °C. La eficacia de inmunización del conjugado mPsaA-Pn14TS con α-GalCer como 
adyuvante se examinó en ratones, comparándose mPsaA y un conjugado modelo de BSA-
Pn14TS. Se demostró que los conjugados mPsaA-Pn14TS (GC) fueron capaces de inducir una 





Objetivo 2: Preparación y caracterización de nanopartículas de quitosano cargadas con GC 
Se prepararon nanopartículas de quitosano (CNP) cargadas con GC mediante un 
procedimiento de gelificación iónica simple. Su dispersión en medio acuoso reveló un 
diámetro medio de 142 ± 18 nm y un potencial zeta de 27 ± 3 mV. Se demostró que el PDI de 
las GC-CNP era inferior a 0.2, indicando homogeneidad de las nanopartículas. La 
representación esquemática de la formación de las CNP se muestra en la figura 3.  
 
Figura 3: Preparación de nanopartículas de quitosano; (A) Representación esquemática de la 
preparación de nanopartículas de quitosano por el método de gelificación iónica; (B) Tamaño de 
partícula y potencial zeta de CNP blancas y GC-CNP.  
La eficiencia de encapsulación (E.E.) de GC en las CNP fue del 70 ± 3% tras incorporar 35 µg 
de GC por miligramo de NP. La formulación contenía aproximadamente 6.000 GC por 
partícula, medido mediante análisis de seguimiento de nanopartículas (NTA) (~ 1.9 x 1010 
partículas por mg de GC-CNP). Las nanopartículas se liofilizaron utilizando 5% de trehalosa, 
las CNP fueron fácilmente redispersables en agua sin alterar el tamaño de las partículas.  
Resumen in extenso 
41 
 
Como se puede observar en la figura 4B, los resultados de la microscopía electrónica de 
barrido muestran una distribución de tamaño estrecha tanto en CNP blancas como en GC-
CNP. Las micrografías SEM demuestran una morfología casi esférica de las CNP sin signos de 
agregación. La distribución del tamaño de las partículas se representa gráficamente como se 
muestra en la figura 4C. Los tamaños medios de partículas fueron de 147 ± 19 nm y 145 ± 28 
nm para las nanopartículas blancas y GC-CNP respectivamente. No se observaron diferencias 
significativas en el patrón de distribución de las NP, a pesar de que las GC-CNP presentaban 
un número ligeramente mayor de partículas en un rango de tamaño por debajo de 100 nm. 
 
   
Figura 4: Determinación del tamaño de partícula por análisis de seguimiento de nanopartículas (NTA) 
y microscopía electrónica de barrido de emisión de campo (FESEM) de las CNP blancas y GC-CNP; A) 
La figura representa la distribución del tamaño de partícula y la concentración de nanopartículas 
blancas y GC-CNP determinadas por NTA; B) La morfología de CNPs blancas y GC-CNPs determinada 
por FESEM muestra que las CNPs presentaron forma esférica; C) La distribución del tamaño de 




Los resultados obtenidos de la interacción de las nanopartículas de quitosano con mucina en 
fluido nasal simulado (SNF) se muestran en las figuras 5A y 5B, indicando un aumento en la 
estabilidad de las nanopartículas en este medio en presencia de mucina. Los tamaños de 
partícula en SNF con 0.1% de mucina fue de alrededor de 320 nm a t = 0, el doble del tamaño 
medio observado cuando las NP se dispersan en agua.  
 
 
Figura 5: Estabilidad coloidal de GC-CNP en medio mucoso. Caracterización del tamaño de partícula 
(A) y tasa de recuento medio (MCR) (B) de las GC-CNP medidas a diferentes intervalos de tiempo 
durante 24 horas; distribución del tamaño de partícula medido por NTA para comparar la estabilidad 
de GC-CNP en agua (C) y tras su incubación en RPMI con 10% de FCS (D). 
Las nanopartículas fueron estables durante un período de 24h, conservando su tamaño y 
numero de partículas en 0.1% de mucina en SNF. Frente a estas observaciones, en el caso de 
las nanopartículas incubadas en SNF, el tamaño de partícula aumentó con el tiempo y el 
número de las mismas se redujo drásticamente. La razón del aumento inicial en el tamaño de 
las nanopartículas con 0.1% de mucina en SNF, a pesar de que fueron estables a partir de 
entonces, podría deberse a la propiedad mucoadhesiva de las nanopartículas de quitosano. 
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Los datos obtenidos por NTA confirman que las GC-CNP no presentaron agregación en medios 
R10 a concentraciones inferiores a 500 μg/mL (Figura 5C y 5D). 
 
Figura 6: Porcentaje de antígeno liberado después de incubar las GC-CNP en SNF durante un período 
de 24 h (N = 3)  
La cantidad de GC liberada a diferentes intervalos de tiempo de las GC-CNP se cuantificó 
frente al sobrenadante de las CNP blancas. Aproximadamente el 18% del antígeno se liberó 
después de 1 h de incubación en SNF. Sin embargo, a partir de ese punto no hubo un aumento 
significativo en el porcentaje del antígeno liberado. Como se puede observar en la figura 6, 
tras 24h, el porcentaje de antígeno liberado fue del 24 ± 9%. Esto podría deberse a una fuerte 
asociación del GC con las CNP. Una liberación inicial rápida podría corresponder al GC no 
encapsulado o al GC que se adsorbe en la superficie de las CNP.  
Objetivo 3: Eficiencia in vivo e in vitro de las nanopartículas cargadas con glicoconjugado 
Interacción de GC-CNP con células dendríticas. 
En primer lugar, se estudió la compatibilidad de las GC-CNP con las células dendríticas, 
mediante el ensayo 7-AAD. El 7-AAD es un colorante de ADN fluorescente con capacidad de 
atravesar la membrana plasmática de células apoptóticas o muertas. La mortalidad de las DCs, 




supervivencia superiores al 90%, en un rango de concentración de 25 a 100 μg/mL. Tanto las 
CNP blancas como las GC-CNP tenían un perfil similar de citocompatibilidad y se consideraron 
menos tóxicas para las DCs a concentraciones inferiores a 100 μg/mL. De manera similar, para 
estudiar la influencia de la concentración de GC-CNP en la actividad metabólica y/o la 
supervivencia de células dendríticas inmaduras (iDCs), se realizó un ensayo MTS. Como se 
observa en la Figura 7B, las GC-CNP mostraron la reducción de la actividad metabólica de las 
iDCs, de manera dependiente de la dosis. Los resultados sugieren que las GC-CNP se 
encontraban en rango no tóxico aceptable a una concentración de 25 a 100 μg/mL. 
 
Figura 7: Citotoxicidad de nanopartículas de quitosano (CNP) en células dendríticas inmaduras (iDCs). 
A) ensayo de tinción MTS; B) Se realizó un ensayo de 7-AAD tanto para GC-CNP (líneas azules) como 
para CNP blancas (líneas rojas) y C) Histogramas representativos obtenidos del análisis de citometría 
de flujo después de la tinción con 7-AAD. Los resultados se presentan como media ± desviación 
estándar (DE) de 4 donantes. 
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Además, se estudió la interacción de las GC-CNP con las DCs (Figura 8A). El patrón de 
internalización de las GC-CNP (50 μg/mL) en las DCs a 37 °C aumenta al incrementarse el 
tiempo de incubación. Sin embargo, no se observa mucha diferencia entre la internalización 
de las GC-CNP a las 2h y 4h tras su incubación a 37 °C. Por otra parte, las DCs incubadas a 4 °C 
como control no mostraron una internalización significativa de las GC-CNP incluso después de 
4h, mostrando una internalización específica de nanopartículas dependientes de energía a 37 
°C.  
 
Figura 8: Internalización de las Cy5-GC-CNP en MoDCs. Como se muestra en (A), se analizó la absorción 
dependiente del tiempo para GC-CNP marcadas con Cy5 (50 μg/mL) a 4 °C y 37 °C utilizando citometría 
de flujo. Las imágenes que se muestran en (B) muestran la comparación de las DCs no tratadas con las 
DCs tratadas con Cy5-GC-CNP (50 μg/mL para 2h a 37 °C).  Los resultados se presentan como media ± 
D.E. de 3 donantes. La diferencia estadística entre los grupos es *, P <0.05; **, P <0,01; ***, P <0,001; 




Se llevó a cabo un estudio de la expresión de marcadores coestimuladores para conocer el 
papel de las GC-CNP en la maduración de las DCs. Como se muestra en la Figura 9, las iDCs 
tratadas con CNP blancas y GC-CNP mostraron una expresión mayor de marcadores CD80, 
CD83 y CD86, aunque esta regulación positiva no fue estadísticamente significativa, 
probablemente debido a la variabilidad observada entre los diferentes donantes. Las DCs 
tratadas con CNP blancas y GC-CNP mostraron un perfil similar de expresión de marcadores 
de activación, y la regulación positiva siempre fue mayor en el caso de las células tratadas con 
GC-CNP. Aunque los resultados no son estadísticamente significativos, esto indica que la 
presencia de GC en las CNP potencia la estimulación de CD80, CD83 y CD86 por parte de las 
DCs. Por otra parte, se observa una clara regulación al alza de todas las moléculas 
coestimuladoras cuando las iDCs se trataron con LPS e INF-γ (Figura 9, columnas violetas).  
El papel de los diferentes componentes de las CNP en la estimulación de linfocitos periféricos 
y monocitos se determinó mediante la cuantificación de la síntesis de TNF-α por estos tipos 
de células. Staphylococcus Enterotoxin-B (SEB) se usó como control positivo para la 
estimulación de linfocitos T, mientras que el lipopolisacárido bacteriano (LPS) se usó como 
control positivo para la estimulación de monocitos. Cuando las PBMCs se trataron con las CNP 
o sus componentes, no se observó una activación significativa de los linfocitos T (medidos 
como células positivas para TNF-α) para ningún tratamiento en particular. 




Figura 9: Las GC-CNP inducen la activación y maduración de MoDCs. La expresión de las moléculas 
coestimuladoras como HLA, CD86, CD88 y CD83 en la superficie de CD1a + MoDCs se determinó por 
citometría de flujo 48 h después de la estimulación con 50 μg/mL CNP blancas o GC-CNP. Las barras 
en los diferentes colores indican GC (azul), CNP blancas (rojo), GC-CNP (verde) y el control con 
tratamiento LPS + INF-γ (púrpura). Los datos representan la media ± desviación estándar de los 
resultados obtenidos de los 4 donantes. No se observó significancia estadística entre los grupos. 
Sin embargo, se observa un resultado diferente en el caso de los monocitos periféricos. El 
tratamiento con CNP blancas estimula la producción de TNF-α por monocitos en comparación 
con las iDCs no tratadas, pero en menor medida en comparación con los PBMCs tratadas con 
GC-CNP. Las iDCs incubadas con GC-CNP sintetizan más TNF- α en comparación con sus 
componentes antigénicos individuales (Pn14TS y mPsaA; Figura 10, monocitos). Sin embargo, 
se puede observar que el GC solo induce la secreción de TNF- α por los monocitos a un nivel 





Figura 10: Los gráficos indican el porcentaje de células positivas para TNF-α después del tratamiento 
con SEB, LPS, Pn14TS, PsaA, GC, CNP blancas y GC-CNP. Las PBMCs se trataron con los componentes 
equivalentes a las GC-CNP de 50 µg/mL durante 48 h. El análisis de citometría de flujo se realizó para 
cuantificar los linfocitos (A) y (B) monocitos positivos para TNF-α. Los resultados se presentan como 
media ± desviación estándar de 4 donantes. La diferencia estadística entre los grupos es *, P <0.05; 
**, P <0,01; ***, P <0,001; ****, P <0,0001. 
La capacidad de las CNP (blancas y GC-CNP) para inducir la secreción de TNF-α principalmente 
por monocitos se relaciona con la capacidad de estas nanopartículas para activar APC (como 
se sugirió anteriormente para las DCs) y sus precursores (es decir, monocitos) dando lugar a 
una mayor activación del sistema inmune adaptativo (de linfocitos T) e induciendo actividad 
protectora contra los patógenos. 
Para determinar el papel de las CNP y mPsaA en la actividad aloestimuladora de las DCs, las 
iDCs se pretrataron con mPsaA, CNP blancas y una mezcla de mPsaA y CNP blancas, y 
posteriormente se incubaron con linfocitos de sangre periférica (PBLs) alogénicos. Las iDCs no 
tratadas y tratadas con LPS se usaron como controles negativos y positivos, respectivamente. 
La expresión de CD25 y CD28 se midió para determinar la activación de los linfocitos T 
alogénicos CD4 y CD8. Como se puede ver en la Figura 11A, hay un aumento significativo en 
las células T alogénicas CD4+ CD25 cuando las DCs se trataron con CNP blancas, en 
comparación con la expresión de CD25 cuando se usaron DCs incubadas con LPS o el antígeno 
PsaA (Figura 11A).  




Figura 11: las DCs tratadas con CNP inducen la proliferación de células T en una reacción mixta de 
linfocitos, las DCs se incubaron durante 24 h en presencia de LPS, PsaA, CNP blancas y PsaA + CNP 
blancas, después se cultivaron con PBLs alogénicos en una proporción de 1:10 durante 48 h. El número 
de CD4 y CD25 positivos (A), y CD8 y CD28 positivos (B), se analizaron por citometría de flujo. Los 
resultados se presentan como media ± D.E. de 4 donantes. La diferencia estadística entre los grupos 
es *, P <0.05; **, P <0,01; ***, P <0,001; ****, P <0,0001. 
Dado que estas últimas no promovieron la activación (es decir, la regulación positiva de CD25) 
de las células T CD4, se puede pensar que las CNP por sí mismas son capaces de activar las 
iDCs. Por otro lado, cuando se examinó la activación de los linfocitos T CD8 (Figura 11B), se 
puede detectar una activación clara de estos linfocitos usando DCs pretratadas con CNP 
blancas o una mezcla de CNP blancas y PsaA. La regulación ascendente de CD28 es 
significativamente mayor en los linfocitos T CD8 estimulados por DCs tratadas con CNP o CNP 
+ PsaA, en comparación con las DCs pretratadas con LPS o PsaA solo (Figura 5B; azul). Se 
observó un mayor porcentaje de linfocitos T CD8 + en cultivos en los que las DCs se 
pretrataron con CNP, en comparación con las observadas en cultivos que utilizan DCs 
pretratadas con LPS o PsaA (Figura 5B; rojo). 
Estudios de inmunización en ratones. 
Se realizó una primera serie de experimentos para evaluar el papel de la nanoencapsulación 




un total de dos veces a intervalos de dos semanas con GC, GC-CNP o PBS adyuvados con α-
GalCer. El nivel de la respuesta de anticuerpos originada por las diferentes formulaciones se 
determinó mediante ELISA. Este estudio se realizó para ver si la encapsulación de GC dentro 
de las CNP mejora la inmunogenicidad contra el GC. Se determinó la respuesta inmune, tanto 
la IgG como la IgM generadas contra los componentes de polisacárido capsular (CP) y proteína 
(PsaA) del glicoconjugado. Ni GC ni GC-CNP indujeron una respuesta IgM anti-mPsaA tras la 
segunda inmunización, mientras que se observó una respuesta baja de IgM anti-CP. Al 
comparar la respuesta IgG de GC y GC-CNPs administradas vía S.C, las GC-CNPs mostraron 
entre 10 y 100 veces mayor respuesta DE IgG anti-CP y anti-PsaA en comparación con el GC 
(Figura 12). Sorprendentemente, la respuesta de IgG inducida por las GC-CNP en ratones 
también fue mayor que la observada previamente para el GC administrado a una dosis seis 
veces mayor [11]. Los resultados muestran que la encapsulación del GC en CNP mejora la 
respuesta de IgG contra la proteína y el polisacárido capsular. 
 
Figura 12: La respuesta de anticuerpos en los ratones inmunizados con PBS, GC y GC-CNP una semana 
después de la inmunización final. La inmunización se realizó dos veces en los días 0 y 14 y la respuesta 
de anticuerpos en suero se determinó en el día 21. Los resultados obtenidos se representan como 
respuesta anti-mPsaA IgG (A), respuesta anti-CP IgM (B) y respuesta anti-CP IgG (C). El análisis 
estadístico se realizó mediante la prueba U de Mann-Whitney. La diferencia estadística entre los 
grupos es *, P <0.01; **, P <0,001; ***, P <0,0005. Los datos representan la media ± desviación 
estándar (n = 6). 
También fue interesante conocer las subclases de IgG que se producían predominantemente 
en el grupo tratado con GC-CNP. Las muestras de suero de ratones inmunizados con GC-CNP 
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mostraron un alto nivel de anticuerpos de la subclase IgG1 y en un grado mucho menor de 
IgG2b contra mPsaA y CP (Figura 13). No hubo activación de otras subclases de IgG como 
IgG2a. En la literatura se observa que los anticuerpos de la subclase IgG1 son inducidos 
principalmente por proteínas bacterianas, mientras que para IgG2 son inducidos por 
polisacáridos capsulares [30]. La generación de anticuerpos anti IgG1 contra PsaA y CP puede 
atribuirse a la activación de la fagocitosis por los macrófagos [31]. 
 
Figura 13: La subclase de respuesta de anticuerpos anti IgG en los ratones inmunizados con GC-CNP 
una semana después de la inmunización final. La inmunización se realizó dos veces en los días 0 y 14 
y la respuesta de anticuerpos en suero se determinó en el día 21. Los resultados obtenidos se 
representan como respuesta IgG anti-mPsaA (A) e IgG anti-CP IgG (B). El análisis estadístico se realizó 
mediante ANOVA unidireccional con análisis de Kruskal-Wallis mediante las comparaciones múltiples 
de Dunn. La diferencia estadística entre los grupos es *, P <0.05; **, P <0.01;. Los datos representan 
la media ± desviación estándar (n = 6). 
Tras la infección por neumococo (Figura 14) en ratones, se observó un 50% de supervivencia 
en el día 20 en el grupo inmunizado por vía SC con GC-CNP mientras que el grupo inmunizado 
con una cantidad equivalente de GC mostró solo un 17% de supervivencia. Curiosamente, 
hubo un 100% de supervivencia hasta el día 13 en los ratones tratados con GC-CNP, mientras 
que en los grupos tratados con GC, la supervivencia se redujo al 50% en el día 10.  
En una segunda serie de experimentos, nuestro objetivo fue determinar la respuesta humoral 




sea subcutánea o intranasal (I.N). Se inmunizaron grupos de 6 ratones (C57BL/6) un total de 
tres veces a intervalos de 2 semanas con GC-CNP (S.C), CNP blancas (SC), Prevnar 13 (S.C), GC 
(I.N), GC-CNP (I.N), CNP blancas (I.N), y CNP blancas GC + (I.N) adyuvantes con α-GalCer. 
 
Figura 14: Supervivencia de ratones vacunados por vía intranasal mediante la administración de 30 
UFC de H3N2 seguido de 1x106 de S. pneumoniae serotipo 14.  
Los sueros de ratones inmunizados con CNP blancas, así como el de ratones inmunizados con 
Prevnar 13 (que no contiene PsaA como inmunógeno) no muestran ninguna respuesta anti-
mPsaA IgG en ninguna de las vías. Mientras que las GC-CNP no lograron producir IgG anti-
PsaA cuando se administraron a través de la mucosa nasal (Figura 15A), las mismas GC-CNP 
produjeron una respuesta de IgG anti-PsaA 100 veces mayor cuando se administraron por vía 
S.C. Esto muestra que las GC-CNP fueron capaces de inducir una respuesta IgG anti-PsaA por 
vía S.C pero no I.N. Los resultados de la inmunización I.N muestran que la respuesta de IgG 
anti-mPsaA es más alta en el grupo inmunizado con GC y se observa una reducción en la 
actividad al mezclar el GC con CNP e inmunizar a los ratones. Se observó una reducción 
adicional de la actividad en la encapsulación de la GC en las CNP. Esto muestra la influencia 
de las CNP en la reducción de la respuesta inmune contra el GC mientras se administra I.N. 
Este hallazgo plantea la necesidad de investigar más a fondo la influencia de la naturaleza y 
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la estructura de las CNP en la inmunogenicidad y el efecto del aclaramiento mucociliar en la 
disminución de la respuesta inmune contra el GC encapsulado.  
 
Figura 15: Se estudió la respuesta de anticuerpos en los ratones inmunizados con GC-CNP (S.C), CNP 
blancas (SC), Prevnar 13 (SC), GC (I.N), GC-CNP (I.N), CNP blancas (I.N) y GC + CNP blancas (I.N). La 
inmunización se realizó tres veces en el período de un mes (0, 14 y 28 días) y la respuesta de 
anticuerpos en suero en los ratones se determinó 2 semanas después de la inmunización final. Los 
resultados se muestran como respuesta anti-mPsaA IgG (A), respuesta anti-CP IgG (B) y respuesta anti-
CP IgM (C). Los datos de las muestras de suero se presentaron como media ± DE de seis ratones por 
grupo. El análisis estadístico se realizó mediante ANOVA unidireccional con análisis de Kruskal-Wallis 
mediante las comparaciones múltiples de Dunn. La diferencia estadística entre los grupos es *, P 
<0.05; **, P <0,01; ***, P <0,001. 
La respuesta de IgM anti-CP 14 fue muy baja y solo se observó en los ratones inmunizados 
con Prevnar 13 (Figura 15C). Mientras, tanto el GC (I.N) como las GC-CNP (S.C) pudieron 
inducir una respuesta de IgG anti-CP. Esta respuesta fue muy baja en el grupo de ratones 
inmunizados con Prevnar 13 y no se observó en los otros grupos. 
Además, los estudios sobre la cuantificación de anticuerpos IgA de los fluidos bronquiales de 
ratones inmunizados no mostraron respuesta de IgA (datos no mostrados). Sin embargo, el 
estudio final sobre la opsonofagocitosis a partir del suero de los ratones inmunizados está en 
marcha. Estos resultados serían críticos para concluir el papel de la nanoencapsulación de GC 
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Approaches for design and delivery of subunit pneumococcal vaccines 
Abstract 
Pneumococcal vaccines have proven to be effective candidates for the prevention of 
pneumococcal infectious diseases. The global pneumonia burden was significantly reduced 
by the promotion of pneumococcal polysaccharide (PPSV23) and pneumococcal conjugate 
(PCV7, 10 and 13) vaccines. Despite their undoubted effectiveness, the serotype dependence 
of these vaccines still needs to be improved. The serotype replacement phenomenon has led 
to the development of protein-based vaccines, consisting of highly conserved pneumococcal 
protein antigens (PPAs). Further improvements rely on understanding the molecular 
mechanism of immune recognition and optimizing the delivery to the antigen-presenting cells 
for eliciting both cellular and humoral responses. The use of innovative delivery systems is a 
new and exciting strategy. In this review, we address the current status of different 
pneumococcal subunit vaccines and nanotechnological approaches employed for their 
delivery.  
Keywords: Glycoconjugates, Capsular polysaccharides, Protein antigens, Nanotechnology, 






Pneumonia is the leading cause of death among infectious diseases. According to the global 
health burden of disease study 2017, pneumonia was responsible for 2.6 million deaths in 
that year. 75% of these deaths were among the children younger than 5 years (809, 000 
deaths) and elderly over 70 years (1.1 million deaths) [1,2]. Streptococcus pneumoniae is the 
leading cause for the occurrence of pneumonia. Besides, S. pneumoniae is responsible for 
bacterial meningitis, sepsis and otitis media. The Institute for Health Metrics and Evaluation 
(IHME) estimates that infections due to S. pneumoniae alone are responsible for ~1.2 million 
deaths annually. Out of these, pneumococcal meningitis and pneumococcal pneumonia were 
estimated to be responsible for 23,000 and 300,000 cases, respectively [1,3]. Two-thirds of 
these deaths are concentrated in Sub-Saharan Africa, South Asia, and South-East Asia. In the 
year 2015, just five countries (India, China, Pakistan, Nigeria and Indonesia) contributed to 
54% of all pneumonia cases [4]. For the year 2017, pneumococcal vaccine market was valued 
at 7,083 million USD and is expected to grow at 5% compound annual growth rate (CAGR) 







Figure 1: Epidemiology of Pneumonia. The figure illustrates the mortality and morbidity occurred due 
to pneumococcal pneumonia infections in the children under 5 years. The data was compiled using 
the report on the global burden of S. pneumonia 2000 – 15, Lancet [6]. The values in the upper 
hemisphere (orange) indicates the % of infections caused by the serotypes that are not included in the 
PCV. The values in the lower hemisphere (transparent) indicates the number (x 1000) of deaths caused 
by pneumococcal pneumonia in the children under 5 years. 
 
Over 96 S. pneumoniae serotypes have been identified based on differences in the 
composition of surface-exposed large polysaccharides which form a capsule around the 
bacteria [7]. Available pneumococcal vaccines target these capsular polysaccharides. Two 
types of pneumococcal vaccines are currently in use; a 23 valent pneumococcal 
polysaccharide vaccine (PPSV23) and 7, 10 or 13 valent pneumococcal conjugate vaccines 
(PCV-7, 10, 13). Although the introduction of the conjugate vaccines has reduced the global 
burden of pneumonia, the currently available pneumococcal vaccines protect against a 
limited number of serotypes. An efficient strategy to improve the coverage and 
immunogenicity is the incorporation of common pneumococcal proteins that are present in 




response in the immunized individuals but whether anti-surface protein Abs are useful to 
diminish the carriage is still debated.  
However efficient the vaccine is, its effective delivery is essential to induce a proper immune 
response. The immunogenicity of subunit vaccines can be enhanced by improving their 
presentation to dendritic cells (DCs). To achieve this, the use of nanoparticulate systems is a 
potential alternative. Within this regard, the insights from immunology and microbiology, the 
advances in the nanotechnology and material science have paved the way for the effective 
delivery of subunit pneumococcal vaccines. 
In this review, we are discussing the current progress in the field of subunit pneumococcal 
vaccines, together with the factors that influence the generation of an immune response 
against such vaccines. Also, their uptake by antigen-presenting cells (APCs) when given in 
nanoparticulate form over the free form are elucidated. This understanding of the 
mechanisms discussed in the review provides an insight into the importance of using the 
particulate systems in the subunit vaccine delivery. 
2. Pneumococcal vaccine development 
The S. pneumoniae was first observed by Klebs (1875) in course of his work with lung fluids 
and sputum from pneumonia patients, while Eberth and Matry (1880) have first coined the 
term Pneumoniekokken. Later, Louis Pasteur and Miller Sternberg (1881), independently 
isolated S. pneumoniae and the possible serological diversity of the pneumococcal serotypes 
were described by Benzancon and Griffin in 1897. However, in 1902, Friedrich Neufeld 
identified the presence of multiple pneumococcal serotypes. In 1917, the landmark papers 
published by Dochez and Avery described an immunologically active soluble substance of 




as polysaccharides from the pneumococcal capsule. These investigations eventually led to the 
identification of the polysaccharide components of the bacterial capsules as possible targets 
for pneumococcal vaccine development [8]. Since then, substantial progress has occurred in 
the development of pneumococcal polysaccharide and conjugate vaccines. It is not difficult 
to imagine the enormous impact of these vaccines on human lives. However, there is a 
continuous effort in developing novel pneumococcal vaccines that are cost-effective and can 
offer broader coverage among all the serotypes. To achieve this, researchers are developing 
vaccines based on common proteins and using nanotechnological approaches for efficient 
delivery of subunit vaccines. 
 
Figure 2: Timeline of pneumococcal vaccine development. 
2.1. Polysaccharide vaccines 
These vaccines are composed of purified polysaccharide components of the bacterial capsule. 
The capsular polysaccharides act both as virulence determinants and targets for protective 
antibodies. Carbohydrates are abundant on the cell surfaces and exist in the form of oligo- or 
polysaccharides attached to lipids or proteins [9]. They are involved in the invasion and the 
attachment process [10,11]. In turn, the immune system recognizes the carbohydrates from 




specific protective antibodies [8,11,12]. The first successful subunit vaccine consisting of 
capsular polysaccharides from 4 serotypes was introduced in 1945. The importance of this 
discovery was not credited due to the availability of newly introduced antibiotics. However, 
Robert Austrian has done extensive research in identifying new serotypes and developed a 
vaccine that offers protection against 14 serotypes. By expanding this work, in 1983, the 
vaccine consisting of polysaccharides from 23 serotypes was developed by Merck to cover 
more than 80 – 90% infectious serotypes. This 23 valent pneumococcal polysaccharide 
vaccine (PPSV23) contains the components from following serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 
9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. It is still in use and 
is recommended for all the adults over 65 years of age. Although the PPSV23 reduced the rate 
of invasive pneumococcal disease in immunized patients, it failed to reduce the 
nasopharyngeal carriage. In addition, due to its inability to produce the B cell memory and 
switching from IgM to IgG isotypes or producing the antibodies with higher affinity during the 
primary immune response, PPSV23 failed to be successful in children younger than 2 years 
and immunocompromised patients. These problems fostered the development of 
glycoconjugate vaccines that could produce long-lasting immunity. 
Isolation of carbohydrate antigens with defined length and specific functional groups from 
natural sources is challenging. The duties of culture, processing, isolation and purification 
include laborious, time-consuming and costly activities. Besides, it is not feasible to cultivate 
all pathogenic bacteria to generate carbohydrate antigens in-vitro. Further to this, indeed, the 
down-stream processing generates glycans with varying lengths that can affect epitope 
integrity. Synthetic oligosaccharides mimicking native capsular polysaccharides have been 
proposed to avoid these shortcomings of carbohydrate antigens [13–17]. The progress in 




synthetic glycan approaches, which make the precise identification of the antigenic 
determinants expressed within the bacterial polysaccharide possible. The chemical synthesis 
of glycans enables to tune the length, structure, ease of characterization, reduces bacterial 
contaminants and increases batch-to-batch reproducibility. This complete understanding of 
polysaccharide vaccines aids in drawing a more robust correlation of the elicited immune 
response by the chemical structure [18].  
In contrast to the native polysaccharides, synthetic glycans can be equipped with a unique 
functional group that enables its coupling to a protein carrier giving rise to 
neoglycoconjugates, that can be more easily characterized [19,20]. Besides, such coupling 
strategy is likely to retain the integrity of sugar epitopes. The site-specific chemical 
modifications paved a path for linking the adjuvants, which can exhibit improved immuno-
stimulant properties [21]. Still, it is often challenging to synthesize the carbohydrate in large 
scale with low manufacturing costs and without process convolution. However, some 
approaches could circumvent these problems [18,22].  
2.1.1. General mechanism: focus on bacterial antigens  
The prerequisite for the adaptive immunity is the activation of T lymphocytes by the DCs, 
which process the antigen and present it in the MHC complex. Intracellularly synthesized 
antigens (e.g. viral and tumoral origin) are presented by MHC I molecules, that activate CD8+ 
T cells. MHC II molecules present extracellular antigens to the CD4+ T cells. In addition, the 
mechanism of cross-presentation also permits such antigens to enter the MHC I pathway and 
stimulate CD8+ T cells. The adaptive immune system mainly comprises humoral (antibodies) 
and cell-mediated mediated responses. Upon activation, the naive CD4+ T cells differentiate 




CD8+ T cells become cytotoxic T lymphocytes (CTLs), which can kill the altered host cells and 
secrete cytokines like INF-γ and TNF-α. Excellent reviews on the detailed mechanism of 
antigen processing by APCs can be found elsewhere [23–26]. 
2.1.2. Immune cell activation by polysaccharide vaccines 
For polysaccharide vaccines, the APCs use distinct endocytosis mechanisms and process the 
carbohydrates to smaller sizes by endo-lysosomes, but these fragments fail to bind directly 
MHCII, and hence, glycans are considered as T cell-independent (TI) [23,27]. However, the 
polysaccharide vaccines generate an immune response on their interaction with B 
lymphocytes [28,29]. Based on their interaction with the B lymphocytes, antigens are either 
classified into TI type 1 or TI type 2. TI type 1 antigens (LPS) are capable of proliferating and 
differentiating both naive and mature B lymphocytes. TI type 1 antigens are effective both in 
neonates and the elderly [30]. TI type 2 antigens (PPSV) are high molecular weight repetitive 
polysaccharides that do not exhibit intrinsic B lymphocyte stimulation. However, they interact 
with the surface immunoglobulins of mature B lymphocytes to generate an immune response. 
Unlike TI type 1 antigens, TI type 2 antigens are not suitable as vaccine candidates in neonates 
and elderly [29]. However, as an exception, zwitterionic polysaccharides can be processed 
and presented by MHCII pathway, that questions this paradigm [31]. 
2.2. Conjugate vaccines   
Glycoconjugate vaccines are prepared by coupling or conjugating the polysaccharide moieties 
to the carrier proteins. The development of glycoconjugates was driven by the ineffectiveness 
of the polysaccharide vaccines to generate a strong immune response in the children. The 
commonly used protein carriers are tetanus toxoid (TT), diphtheria toxoid (DT) and cross-




polysaccharide moieties to carrier proteins enhances T cell-dependent responses against the 
polysaccharides. In the late 1920s and early 1930s, the synthesis of glycoconjugates using 
covalent conjugation was pioneered by Avery and Goebel [32]. This early work formed the 
basis for the further development of the glycoconjugate vaccines. Applying this principle, 
several investigators have made significant contributions to the development of the 
glycoconjugates [33–36]. Pfizer launched the first glycoconjugate vaccine covering 7 (PCV7) 
serotypes in the year 2000. The PCV7 greatly reduced the rate of infections in vaccinated 
children under 2 years and the non-immunized people within the community through herd 
effect. Later in 2010, PCV7 was replaced by PCV13 that covers the 13 serotypes.  
The PCV13 increased the serotype coverage to 80% and showed broader protection against 
the pneumococcal infections. As a result, the rate of invasive and non-invasive pneumococcal 
infections reduced further. Despite their undoubted success in reducing the number of 
invasive pneumococcal disease in infants and children < 5 years of age, the concern of 
serotype replacement is still haunting the pneumococcal vaccines [37,38]. The term serotype 
replacement has been coined to describe the increase in the rate of infections caused by 
serotypes not covered in PCV7 and PCV13. Serotype replacement thus leads to the emergence 
of infections caused by serotype, which were not prevalent until then as observed for 
serotype 35B. Besides this, currently employed technologies in the synthesis of 
glycoconjugates involve multi-step processes and are cost intense. Seeberger and his 
coworkers have done significant work in developing semi-synthetic glycoconjugates (serotype 
1, 2, 3, 5, 7F and 8) to protect against the serotypes that are not included in the marketed 
PCVs [39–44]. Their work demonstrates synthetic oligosaccharides can be used as an 
alternative for purified polysaccharides that are commonly in use. Semi-synthetic 




Besides, these researchers have also formulated pentavalent semisynthetic vaccines based 
on purely synthetic oligosaccharide antigens and claimed that adding these to the marketed 
pneumococcal vaccines can increase their coverage [45]. Despite several advantages and 
extensive research, only one glycoconjugate based on a synthetic carbohydrate antigen is 
available in the market. It was developed and licensed in 2003 by Heber Biotech developed 
and licensed as Quimi-Hib in Cuba [13,46,47]. It consists of a fully synthetic oligosaccharide 
Hib vaccine conjugated to tetanus toxoid. Overall, Quimi-Hib proved the possibility of 
translating the synthetic approach from the bench to the industrial scale. 
2.2.1. Conjugation methods 
The approaches employed to engineer the glycoconjugates aim to produce vaccines with 
higher batch-to-batch consistency and enhanced potential or biological activity [48]. This 
involves three major areas (i) glycan assembly, (ii) conjugation approaches, and (iii) 
construction of multicomponent glycoconjugates. The first approach focuses on obtaining a 
series of glycans from the pathogens or producing synthetic mimics of the glycans. Glycan 
assembly involves methods like chemoenzymatic approaches [49], one-pot protocols [50], 
and automated solid-phase synthesis [51–53]. Conjugation approaches are based on both 
random and selective methods [22]. In random conjugation, reactive functional groups of the 
proteins are targeted, such as the amines of lysines, thiols of cysteines, the carboxyl groups 
from the aspartates/glutamates or the tyrosine residues. While the selective conjugation is 
performed depending on the targeted functional group frequency and its surface accessibility, 
this leads to heterogeneous conjugates of different sugar/protein ratios [54]. In the case of 
multicomponent glycoconjugates, the method involves the attachment of multiple antigens 





Figure 3: Schematic representation of glycoconjugate (GC) synthesis; A) a simple glycoconjugation 
method where the carrier protein and the capsular polysaccharides (CPS) are separately produced and 
conjugated by using the linkers; B) Protein capsular matrix vaccine (PCMV) in which multiple 
polysaccharide antigens are entrapped in a cross-linked protein matrix; C) Protein glycan coupling 
technology (PGCT), production of conjugate vaccines via in vivo biosynthesis. 
Furthermore, advances in the glycoengineering approach pioneered new techniques like 
protein glycan coupling technology (PGCT), developed by GlycoVaxyn (now acquired by GSK) 
[22,48,55,56]. In PGCT, polysaccharide antigens are synthesized by the stepwise action of 
glycosyltransferases at the cytoplasmic side of the bacterial membrane and polymerized after 




residue of the carrier protein synthesized within the same bacterial cell by PglB, an N-
oligosaccharyltransferase from Campylobacter jejuni’s protein glycosylation system [57–60]. 
Alternative approaches such as protein capsular matrix vaccine (PCMV) technology are used 
in the preparation of GCs, where CPS is non covalently trapped in the protein matrix. 
Currently, Matrivax is developing a pneumococcal vaccine based on PCMV which is in late 
preclinical phase [61]. Affinivax Inc has developed a multiple antigen-presenting system 
(MAPS) platform technology that simplifies the preparation of GCs. The MAPS technology 
involves highly specific and non-covalent binding between biotinylated polysaccharides and 
biotin-binding proteins. In contrast to marketed pneumococcal vaccines, MAPS offers a 
unique way to present the key epitopes of the desired antigens to induce potent immune 
response [62,63]. Recently, Affinivax Inc and Aestellas have jointly initiated phase 1 clinical 
trials on pneumococcal vaccine based on MAPS technology. 
2.2.2. Uptake and processing of glycoconjugates 
The carbohydrate moieties of the conjugate vaccines are key for the induction of pathogen-
specific responses. Carbohydrates alone are T cell-independent antigens and cannot be 
presented to the MHC II after processing by APCs. The covalent linkage to a carrier protein 
enables the carbohydrates to take a T cell-dependent pathway, that involves the binding of 
the glycoconjugate complex to the B cell receptor. The glycoconjugate is internalized by the 
APCs and processed by proteolytic enzymes. The small fragmented peptides or the 
carbohydrate fragments associated with the peptides are represented by MHC II complex and 
are recognized by T cells. However, the carbohydrate fragments alone will not be presented 
by MHC II complex and will follow T cell-independent pathway. T cells produce signals either 




Interleukin 2 (IL2) or by inducing the maturation of B cells into antibody-producing plasma 
cells [23,64].  
 
Figure 4: Processing and presentation of glycoconjugate vaccines by immune cells. The schematic 
representation shows the carrier-mediated uptake GCs. The internalized GCs are processed inside the 
endosomes and presented to T cells via MHC complexes. The carbohydrate associated with peptide 
or the peptide fragments alone is presented to CD4 T cells via MHC II, and the activated CD4 T cells 
stimulate B cells. The B cells activated by CD4 T cells either transform memory cells or antibody-
secreting plasma cells.  
For soluble antigens, the APCs use distinct endocytosis mechanisms. The strong covalent 
linkage in glycoconjugates is unlikely to be broken in the endosome, and thus the presentation 




recognized by the T cells. This undersells the hypothesis of “peptide only” presentation. T cells 
fail to respond to the glycans due to the inability of the MHCII to present them, rather than 
due to their inability to recognize the glycans [65]. 
2.3. Pneumococcal protein vaccines  
Despite the enormous success of PCVs, the increasing incidence of infections caused by the 
non-vaccine serotype strains have led the search of alternative vaccine candidates. 
Pneumococci express highly conserved protein-based antigens that are present in all 
serotypes. This approach hopes to offer broad cross-protection against multiple 
pneumococcal strains. Pneumococcal protein candidates are T cell-dependent antigens which 
are highly immunogenic and can elicit immunologic memory. These protein antigens can 
either be used alone, in association or as a protein carrier in conjugate vaccines. Protein 
antigens can be engineered and expressed in a relatively simple and cost-effective manner. 
An extensive list of PPAs has been evaluated for their potential as vaccine candidates, 
importantly PspA, PsaA, PspC, PcpA, Ply, and PhtD are at the forefront of the investigation 
(see in table 1). 





Surface-exposed 37-kD multi-functional lipoprotein [66]. 
Lipoprotein belonging to ABC-type protein complex that transports Mn2+ 
[67] 




66 to 99 kDa surface-exposed choline-binding protein 





85 kDa surface protein present in 75% of all pneumococcal serotypes 
Plays a major role in the colonization of nasopharynx 
PhtD 
Polyhistidine triad D 
95 kDa surface-expressed polyhistidine triad protein 
Helps attachment to the bronchial epithelium 




Pneumolysin Cholesterol dependent pore-forming cytolysin 
Helps surface adhesion and forms pores in target cells 
PcpA 
Pneumococcal choline-
binding protein A 
79 kDa choline binding protein 
The surface protein expressed in more than 90% of serotypes 
PcpA is ideal candidate against invasive disease as it is expressed during 
invasive disease but not in the nasal mucosa. 
IgA1 protease 
130 to 200 kDa endopeptidase [70] 
Promotes adherence and persistence at mucosal surfaces 
SP0148 
31 kDa member of ABC transport system 
Plays an important role in nasopharyngeal colonization [71] 
PcsB 
38 – 41 kDa protein 
Hydrolase essential in separation of dividing cells [72] 
PavA 
Adherence and 
virulence protein A 




72 kDa protein kinase 
Plays a crucial role in regulating cell shape and cell division 
Plays an important role in providing resistance during the stress conditions 










79 kDa protein that binds to human serum proteins 
Helps in fibronectin dependent adhesion and invasion [76] 
ZmpB 
Zinc metalloprotease B 
213 kDa surface bound metalloprotease present in all serotypes 
Strongly contribute to infection and virulence. Inhibits complement 
activation [77,78] 
PrtA 
cell wall associated 
serine protease A 
240 kDa surface-associated subtilisin-like serine protease 




120 kDa hyaluronidase protein 
Helps in breaking down the important component of connective tissue 
during the invasion [80] 
NanA 
Neuramidase A 
110 -140 kDa neuramidase present in all serotypes 




72 kDa plasminogen and fibronectin binding protein 
Plays important role in invasion of host cells and immune evasion [82] 
GHIP 
Pneumococcus-specific 
glycosyl hydrolase 25 
30 kDa protein 





41 kDa membrane protein 
Helps in polyamine transport and plays significant role in pathogenesis [84] 
PitB 
Pilus backbone protein 
B 
37 kDa protein 







rich repeat protein 
412 kDa, extremely large glycosylated cell surface protein 
Promotes adherence to nasopharyngeal epithelial cells and lung cells [86] 
CbpE 
Choline binding protein 
E 
72 kDa protein choline binding protein 
Helps in nasopharynx colonization and adherence to epithelial cells [87] 
EndA 
Endonuclease A 
30 kDa membrane nuclease [88] 
Helps in escaping from nuclear extracellular traps [89] 
PD 
Protein D 
Non lipidated cell surface lipoprotein 
PPAs are increasingly being tested as potential vaccine candidates both in pre-clinical and 
clinical trials. Currently, Sanofi S.A is working to develop new pneumococcal protein vaccines 
for pneumonia, solely based on the PPAs like PhtD/dPly/PcpA (NCT01446926, NCT01764126), 
which are in phase 2 clinical trials (see Table 2). Genocea Biosciences, Inc. was working on 
developing a trivalent protein vaccine (NCT02116998) comprising of maltose/maltodextrin-
binding protein (SP2108), ABC transporter substrate-binding protein (SP0148), and surface-
exposed T cell protein antigen (SP1912). The studies successfully demonstrated safety and 
immunogenicity of the vaccine during the phase II trials. However, due to the lack of statistical 
significance between the placebo and immunized groups, the studies were terminated. GSK 
is working on developing a monovalent protein vaccine based on PhtD alone or divalent 
protein vaccine consisting of dPly and PhtD. 
Furthermore, efforts are made to co-administer existing PCVs with pneumococcal proteins. 
GSK together with PATH is developing vaccines (GSK2189242A) based on the combination of 
pathogen-specific protein (PhtD/ PlyD1) and Prevenar 13 (NCT01262872). This vaccine 
combination should not only offer protection against the 13 serotypes whose polysaccharide 
components are incorporated but, would also provide cross-protection against other 
serotypes of S. pneumoniae that are not included in the existing pneumococcal vaccines. 




evoking the immune response [90,91]. Some investigators also used fusion proteins which are 
conjugates of two different proteins (PsaA-PspA) of the same pathogen [92]. Mucosis had 
developed a platform technology (PneuGEM), in which pneumococcal proteins (PpmA, SlrA 
and IgA1-protease) are anchored to a bacterium like particles (BLPs) for mucosal 
immunization. The detailed list of pneumococcal vaccines under development is elaborated 
in Table 2. 
Table 2: Subunit pneumococcal vaccines in pipeline/ clinical trials 
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SII: Serum Institute of India; icddrb: International Centre for Diarrhoeal Disease Research, Bangladesh; 
GSK: GlaxoSmithKline 
3. Nanotechnology approaches for pneumococcal vaccine delivery 
Although conventional pneumococcal vaccines have significantly reduced the disease burden, 
there are certain unmet concerns such as sub-optimal immunogenicity profile and intrinsic 
instability. These subunit vaccines need repeated administrations (two injections at two 
months interval followed by a boost several months later) to generate an optimal immune 
response. Besides, available subunit vaccines are administered by a parenteral route that 
involves the use of needles and these vaccines in their free form are thermolabile. They often 
require to be co-administered with adjuvants to elicit the promising immune response. Over 
the past decades, many drug delivery systems, including polymeric micro- and nanoparticles, 
have been studied to overcome the bottlenecks mentioned above. Apart from encapsulating 
and delivering the antigens, particulate delivery systems can act as adjuvants [93]. Their 
ability to mimic the pathogens and interact with the immune cells makes them an attractive 
strategy for vaccine delivery [94]. Rapid progress in the pharmaceutical field has provided 
insights for the selection of biodegradable and biocompatible polymers from natural and 
synthetic sources [95]. In general, particles larger than 500 nm are readily internalized by APCs 




drain to the lymph nodes and preferably taken up by lymph node resident DCs [96]. Besides, 
it is also believed that only the particles in the nanometer range transport via the lysosomal 
pathway and are consistent with their uptake mechanism [97]. More importantly, targeting 
DCs with an antigen-loaded particulate system can play a substantial role in activating the T 
cell-mediated immune system by processing the antigens through MHCs. Presenting the 
fragmented antigen peptides to CD4+ and CD8+ cells result in a humoral and cell-mediated 
response. Among the nanocarriers used for the delivery of vaccines, relevant examples are 
polymeric nanoparticles, liposomes, nanoemulsions, nanocapsules and VLPs. However, the 
mechanism at molecular/cellular levels is poorly understood. It is known that the inherent 
immunogenicity of the particulate structures can be enhanced by engineering chemical 
composition (immunostimulating ligands, multiple antigens) and/or the physicochemical 
properties of the delivery system.  
3.1. Nanotechnology strategies for the delivery of subunit pneumococcal vaccines 
In the field of vaccine delivery, nanoparticulate systems offer several advantages over the 
traditional formulations. The strategy like encapsulation or surface conjugation is employed 
for the incorporation of the carbohydrate antigens (CAs) or protein antigens or 
glycoconjugates into the nanoparticles. The encapsulation of glycoconjugates into the 
nanoparticles protect them from the degradation, increases the density of antigens and 
control the rate of antigen release. In general, the glycoconjugates or protein antigens are 
incorporated during the fabrication of nanoparticulate vaccines [98,99]. To deliver the 
pneumococcal antigens, Liposomes were either used as a vehicle or co-administered with the 
antigens. In 2018, Tada et al. developed liposomes based on DOTAP that was co-administered 




to elicit PsaA specific Th17 responses, which played a pivotal role in controlling the infection 
[101] and proved superior to PspA administered alone in inducing a protective immune 
response. In 2018, Hill et al. developed liposomes that mimic the structure of the pathogen 
(Figure 5A), in which, 20 CPS were encapsulated in the core and surface decorated with 
protein antigens GlpO and PncO [102]. This liposomal vaccine platform was claimed to be 
capable of surpassing the effectiveness of the best-in-class commercial pneumococcal 
glycoconjugate vaccine. However, these studies are preclinical and further progress on the 
work is not reported. 
Apart from this, there is substantial literature, in which the pathogen-specific proteins are 
delivered using nanotechnologies based on the polymers like chitosan [103], polyanhydride 
[104], PLGA [105] and PLA [106]. Xu et al. showed that nanoparticles made of chitosan and 
encapsulating the PsaA were effective in protecting the mice against an invasive 
pneumococcal challenge after mucosal immunization [98]. Mott et al., used PLGA 
nanoparticles to ferry the pneumococcal CPS and were effective in generating immune 
response after intranasal immunization in mice [105]. Similarly, researchers were successful 
in developing self-assembled nanoparticles [94] or nanocomplexes for the delivery of PPAs 
[107]. Researchers also explored virus-like particles based on synthetic lipopeptide and they 
were successful in generating significant protection against the lethal doses of S. pneumoniae 
[94]. Alginate microparticles have been widely explored for the delivery of both the CPS and 
PPA based pneumococcal vaccines [108–110]. The PspA encapsulated in the alginate 
microparticles were effective in inducing cross-protection against five serotypes of S. 
pneumoniae after oral immunization [108]. In addition, attempts have been made to deliver 




drying [111,112]. These formulations claimed to maintain the stability, integrity and 
antigenicity of the encapsulated protein antigen. 
 Conjugation strategies have been equally explored to attach of the glycoconjugates or CAs or 
protein antigens to the nanoparticles [103,113,114]. In most of the cases, functionalized 
nanoparticles are attached to the glycoconjugate using a linker, which can be either one or 
two-step processes [113]. In a single-step process, the nanoparticles are directly associated 
with glycoconjugate using a linker. Whereas in a two-step process the nanoparticles are 
initially linked with the protein, and then CAs are associated with the protein nanoparticle 
conjugate. Safari et al. in 2012, conjugated a synthetic oligosaccharide known to mimic S. 
pneumoniae serotype 14 capsular polysaccharide (Pn14PS) and the ubiquitous OVA T-helper 
peptide to GNPs [114]. The intracutaneous injection of these glyco-nanoparticles with MPLA 
and Quilla saponin as adjuvants promoted the immune response. However, the phagocytic 
titer was higher in the case of the glycoconjugate [114]. Recently, the same group prepared 
the nano glycoconjugates by surface conjugating OVA, Pn14PS, D-glucose and a synthetic 
trisaccharide mimic of S. pneumoniae serotype 19F (Figure 5B). The glyco-nanoparticles were 
administered intracutaneously with Quil-A as an adjuvant and PCV 13 was used as a positive 
control. The results showed an enhanced IgG response against Pn14PS when co-administered 
with Pn19FPS in particulate form, compared to the groups administered with Pn14PS alone. 
This is a step forward in the delivery of GCs, where the antigens from two different serotypes 






Figure 5: Schematic representation of different nanoparticulate approaches employed for the delivery 
of pneumococcal vaccine antigens. 
The use of nanotechnologies can also help in co-administration of adjuvants and 
immunomodulatory agents. This can enhance the vaccine efficacy and delivery to the immune 
cells. They can be incorporated into the nanoparticles either by encapsulation, covalent 
conjugation or physical adsorption. It has been reported that emulsifying the antigens in an 
oil-based adjuvant could control the rate of antigen release from the emulsion [115,116], 
which in turn enhanced the immune potential of the vaccine. Apart from using synthetic or 
polymeric nanoparticles, the immune system has also been targeted using non-pathogenic 
bacteria, which themselves can act as a particulate carrier and exhibit adjuvant effects. In 
2007, Hanniffy et al., investigated the use of L. lactis as a particulate vaccine consisting of 
intracellularly expressed PspA. The results showed that immunization with lactococcal PspA 
showed better protection against pneumococcal respiratory challenge over the purified PspA 
[117]. The use of mucoadhesive polymers for surface modification [118] or fabricating the 




Despite several studies being conducted for the effective delivery of the glycoconjugate 
antigens, we still lack enough literature on the approaches that include both nanotechnology 
and mucosal targeting for the delivery of pneumococcal antigens. There is a need for research 
in this area, that can offer multiple benefits like protecting the antigens from degradation, 
targeting and inducing both mucosal and systemic immunity. 
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PsaA: Pneumococcal surface adhesin A; CT: Cholera toxin; PspA: Pneumococcal surface protein A; 
PLGA: Poly (lactic-co-glycolic acid); PLA: Polylactic acid; PVA: Polyvinyl alcohol; CPH: 1,6-bis(p-
carboxyphenoxy) hexane; CPTEG: 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane; PS: Pneumococcal 
polysaccharide; OVA: Ovalbumin; GNP: Gold nanoparticles; MPLA: Monophoshyl lipid A; Ply: 
Pneumolysin; PCV: Pneumococcal Conjugate Vaccine; CNP: Chitosan Nanoparticles; GFP: Green 
Fluorescent Protein; DOPG: 1,2-Dioleoylphosphatidylglycerol; DSPE: 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine; PEG: Polyethylene glycol; GlpO: α-Glycerophosphate oxidase; PncO: 
bacteriocin ABC transporter transmembrane protein; CpG-ODN: Cytosine phosphate Guanine-oligo 
deoxynucleotide; OmpC: Outer membrane protein C; PVP: Polyvinylpyrrolidone; MAA: Methacrylic 
acid; SVLP: Synthetic virus-like particles; BLP: Bacterium-like particles. 
3.2. Nanoparticle properties that affect the delivery of subunit vaccines  
There is a substantial influence of the size of nano vaccines on their biodistribution, lymph 
node trafficking, cross-protection, and evoking adaptive immune responses. Nanoparticles of 




to the lymph nodes. Studies have shown that without the aid of migratory APCs, smaller 
nanoparticles (< 100 nm) could traffic directly to the lymph nodes in less than 2 h, by using 
the convective flow from the interstitium [132]. Usually, the Th1 cell activation (cell-mediated 
immunity) is induced by particles with a size greater than 1 μm as they are taken up by 
phagocytosis that enables cross-presentation. The Th2 activation (humoral immunity) is 
induced by particles smaller than ~600 nm [133]. This is not always true; some studies have 
reported that particles smaller than ~600 nm have induced the Th1 response when they are 
co-administered with immunomodulators [134,135]. Also, such small-sized particles have 
shown to increase the efficiency of cross-presentation [133]. On the other hand, few studies 
suggested that particles of all ranges up to 1 μm may access the lymph nodes directly via 
afferent lymphatics, similar to bacterial and virus infection [97,136–138].  
Particle charge and shape play a dominant role in the cellular uptake; some studies 
demonstrate enhanced internalization of spherical particles over rod-shaped nanoparticles 
[136,139]. However, that is not the only criteria. The spherical nanoparticles were effective 
in inducing Th1 response, while the rod-shaped particles produced Th2 response [138]. In 
addition, surface properties like charge and particle hydrophobicity play a crucial role in 
delivering the antigens through the mucosal route. Positively charged nanoparticles usually 
bind to the negatively charged mucosal surfaces, increasing the contact with the mucosal 
epithelium. This can enhance the uptake of nano vaccines and generate mucosal immune 
responses [140]. Positively charged nanoparticles usually own a higher inflammatory 
potential than negatively charged or neutral nanoparticles. However, this can also be a 
disadvantage if the cationic charge is too high as it restricts the route of administration. This 
generation of an inflammatory response is essential and helps in targeting the nanoparticles 




Hydrophobicity of the particles is recognized as a danger signal by the innate immune system. 
In the human body, hydrophobic materials are mainly exposed to the immune system when 
there is an abnormal condition such as cellular disruption, against which the immune system 
is evolved to act on the basic principle of self vs non self-recognition [141,142]. This property 
can be exploited for the activation of the immune system, where the increase in 
hydrophobicity is associated with enhanced internalization by DCs and induce increased 
secretion of cytokines. In conclusion, appropriate design in the nano-vaccines can induce the 
desired immune response. Excellent reviews are available in this field that describes the 
influence of nanoparticle properties in the vaccine delivery [136,140,143].  
3.3. Uptake and processing of glycoconjugates in a nanoparticulate form:  
When particulate vaccines are administered, their fate is dependent upon the size, 
immunomodulators and the adjuvants incorporated in it. Depending on the above 
parameters, the nanoparticulate vaccines can be either phagocytosed by APCs or will be taken 
up by carrier-mediated endocytosis. The phagocytic mechanism involves the formation of the 
pseudopods around the particle, which in turn engulfs the particles forming the phagosomes. 
Internalization of the particulate vaccines by phagocytosis into phagosomes has an essential 
consequence because phagosomes are competent organelles for the antigen cross-
presentation [144,145]. The process of phagosome formation not only requires the plasma 
membrane but also involves the contribution of intracellular membranes. The endocytic 
compartments undergo fission and partial fusion with the phagosome and later mature to 





Figure 6: Processing and presentation of antigen-loaded nanoparticle by immune cells. The schematic 
representation shows the NPs are engulfed by phagocytosis. The internalized particles are processed 
inside the endosomes and presented to T cells via MHC complexes. The carbohydrates associated with 
peptides or the peptide fragments are presented to CD4 T cells via MHC II, and the activated CD4 T 
cells stimulate B cells. The B cells activated by CD4 T cells either transform memory cells or antibody-
secreting plasma cells. The peptides presented via MHC I stimulate the CD8 T cells, which in turn 
activates cytotoxic T lymphocytes that attack the infected cells.  
Furthermore, the phagocytosed particulate vaccines will undergo degradation to generate 
peptide antigens that can be loaded on to the MHC molecules [24]. After the presentation of 




complex will be recognized by the T-cell receptors (TCRs). In addition to this, a co-stimulatory 
signal is essential to induce the clonal expression and differentiation of the T-cells into the 
effector and memory cells. The absence of a co-stimulatory signal may not produce any 
immune response. The peptide-MHC II complex is recognized by B cells, which are co 
stimulated by CD4 T cells or cytokines. These B cells will undergo clonal expansion and 
differentiate to become antibody-secreting plasma cells [24]. The ability of these 
nanoparticulate vaccines to induce both the cell-mediated and humoral immunity makes 
them a distinct and appealing strategy for the delivery of the conjugate vaccines.  
4. Conclusions and perspectives 
Marketed pneumococcal vaccines are either unconjugated polysaccharides or 
polysaccharide-protein conjugates that contain the capsular polysaccharides from most 
prevalent serotypes. As the predominant serotype changes with the geographic distribution, 
the serotype dependent vaccine may not be optimal worldwide. Even though the 
polysaccharide-based conjugate vaccines have conferred greater protection in the children 
and elderly. A protein-based vaccine containing several pneumococcal proteins in a single 
formulation, which is a serotype independent, could be a better and cheaper alternative for 
existing vaccines. Currently, several subunit pneumococcal vaccines are in the pipeline and 
clinical market, and they are discussed in detail in this review. However, to date, there are no 
pneumococcal vaccines based on PPAs available in the market. Recently, there is progress in 
the use of nanotechnological approaches for encapsulating several pneumococcal proteins 
and polysaccharides. This advancement using the nanotechnological approach is mainly 
focused on augmenting the vaccine efficiency and delivery of the sub-unit vaccines. The 




future, may produce a needle-free and adjuvant free delivery system that can render the 
protection against all the pneumococcal serotypes. Even though, these novel technologies 
provide the hope of safer and efficient vaccine delivery, their translation to demonstrate their 
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Polysaccharide vaccines alone are weak antigens and fail to generate the strong immune 
response in the children and immunocompromised patients [1] and therefore, they are 
generally conjugated to carrier proteins like TT, DT or CRM 197. In diseases like Pneumonia, 
96 different pneumococcal serotypes are responsible for causing the infection [2]. In this case, 
the polysaccharide component from each serotype needs to be incorporated in the vaccine 
to elicit the protection. However, the preparation of the vaccine comprising of capsular 
polysaccharide components from each serotype is highly difficult, expensive and time 
consuming. Currently, two types of pneumococcal vaccines are in use; a 23 valent 
pneumococcal polysaccharide vaccine (PPV23) that consists of mixture of polysaccharide 
antigens from different pneumococcal serotypes; and the other group consists of 
pneumococcal conjugate vaccines (PCV-7, 10, 13), in which the polysaccharide antigens are 
conjugated to carrier proteins to generate potent immune response in children. However, 
these pneumococcal vaccines can protect only against the infections caused by a limited 
number of serotypes, whose polysaccharides are incorporated in the vaccine and at the same 
time, they are associated with the problem of serotype replacement.  
In this line, researchers have identified proteins that are commonly present in all the 
pneumococcal serotypes and can act as an antigen [3]. These pneumococcal proteins have 
been effective in generating a protective response in the immunized individuals [4–6]. As the 
protein antigens are sub-unit vaccines, they should be either accompanied with suitable 
adjuvant, carrier or both. However, the major hurdle lies in developing an efficient vaccine 
delivery system. In recent years, the use of biocompatible and biodegradable polymers has 
been investigated as adjuvants and antigen carriers. Amongst them, chitosan continues to 
show tremendous potential as it is non-toxic, biocompatible, biodegradable polymer that has 
mucoadhesive and immunostimulatory properties [7]. Use of these particulate systems will 
help in protecting the antigen from degradation and the mimic the pathogen in size, shape or 
by carrying the antigens on the surface. Therefore, in our studies, we adopted chitosan 





- The use of common pneumococcal protein, Pneumococcal surface adhesin A (PsaA), as a 
carrier protein for preparation of glycoconjugate, might produce serotype-independent 
immune response. We hypothesize that it would be possible to replace the traditional carrier 
proteins like TT, DT and CRM 197 with PsaA. The PsaA conjugated to tetrasaccharide in this 
study can act both as carrier and the antigen. 
- Further encapsulation of these glycoconjugates into the polymeric nano-systems could 
improve their presentation to the immune cells, thereby generating enhanced immune 
response. The utilization of chitosan nanoparticles that are biocompatible, biodegradable, 
mucoadhesive and immunostimulatory properties can help in the effective delivery of the 
glycoconjugate antigens via mucosal route.  
- Targeting of glycoconjugates via mucosal routes using the chitosan nanoparticles might 
generate both systemic (IgG) and mucosal (IgA) immune responses and offer protection 
against invasive pneumococcal infections. 
In summary, we hypothesize that the strategies proposed in this thesis might result in an 
improved pneumococcal vaccine formulation that enables needle free vaccine delivery and 
protect against invasive pneumococcal infections.  
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Objectives:   
 
The overall goal of this thesis is to develop a improved pneumococcal vaccine formulation 
based on semisynthetic glycoconjugate antigen. In order accomplish this, studies are 
organised into several specific goals as shown below. 
Objective 1: Preparation and characterization of a semisynthetic glycoconjugate antigen, 
including:   
• Synthesis of the tetrasaccharide antigen that mimic the capsular polysaccharide of 
Streptococcus pneumoniae serotype 14 (Pn14TS). 
• Expression and purification of Pneumococcal surface adhesin A (PsaA) using 
recombinant DNA technology in E. coli. 
• Synthesis and characterization of glycoconjugate vaccine (GC) using produced Pn14TS 
and PsaA. 
The results corresponding to this objective are presented in the chapter 1: “Semisynthetic 
glycoconjugate based on dual role protein/PsaA as a pneumococcal vaccine” and have already 
been published. 
 
Objective 2: Development and characterization of polymeric nanosystems encapsulating the 
synthesised glycoconjugate antigen. 
• Preparation of glycoconjugate loaded chitosan nanoparticles using ionic gelation 
method, and their characterization. 
• To study the ability of the nanosystems to enhance the immune response against the 
glycoconjugate antigens. 
• To compare the immune response obtained after systemic and mucosal 
immunizations. 
The results corresponding to this objective are presented in the chapter 2: “Chitosan 





Objective 3: Evaluation of in vitro efficiency of glycoconjugate loaded nanoparticles 
• To study the cytocompatibility and internalization of prepared nanoparticles with the 
human monocyte-derived dendritic cells. 
• To study the interaction of the prepared nanosystems with the dendritic cells. 
The results corresponding to this objective are presented in the chapter 3: “Interaction of 
glycoconjugate loaded chitosan nanoparticles with human dendritic cells”. 
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Semisynthetic glycoconjugate based on dual role protein/PsaA as a pneumococcal vaccine 
 
Abstract 
Pneumococcal infections remain a major public health concern worldwide. The currently 
available vaccines in the market are based on pneumococcal capsular polysaccharides but 
they still need to be improved to secure an optimal coverage notably in population at risk. To 
circumvent this, association of virulence pneumococcal proteins to the polysaccharide 
valencies has been proposed with the hope to observe an additive - if not synergistic - 
protective effect. Along this line, the use of the highly conserved and ubiquitous 
pneumococcal surface adhesin A (PsaA) as a protein carrier for a synthetic pneumococcal 
oligosaccharide is demonstrated herein for the first time. A tetrasaccharide mimicking 
functional antigenic determinants from the S. pneumoniae serotype 14 capsular 
polysaccharide (Pn14TS) was chemically synthesised. The mature PsaA (mPsaA) was 
expressed in E. coli and purified using affinity chromatography. The Pn14PS was conjugated 
to mPsaA using maleimide-thiol coupling chemistry to obtain mPsaA-Pn14PS conjugate 
(protein/sugar molar ratio: 1/5.4). The mPsaA retained the structural conformation after the 
conjugation and lyophilisation. The prepared glycoconjugate adjuvanted with α-
galactosylceramide, a potent activator of invariant Natural Killer T cells, was tested in mice 
for its immunological response upon subcutaneous injection in comparison with mPsaA alone 
and a model BSA conjugate (BSA-Pn14PS, used here as a control). Mice immunised with the 
mPsaA-Pn14TS produced a robust IgG response against mPsaA and against the capsular 
polysaccharide from pneumococcal serotype 14. These data provide the basis for novel 
pneumococcal vaccine development. 
 
Keywords: Glycoconjugate vaccine, Carbohydrate antigens, pneumococcal surface adhesin 














Streptococcus pneumoniae is a leading cause of mortality and morbidity in children and the 
elderly population. It is responsible for infections like pneumonia, otitis media, meningitis and 
bacteraemia which accounts for an estimated number of 800,000 deaths in children annually 
[1]. The polysaccharide subunits expressed by pneumococci are anchored to the cell wall 
surface and preventing the clearance of pneumococci from the lung and protecting them from 
complement-mediated opsonophagocytosis [2]. Polysaccharide chains act as early target 
antigens as their production is essential for pneumococcal colonisation and virulence. These 
polysaccharides are highly immunogenic and induce the production of antibodies that react 
with homologous serotype [3].  
Capsular polysaccharide (CP) vaccines currently in use for adults have only weak or no efficacy 
towards pneumonia and bronchitis caused by S. pneumoniae [3]. The protection level of a 
vaccinated individual varies depending on the location as the prevalence of serotype varies 
significantly among the continents. Due to this phenomenon, the capsular serotypes used as 
vaccine antigens are monitored internationally [1]. The inability of the polysaccharide 
vaccines to elicit a protective immune response in toddlers and young children have given 
way for the development of improved vaccines. Polysaccharides are T-cell independent 
antigens, and they do not elicit any protective immune response in infants and children, but 
conjugating them to a protein makes them T-cell dependent and immunogenic in the same 
population [4].  Researchers have tried conjugating capsular polysaccharide to carrier 
proteins like tetanus toxoid, diphtheria toxin, and cross-reactive material of diphtheria toxoid 




dependent antibody response and higher antibody titers in children and high-risk individuals 
[5,6]. Glycoconjugate vaccines such as the heptavalent (PCV7) vaccine and the more recent 
tridecavalent (PCV13) pneumococcal vaccine are promising in preventing pneumonia caused 
by the corresponding serotypes. However, it is still not clear whether it is by preventing 
nasopharyngeal colonisation or by improving adaptive immune response in the lungs. The 
overall protection mechanism against the S. pneumoniae infection is not clearly understood, 
which hinders the design of more efficacious novel vaccines [7]. 
There is a need for pneumococcal vaccines with broader coverage against the pneumococcal 
serotypes. As capsular polysaccharides are serotype specific, researchers have focused on 
identifying protein immunogens which can offer complete serotype coverage and generate 
enhanced protection. Along with this line, pneumococcal surface adhesin A (PsaA) is a 
membrane-associated metal binding lipoprotein [8], which is highly conserved and essential 
for the survival and virulence of the bacteria [9]. PsaA is involved in the adhesion and 
colonisation of nasopharyngeal epithelium by the pneumococci. Its presence in all serotypes 
of pneumococci along with its ability to generate robust responses in infants or elderly 
population further contribute to make it an ideal candidate for pneumococcal vaccine 
formulations [10,11]. Indeed, PsaA used as immunogen was able to prevent entry of the 
pathogen noticeably by reducing the nasal carriage of the pathogen and even to confer 
protection when combined with adjuvants in animal models [12–15]. Alternatively, PsaA has 
also been used as a carrier protein in glycoconjugate vaccines which has already 
demonstrated protection in animal models [16,17]. Additionally, the concomitant 
administration of PsaA with PCV7 reduced the colonization in the murine models [18]. In 




PsaA as a carrier for synthetic oligosaccharides mimicking full-length CP remains to be 
documented. To this aim, the capsular polysaccharide of the S. Pneumoniae type 14 consists 
of the repeating units of {6)-[β-D-Galp-(1→4)-]β-D-GlcpNAc-(1→3)-β-D-Galp-(1→4)-β-D-Glcp-
(1→}n [19]. The tetrasaccharide β-D-Galp-(1→4)-β-D-Glcp-(1→6)-[β-D-Galp-(1→4)]-β-D-
GlcpNAc (referred to as Pn14TS) has been identified as the smallest oligosaccharide of the 
serotype 14 that is capable of inducing opsonophagocytic response when coupled to the 
carrier proteins like CRM197 [20]. It possesses higher protective properties as compared to 
related hexa- or octasaccharides when conjugated [21]. In this study, we thus propose to 
produce this synthetic mimic of S. pneumoniae type 14 CP and to conjugate it to 
pneumococcal PsaA, using thiol maleimide coupling chemistry to obtain a semisynthetic 
glycoconjugate vaccine. The immunogenicity of the obtained glycoconjugate was studied in 
BALB/c mice. As an adjuvant, we chose α-galactosylceramide (α-GalCer), a potent activator of 
invariant Natural Killer T (iNKT) cells [22,23]. 
2. Materials and Methods 
2.1. Mice and ethics statement 
Specific pathogen-free C57BL/6 mice (6 week-old, female) were purchased from Janvier (Le 
Genest-St-Isle, France). Mice were maintained in a biosafety level 2 facility in the Animal 
Resource Centre at the Lille Pasteur Institute for at least two weeks prior to usage, to allow 
appropriate acclimation. Mice were fed a standard rodent chow (SAFE A04) (SAFE, Augy, 
France) and water ad libitium. The diet contains ~11.8% fiber including ~10% water-insoluble 
fiber (3.6% cellulose) and 1.8% water-soluble fiber. All the animal experiments were 
performed at Lille Pasteur institute according to the ethical guidelines (agreement number AF 




2.2. Materials and general methods 
The antibiotic ampicillin was purchased from PanReac Applichem, chloramphenicol and 
kanamycin were purchased from Sigma Aldrich, and the LB culture medium was purchased 
from VWR. The isopropyl thiogalactoside (IPTG) used in the induction of protein was obtained 
from Alfa-Aesar. The NiNTA beads used in the affinity chromatography for the purification of 
the PsaA were obtained from Macherey-Nagel. The linker S-acetylthioacetate N-Hydroxy 
succinimide (SATA-NHS) and 6-maleimidocaproic acid succinimidyl ester were obtained from 
Merck and Interchim, respectively. The adjuvant α-GalCer was produced by Dr. B. Frisch 
(University of Strasbourg).  All reagents were purchased from commercial sources and used 
without further purification. Reactions were monitored by thin-layer chromatography (TLC) 
on 0.25 mm silica gel plates with fluorescent indicator (GF254) and visualised under UV light. 
Detection was done by charring with vanillin in sulfuric acid/ethanol (1.5:95 v/v). Flash-
chromatography purifications were made on silica gel columns (4 to 80 g, 240-400 mesh) 
using an automated Reveleris Flash Chromatography System (Grace Alltech) equipped by 
both ELS (Evaporative Light Scattering) and UV/diode array allowing the simultaneous use of 
two customizable wavelength detectors.   
RP-HPLC separation was performed on a Uptisphere Strategy 100 Å C18HQ (Interchim, 
France) (5 µm, 21.2 × 250 mm) column at a flow rate of 6 mL min−1 with ELSD and UV (225 
nm) detection. Gradient: 0% B for 5 min, 0–5% B over 5 min, 10–80% B over 30 min, 80% B 
for 5 min; Solvent system A:  H2O; solvent system B: MeOH. 
All NMR experiments were performed at 400 MHz using Bruker Avance 400 MHz 
spectrometers equipped with a DUAL+ 1H/13C ATMA grad 5 mm probe. Assignments were 




programs from the Bruker library. Chemical shifts are given relative to external TMS with 
calibration involving the residual solvent signals. 
High-resolution mass spectra were recorded in positive mode on Waters SYNAPT G2-Si HDMS 
with detection with a hybrid quadrupole time of flight (Q-TOF) detector. The compounds were 
individually dissolved in MeOH at a concentration of 1 mg/mL and then infused into the 
electrospray ion source at a flow rate of 10 µl.min−1 at 100°C. The mass spectrometer was 
operated at 3 kV while scanning the magnet at a typical range of 4000-100 Da. The mass 
spectra were collected as continuum profile data. An accurate mass measurement was 
achieved based on every five-second auto-calibration using leucine-enkephalin ([M+H]+ = 
556.2771 m/z) as an internal standard. PsaA mass spectra were determined on an Autoflex III 
MALDI-TOF/TOF spectrometer (Bruker Daltonics) in positive ionisation modes and with a 
linear detection. 75 pmol of each sample was deposited on the MALDI target plate and were 
mixed with sinapinic acid as the matrix (10 mg mL−1; H2O–CH3CN–TFA, 50:50:0.1). The mass 
spectrometer was calibrated with a standard of BSA (15 pmol on target) on dimer and 





2.3. Synthesis of Pneumococcal serotype 14 tetrasaccharide (Pn14TS) 
2.3.1. 2-azidoethyl (2,3,4,6-tetra-O-benzoyl--D-galactopyranosyl)-(1→4)-6-O-tert-
butyldimethylsilyl-2-deoxy-2-phtalimido--D-glucopyranoside 3 
2,3,4,6-tera-O-benzoyl-D-galactopyranose trichloroacetimidate donor 1 (446 mg, 0.60 mmol) 
and 2-azidoethyl 2-deoxy-6-O-TBDMS-2-phtalimido-β-D-glucopyranoside acceptor 2 (270 mg, 
0.55 mmol) were mixed with molecular sieves (MS4Å) in CH2Cl2 (5 mL). The mixture was 
cooled to 0°C, then TMSOTf (32 µl) was added and the reaction mixture stirred at this 
temperature for 1h. The reaction was quenched upon addition of Et3N (0.1 mL), and the 
resulting mixture was filtered through a Celite pad. The filtrate was concentrated, and the 
crude residue was purified by flash-chromatography on silica gel (eluent gradient of 
cyclohexane/EtOAc) to give disaccharide 3 (352 mg, 60%). (Rf = 0.63, EtOAc/Cyclohexane = 
6:4); 1H NMR (400 MHz, CDCl3): δ 8.02-7.15 (m, 24H), 5.88 (d, J = 3.5 Hz, 1H), 5.77 (dd, J = 8.0, 
10.5 Hz, 1H), 5.49 (dd, J = 3.5, 10.5 Hz, 1H), 5.18 (d, J = 8.5 Hz, 1H), 4.94 (d, J = 8.0 Hz, 1H), 
4.63-4.49 (m, 2H), 4.32-4.27 (m, 2H), 4.19 (d, J = 1.5 Hz, 1H), 4.10 (dd, J = 8.5, 10.8 Hz, 1H), 
3.85 (ddd, J = 3.6, 5.3, 10.6 Hz, 1H), 3.74 (t, J = 8.7 Hz, 1H), 3.60-3.55 (m, 1H), 3.52 (ddd, J = 
3.6, 7.6, 10.6 Hz, 1H), 3.43 (dt, J = 2.2, 9.7 Hz, 1H), 3.27 (ddd, J = 3.7, 7.8, 13.3 Hz, 1H), 3.07 
(ddd, J = 3.6, 5.3, 13.3 Hz, 1H), 0.76 (s, 9H), -0.14 (s, 3H), -0.15 (s, 3H); HR-ESI-MS: m/z Calcd 
for C56H58N4O16Si. [M+Na]+ 1093.3539, found 1093.3508. 
2.3.2. 2-azidoethyl 2,3,4,6-tetra-O-acetyl-(2,3,4,6-tetra-O-benzoyl-β-D-galactopyranosyl)-
(1→4)-2-deoxy-2-phtalimido--D-glucopyranoside 4 
To disaccharide 3 (250 mg, 0.23 mmol) dissolved in CH3CN (5.8 mL) in a 15 mL teflon tube, 
was added aqueous solution of HF (48%, 306 µl) at 0°C. The reaction mixture was stirred for 
30 min at RT and then neutralized upon addition of solid NaHCO3. The mixture was diluted in 




concentrated under reduced pressure. The crude residue was purified by flash-
chromatography on silica gel (eluent gradient of cyclohexane/EtOAc) to give disaccharide 4 
(169 mg, 76%). (Rf = 0.40, EtOAc/Cyclohexane = 4:6); 1H NMR (400 MHz, CDCl3): δ 8.08-7.23 
(m, 24H), 5.97 (d, J = 3.4 Hz, 1H), 5.87 (dd, J = 8.0, 10.4 Hz, 1H), 5.60 (dd, J = 3.4, 10.4 Hz, 1H), 
5.32 (d, J = 8.5 Hz, 1H), 5.04 (d, J = 8.0 Hz, 1H), 4.67 (dd, J = 3.4, 11.5 Hz, 1H), 4.60 (broad d t, 
J = 9.5 Hz, 1H), 4.43-4.32 (m, 3H), 4.23 (dd, J = 8.6, 10.7 Hz, 1H), 3.85 (ddd, J = 2.4, 5.2, 10.7 
Hz, 1H), 3.74 (t, J = 8.9 Hz, 1H), 3.60-3.50 (m, 4H), 3.33 (ddd, J = 3.4, 5.8, 13.3 Hz, 1H), 3.17 
(ddd, J = 3.4, 5.2, 13.3 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ 168.0, 166.1, 165.8, 165.3, 133.9, 
133.7, 133.6, 133.3, 133.2, 131.9, 130.0, 129.9, 129.8, 129.0, 128.8, 128.7, 128.7, 128.6, 
128.4, 128.3, 102.2, 98.4, 82.1, 74.3, 72.4, 71.5, 69.6, 69.6, 68.6, 68.1, 62.7, 60.6, 55.8, 50.4; 




Imidate donor 5 (134 mg, 0.17 mmol, 1.2 equiv) and acceptor 4 (137 mg, 0.143 mmol) were 
mixed with molecular sieves (MS 4 Å) in CH2Cl2 (5 mL). Then TMSOTf (28 µl) was added and 
the reaction mixture stirred at RT overnight. The reaction was quenched upon addition of 
Et3N (0.1 mL), and the resulting mixture was filtered through a Celite pad. The filtrate was 
concentrated, and the crude residue was purified by flash-chromatography on silica gel 
(eluent gradient of cyclohexane/EtOAc) to give tetrasaccharide 6 (124 mg, 55%). (Rf = 0.48, 
EtOAc/Cyclohexane = 6:4); 1H NMR (400 MHz, CDCl3): δ 7.98-7.13 (m, 24H), 5.87 (d, J = 3.50 
Hz, 1H), 5.76 (dd, J = 7.9, 10.4 Hz, 1H), 5.57 (dd, J = 3.5, 10.4 Hz, 1H), 5.28 (d, J = 3.6 Hz, 1H), 
5.15 (d, J = 10.5 Hz, 1H), 5.04 (dd, J = 7.9, 10.4 Hz, 1H), 4.93-4.87 (m, 3H), 4.75 (dd, J = 7.5, 8.8 




= 2.2, 12.9 Hz, 1H), 4.26 (dd, J = 8.4, 11.6 Hz, 1H), 4.10 (dd, J = 8.6, 10.9 Hz, 1H), 4.04-3.99 (m, 
2H), 3.95 (dd, J = 5.4, 12.0 Hz, 1H), 3.89-3.81 (m, 2H), 3.70-3.59 (m, 3H), 3.54-3.42 (m, 2H), 
3.28 (ddd, J = 3.5, 8.1, 13.5 Hz, 1H), 3.17-3.14 (ddd, J = 3.4, 5.8, 13.3 Hz, 1H), 3.08 (ddd, J = 
3.4, 5.2, 13.3 Hz, 1H), 2.23 (s, 3H), 2.08 (s, 3H), 2.06 (s, 3H), 2.00 (s, 6H), 1.97 (s, 3H), 1.96 (s, 
3H), 1.89 (s, 3H);  13C NMR (100 MHz, CDCl3): δ 171.0, 170.5, 170.4, 170.2, 170.1, 169.9, 169.5, 
169.2, 168.0, 166.2, 166.4, 166.4, 164.9, 134.1, 133.9, 133.7, 133.4, 130.8, 130.0, 129.9, 
129.9, 129.8, 129.7, 128.0, 128.9, 128.8, 128.7, 128.7, 128.5, 128.4, 128.3, 126.1, 101.9, 
101.2, 100.4, 98.2, 83.1,  76.1, 73.5, 72.9, 72.5, 72.3, 71.8, 71.4, 71.0, 70.6, 69.8, 69.2, 68.5, 
68.2, 66.8, 62.7, 62.0, 60.9, 60.4, 55.7, 55.5, 50.4, 21.0, 20.9, 20.8, 20.6, 20.5, 19.8; HR-ESI-
MS: m/z Calcd for C76H78N4O33. [M+Na]+ 1597.4446, found 1597.4384. 
2.3.4. 2-azidoethyl (-D-galactopyranosyl)-(1→4)-(-D-galactopyranosyl)-(1→6)-[(-D-
galactopyranosyl)-(1→4)]-2-deoxy-2-acetamido--D-glucopyranoside 8 
Per acetylated tetrasaccharide 7 (45 mg, 0.035 mmol) dissolved in MeOH (400 µl) was reacted 
with a 2.5M solution of sodium methoxide in MeOH (5 µl) overnight at RT. The reaction 
mixture was quenched with Amberlite® resin IR120 (H+ form), filtered and concentrated to 
reduced pressure to furnished tetrasaccharide 8 (27 mg, quantitative); (Rf = 0.50, 
nBuOH/EtOH/H2O = 5:5:3); 1H NMR (400 MHz, D2O): δ 4.58 (d, J = 8.2 Hz, 1H), 4.53 (d, J = 8.0 
Hz, 1H), 4.50 (d, J = 7.8 Hz, 1H), 4.42 (d, J = 7.8 Hz, 1H), 4.27 (dd, J = 2.7, 11.2 Hz, 1H), 4.02 
(ddd, J = 3.1, 5.5, 11.4 Hz, 1H), 3.97-3.92 (m, 2H), 3.90 (d, J = 3.3 Hz, 1H), 3.84-3.77 (m, 2H),  
3.76-3.67 (m, 11H), 3.66-3.62 (m, 5H), 3.60-3.55 (m, 1H), 3.54-3.47 (m, 2H), 3.42 (ddd, J = 3.1, 
7.3, 10.4 Hz, 1H), 3.36 (ddd, J = 3.1, 4.5, 13.3 Hz, 1H), 2.01 (s, 3H); 13C NMR (100 MHz, D2O): δ 
174.7, 103.0, 102.8, 102.5, 101.1, 78.5, 77.9, 75.4, 75.3, 74.8, 74.3, 73.6, 72.7, 72.6, 72.6, 72.4, 






To a mixture of NaBH4 (2.60 mg) and 10% Pd/C (1.15 mg) in H2O was added azide derivative 
8 (25 mg) dissolved in aqueous NaOH 0.1M (305 µl). The reaction mixture was stirred until 
complete reduction of the azide (monitored by TLC). Then the reaction mixture is filtered over 
a Celite pad, neutralized with amberlite IR120 (H+ form), filtered and lyophilised to furnish 9 
(22 mg, 91%); Rf = 0, nBuOH/EtOH/H2O = 5:5:3); 1H NMR (400 MHz, D2O): δ 4.55 (d, J = 8.3 Hz, 
1H), 4.52 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 7.8 Hz, 1H), 4.42 (d, J = 7.8 Hz, 1H), 4.27 (dd, J = 2.2, 
11.4 Hz, 1H), 4.03-3.92 (m, 3H), 3.89 (d, J = 3.3 Hz, 1H), 3.86-3.60 (m, 19H),  3.60-3.55 (m, 1H), 
3.54-3.47 (m, 2H), 3.36-3.31 (m, 1H), 3.16-3.15 (m, 2H), 2.01 (s, 3H); 13C NMR (100 MHz, D2O): 
δ 174.9, 103.0, 102.8, 102.4, 101.1, 78.5, 77.7, 75.4, 75.3, 74.7, 74.4, 73.3, 72.7, 72.6, 72.5, 
72.2, 71.0, 71.0, 68.6, 68.6, 67.4, 66.4, 61.1, 61.0, 60.1, 55.0, 39.5, 22.2;  HR-ESI-MS: m/z Calcd 
for C28H50N2O21 [M+H]+ 751.2984, found 751.3016. 
2.3.6. 2-(N-6-maleimidocaproyl)ethyl (-D-galactopyranosyl)-(1→4)-(-D-
galactopyranosyl)-(1→6)-[(-D-galactopyranosyl)-(1→4)]-2-deoxy-2-acetamido--D-
glucopyranoside 10 (Pn14TS-mal) 
To a solution of compound 9 (20 mg, 0.026 mmol, 1.03 equiv) in DMSO were successively 
added 6-maleimido-caproic acid succinimidyl ester (8 mg, 1 equiv) and DIEA (10 µl) at RT. The 
reaction mixture was stirred at 30°C overnight, diluted in water and freeze-dried. The crude 
residue was purified by RP-HPLC to provide 10 (Pn14TS-mal) (11.5 mg, 46% yield); 1H NMR 
(400 MHz, D2O): δ 4.54-4.50 (m, 3H), 4.43 (d, J = 7.8 Hz, 1H), 4.26 (dd, J = 2.4, 11.2 Hz, 1H), 
3.97-3.47 (m, 24H), 3.38-3.31 (m, 3H), 2.21 (t, J = 7.4 Hz, 2H), 2.00 (s, 3H), 1.61-1.62 (m, 4H), 




2.4. mPsaA expression vector 
The HtTEV-mPsaA plasmid, consisting of the gene coding for mature PsaA (without signal 
peptide) from S. pneumoniae in fusion with a histidine tag separated by a TEV protease 
cleavage site cloned between NdeI and BamHI sites of the pEt11a vector, was purchased from 
Genscript. The recombinant plasmid was transformed into Escherichia coli BL21(DE3) using 
the heat shock method, and the stocks were maintained at -80°C in 20% glycerol. The host 
bacteria E. coli strains XL1 blue and BL21(DE3), used for cloning and protein expression were 
obtained from Millipore. 
2.5. Expression and purification of HtTEV-mPsaA 
The expression of HtTEV-mPsaA protein was performed according to the following protocol. 
Briefly, 1000 mL of fresh LB medium with 25 µg/mL ampicillin were inoculated with 50 mL of 
overnight pre-culture and left to grow at 37°C, 180 rpm until they reached an exponential 
phase (approximately OD of 0.6/0.7) and at this point the HtTEV-mPsaA expression in the 
cultures was induced with IPTG (1mM final concentration). The cultures were left to grow for 
another 4h at 37°C and 180 rpm. The cells were harvested by centrifugation at 10 000 rpm. 
The pellet was resuspended in 50 mL cold lysis buffer (50 mM NaH2PO4, 150 mM NaCl, pH 
8.0) and was subjected to sonication (10-20 min, 50% amplitude, pulse of 5 sec ON/OFF) in 
ice, and the cell debris was removed by centrifugation (20 min, 13,000 rpm). The protein was 
then purified by affinity chromatography as follows. The obtained supernatant was incubated 
with 1 mL of preconditioned NiNTA beads for 1h on rotating disk at 4°C, 12 rpm. Unbound 
fraction was collected, and the beads were washed with a lysis buffer containing 20 mM 
imidazole. The elution was performed with a lysis buffer containing different fractions of 




fractions containing target protein. The eluted fractions, containing the target protein (40 
mg/l of culture), were pooled and dialysed against 0.1 M PBS at 4°C. 
2.6. Removal of histidine tag from HtTEV-mPsaA and western blot analysis 
The enzymatic cleavage of the histidine tag from the HtTEV-mPsaA was performed using the 
AcTEVTM protease (Invitrogen) flanked with a 6-histidine tag. The removal of the histidine tag 
was performed using at 8:1 HtTEV-mPsaA/ AcTEVTM protease ratio in the reaction buffer (50 
mM Tris-HCl (pH 7.6), 1 mM EDTA, 1 mM DTT), for 4h at 4°C. The reaction mixture was 
incubated with the NiNTA beads for the separation of the cleaved mPsaA from the histidine 
tag, not digested HtTEV-mPsaA and the TEV protease. The eluate was collected and subjected 
to SDS-PAGE, western blot and MALDI TOF mass spectrometry to confirm the complete 
removal of the histidine tag. 
For the western blot, the vertical SDS-PAGE was carried out using 12% acrylamide gels with 
the loadings of the reaction mixture and HtPsaA and AcTEV™ protease as controls using the 
Bio-rad system. The proteins were transferred to a nitrocellulose membrane at 200 V for 60 
min. For the antibody probing, the nitrocellulose membrane was initially blocked with PBS 
containing 5% skimmed milk and 0.1% tween 20 for 1 h at room temperature. A primary 
antibody to mouse anti-poly his (Sigma H1029, diluted 1:1000) was applied to the membrane 
and incubated for 1h at RT. The membranes were washed thrice with PBS containing 0.1% 
Tween 20® and incubated with secondary antibody (Goat anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor 680) for 30 min at RT on a shaker. Membranes were subjected to a final 






2.7. Glycoconjugate synthesis 
S-acetyl-thioacetate succinimidyl ester was added to a solution of purified mPsaA (10 mg) in 
PBS 0.2M, pH 7.4 (1mL), in three portions every 45 min (3× 2.85 mg, 3×40 equiv) and the 
resulting mixture stirred for further 45min to give rise to mPsaA-SATA. The excess of reagents 
was removed by dialysis using 0.1M potassium phosphate buffer, pH 6.6. Later, a 2M solution 
of NH2OH-HCl (4.61 µl) was to a mixture of mPsaA-SATA (3 mg) and Pn14TS-maleimide (1.31 
mg) (1:15 ratio) in 0.1M potassium phosphate buffer, pH 6.6. The reaction mixture was stirred 
at RT for 1 h and then purified by gel filtration using a HiLoad 15/600 Superdex™ 75pg (GE 
Healthcare) column and PBS 0.1M, pH7.3 as eluent. BSA-Pn14TS conjugate was prepared 
analogously. 
The colorimetric methods were used to determined sugar/protein ratios in the 
glycoconjugates. (i) Bradford assay (BioRad protein assay) was used to determine the 
concentration of the protein. (ii) The anthrone /sulphuric acid method [24] was used for the 
quantification of the tetrasaccharide. 
2.8. Conformational stability of the PsaA derivatives 
The conformational stability of the protein at different storage conditions was monitored by 
Circular Dichroism (CD) spectroscopy (Jasco J-810 spectropolarimeter). The PsaA samples 
with the concentration of 0.05 mg/mL in 0.1M PBS were prepared and measured using the 
quartz cells with 1 mm path length. The instrument parameters were 0.1 nm bandwidth, with 
a scanning range between 190 to 250 nm at the scanning speed of 50 nm/min, a temperature 





2.9. Immunizations and preparation of the hyperimmune serum 
Female BALB/c mice were injected sub-cutaneously (s.c.) with PBS, mPsaA, mPsaA-Pn14TS or 
BSA-Pn14TS, (25 μg protein/dose). All mice were administered with 250 ng of α-GalCer as an 
adjuvant. The mice were immunized on day 0 and boosted at day 21, 90 and 120. The serum 
was collected on day 28, 98 and 128. To obtain anti-Sp14 Abs, mice were infected (i.n.) at day 
0 and 15 with S. pneumoniae serotype 14 (1x106 c.f.u.). Two weeks off the last challenge, mice 
were bled. Sera were stored at -80 °C. 
2.10. Measurement of humoral response 
The Ab responses induced upon immunisation were assessed one week after the second, the 
third and the fourth injections by ELISA. mPsaA, mPsaA-Pn14TS, mPsaA-BSA and CP14 
(Alliance Bio Expertise), were used as coated antigens to define the anti-mPsaA, anti-Pn14TS, 
and anti-CP14 Ab titers. mPsaA (0.1 µg/well) or conjugates (0.2 µg/well) in 10mM PBS, pH 7.3 
(100 µl/well), were coated on 96 wells microtitre Nunc Maxisorp (ThermoFisher Scientific) 
plates overnight at 4 °C. CP14 (1 µg/well) was coated for 48h at 4°C in in 10mM PBS, pH 7.3 
(100 µg/well). Plates were then washed with PBS 0.05% Tween ® 20 (3×200 µl), saturated 
using PBS containing 10% skimmed milk at 37°C for 2h, then washed using PBS -Tris-Tween ® 
20 (TBST, 50mM Tris, 150mM NaCl, 0,1% Tween 20) (3×200 µl). Series of dilution of sera in 
PBS containing 10% skimmed milk (100 µl/well), were incubated at 37°C for 2h. Plates were 
then washed with TBST (3×200 µl) and then incubated with goat anti-mouse IgG(H+L)-horse 
radish peroxidase-labelled conjugate (CliniSciences) used as secondary Ab at a dilution of 
1/6,000, for 1h at 37°C and further washed with TPBS (5×200 µl). The enzyme substrate, o-
phenylenediamine dihydrochloride (100 μL at 0.4 mg mL−1) in 0.1 M sodium citrate (pH 5.2), 




min at RT in the dark. The reaction was terminated by adding 3 M HCl (1000 μL per well), and 
the A492 was read in an Infinite M1000 spectrophotometer (TECAN). The Ab titer was defined 
as the dilution of immune serum that gave an OD (405 nm) at least twice that observed with 
pre-immune serum.  
2.11. Statistical analysis 
Statistical analysis was done using Graph pad 7. To analyse multiple serum samples, the 
follow-up study Kruskal-Wallis analysis with Dunn's test was adopted, and the comparison of 
paired values was performed with the use of the analysis of variance (ANOVA for repeated 
measures test. Two-tailed p values less than 0.05 were considered significant. 
3. Results 
3.1. Synthesis of antigen tetrasaccharide  
Chemo-enzymatic and chemical synthesis of the pneumococcal serotype 14 tetrasaccharides 
have been previously reported in the literature. The former relies on the beta-(1-->4)-
connection of the galactose residue to the N-acetyl-β-D-glucosamine residue by using bovine 
milk β-1,4-galactosyltransferase [25,26]. Chemical synthesis is based on an obvious [2+2] 
approach consisting in the glycosylation of lactose donor with a lactosamine acceptor which, 
in turn, is obtained from a glycosylation between a galactose donor and a glucosamine 
acceptor [20,27–31]. Our synthetic strategy was inspired mainly by that reported by Deng et 
al. [31] without improved yield but lesser synthetic steps. We elected to carry out the first 
glycosylation using perbenzoylated trichloracetimidate donor 1 [32] with diol 2 (Scheme 1). 
Indeed, the full protection of the glucosamine acceptor is not required as the glycosylation is 




by the 2-naphthamido protecting group in derivative 2 [27,33]. Thus, glycosylation of 1 and 2 
in the presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf) gave rise to 
disaccharide 3 in 60% yield, further treated with HF-pyridine complex to remove the silyl 
protecting group at the 6-OH position of the glucosamine moiety to furnish the disaccharide 
acceptor 4 in 76% yield.  Next, acceptor 4 was glycosylated with imidate 5 used in slight excess 
using TMSOTf as the promoter to give tetrasaccharide 6 in 55% yield. Exchange of 
naphthamide to acetamide group was carried out according to Deng et al. procedure [31] to 
give intermediate 7 which was treated under Zemplén condition to provide target Pn14TS 
antigen 8 equipped with a 2-azidoethyl spacer arm downstream. Derivative 10 ready for 
conjugation was finally obtained after azide reduction in 8 to give amine intermediate 9 
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Scheme 1. Synthesis of Pn14TS antigen. Reagents and conditions: a, cat TMSOTf , MS4Å, 
CH2Cl2, 0°C, 1h, 60%; b) HF.pyridine, CH3CN, RT, 30min, 76%; c) cat TMSOTf , MS4Å, CH2Cl2, 
RT, overnight, 55%; d) MeONa, MeOH, RT, 2h; e) H2N-NH2, MeOH, RT, 12h; f) Ac2O, Et3N, cat 
DMAP, CH2Cl2, 0°C to RT, 12h, 66%; g) NaBH4, cat 10% Pd/C, aqueous NaOH, 30 min, 91%; h) 
N-ε-maleimidocaproyl-oxysuccinimide ester,DIEA, DMSO,30°C, overnight, 46%.  
3.2. Expression and purification of mPsaA 
PsaA is a 37-kDa protein composed of 309 amino acid residues. The full-length protein 
possesses a signal peptide at its N-terminus as a transmembrane region. The presence of this 
leader sequence significantly reduces the expression of the protein [34]. To circumvent this 




produced. pET11a plasmid harbouring the PsaA gene along with a poly-histidine tag 
(HHHHHH) and TEV sequence (ENLYFQS) at the N-terminus was constructed and transformed 
into E. coli BL21(DE3) by heat shock method. This extra sequence was introduced to facilitate 
the purification of the protein, although its expression and purification in the absence of tag 
have been reported [34]  enabling its removal to ensure the absence of interference with the 
immune response. Interestingly, the TEV protease operates at the Q-S peptide bond leaving 
in place a serine residue. This serine residue naturally occurs at this position meaning that 
native mPsaA will be recovered after TEV protease digestion. SDS-PAGE confirmed the 
expression of the PsaA by visualising the protein band at an expected molecular weight (Fig. 
1, Lanes 2). The histidine tag from the HtTEV-mPsaA was cleaved using AcTEV™ protease, and 
the resultant mPsaA was purified using NiNTA beads to remove the histidine tag. The 
experimental results obtained from the western blot technique using anti-histidine tag 
antibodies confirmed the identity and purity of HtTEV-mPsaA and the removal of the poly-
histidine tag. The sample corresponding to the unbound fraction of affinity chromatography 
shows a band appearing slightly below that of HtTEV-mPsaA SDS-PAGE when revealed by 
Coomassie blue, which is absent in western blot analysis (Fig.1A and B, Lanes 4). A band 
corresponding to HtTEV protease and a second one corresponding to uncleaved HtTEV-mPsaA 
with very low intensity - meaning that the cleavage was efficient - are detected in the eluate 
after purification on NiNTA beads (Fig. 1, Lane 5B). The identity of both forms of PsaA was 
confirmed by MALDI-TOF mass experiments (Fig. 1 C). The molecular weight of the two 
proteins differs from 1751 mass unit which corresponds to the tag and the terminal 
methionine residue. The molecular weight of mPsaA was found equal to 32,395 Da, 1 mass 





Figure 1: mPsaA characterisation. Analysis of histidine tag removal from HtTEV-mPsaA by 
SDS-PAGE (A) and by Western blot (B). Lane 1: unstained protein marker; Lane 2: HtTEV-
mPsaA; Lane 3: AcTEV™ protease used for the cleavage; Lane 4: purified mPsaA after removal 
of poly-histidine tag; Lane 5: eluate after purification of mPsaA protein on NiNTA beads; 
MALDI-TOF-MS spectra of PsaA before and after histidine tag removal (C)  
3.3. Preparation and identification of PsaA-Pn14TS and BSA-Pn14TS conjugates 
The mPsaA was conjugated to Pn14TS by thiol/maleimide coupling chemistry (Scheme 2). To 
this aim, free amine functional groups of the surface exposed lysines of this protein was 
derivatised by treatment with excess (120 molar ratio) of SATA-NHS reagent. The excess of 





Scheme 2: Schematic representation of the basic conjugation strategy used to couple Pn14TS 
to mPsaA. (mPsaA structure PDB 3ZK9 is from Counago et al., 2014 and was drawn in PyMol) 
Subsequently, the modified carrier was conjugated to Pn14TS-mal in a 1:16 molar ratio in the 
presence of excess hydroxylamine hydrochloride to generate in situ thiol-reactive groups. The 
resultant PsaA-Pn14TS conjugate was purified by gel filtration (Figure 2A), lyophilised and 
stored at -80°C. Similarly, a control BSA-Pn14TS conjugate was prepared to evaluate the 
importance of PsaA as a carrier moiety. SDS-PAGE of the conjugates and synthetic 
intermediates thereof was consistent with increasing molecular weight at every incremental 
step of the process (Figure 2B). 
The analysis of chemical composition of the glycoconjugates by the phenol-sulphuric method 
and Bradford assay revealed that the sugar/protein molar ratios of the two conjugates were 





Figure 2. (A) Size exclusion chromatography profile of mPsaA-Pn14TS conjugate; (B) 12% SDS-
PAGE; Lane 1: mPsaA; Lane 2: mPsaA-Pn14TS; Lane 3: BSA; Lane 4: BSA-SATA; Lane 5: BSA-
Pn14TS. Column HiLoad 15/600 Superdex™ 75pg (GE Healthcare) column and PBS 0.1M, 
pH7.3 as eluent. 
The CD analysis of mPsaA-Pn14TS conjugate and the intermediates in comparison to the 
mPsaA revealed that there is no change in the secondary structure of the protein. The PsaA 
exhibited negative peaks at 208 nm and 222 nm in all the stages of conjugation and 
lyophilisation, which is indicative of similar protein folding and possess a significant number 
of alpha helixes, beta sheets in agreement with the determined mPsaA structure [35]. The 
similar folding pattern observed after the superimposition of the CD spectra of HtTEV-PsaA, 
mPsaA and mPsaA-Pn14TS confirms the stability in the protein during the process of 
conjugation (Figure 3). The conservation of mPsaA and mPsaA-Pn14TS was done by storing 
them at -80 °C after lyophilisation or in 40% glycerol and both cases the mPsaA has maintained 





Figure 3: The overlay of the CD spectra of the protein at the different stages of purification, 
conjugation and lyophilisation 
3.4. Immunization of mice and antibody response 
The immunisation efficiency of the different formulations was evaluated by the 
determination of the humoral IgG response in the mice antisera immunised subcutaneously 
with mPsaA, mPsaA-Pn14TS, BSA-Pn14TS, and PBS four times at 25 µg of protein/dose. 
3.4.1. Anti-mPsaA response 
The titers of anti-mPsaA IgG were first measured using mPsaA as a coating antigen (Figure 
4A). Both mPsaA and mPsaA-Pn14TS conjugates were able to induce anti-mPsaA IgGs while 
such response was not observed for either BSA conjugate or PBS control. High level of Abs 
was detected after the second immunisation (Day 28, blue bars) and maintained after the 
boosts in the groups immunised with mPsaA. Anti-mPsaA Abs were also raised in the sera of 
mice immunised with mPsaA-Pn14TS albeit at a much lower extent and wider variability with 
no boost effect (green bars Day 28 vs Day 98 vs Day 128). Comparison of these observations 
suggests that mPsaA derivatisation followed by conjugation to Pn14TS antigen might have 




4A). However, this hypothesis was not confirmed when sera of mice immunized with mPsaA 
alone were tested against mPsaA-Pn14TS conjugate coated on the microtiter plate (Figure 4B, 
blue bars).  Indeed, the level of Ab titers was comparable to that observed when mPsaA was 
the coated antigen (1/1000 -1/10,000; compare blue bars in Figure 4A and 4B).  Moreover, 
the Abs seemed to be mPsaA specific as no titer (<1/100) could be measured when assessed 
against BSA-Pn14TS as the coated antigen (Figure 4C, blue bars). Taken together, these results 
are in favour of a competition between the mPsaA B epitopes and the antigenic determinants 
expressed by Pn14TS rather than epitope masking to explain the observed difference in anti-
mPsaA response whether mPsaA or mPsaA-Pn14TS was the immunogen.  
3.4.2. Anti-carbohydrate response 
We next turned our attention to the anti-carbohydrate response first focusing on the anti-
synthetic tetrasaccharide IgG response. The BSA conjugate was used as the coated antigen to 
reveal the anti-Pn14TS IgG raised in mice immunized with the corresponding mPsaA-Pn14TS 
conjugate (Figure 4C). Anti-Pn14TS IgG response was present at Day 28 (Figure 4C, green bar) 
and consistently increased after the first (Day 98) and the second boost (Day 128 P<0.01). 
Conversely, mPsaA-Pn14TS conjugate was used as the coated antigen to measure the anti-
Pn14TS response raised by the BSA conjugate and the global anti-IgG directed against both 
tetrasaccharide and protein valences in mice immunized with mPsaA-Pn14TS (Figure 4B). A 
103-104 anti-Pn14TS IgG titer range was measured only after the fourth immunization in mice 
immunized with the BSA conjugate (orange bars Day 28 and Day 98 vs Day 198).  Besides, a 
significant (P<0.05) global anti-IgG titer was measured after booster dose, in the immune sera 





Figure 4. Titers of IgG Abs of mice immunised with PBS, mPsaA, mPsaA-Pn14TS conjugate, 
BSA-Pn14TS-conjugate, and Sp14 one week after the 2nd (J28), the 3rd (J98) and the 4th (J128) 
immunisation. (A) Against mPsaA (coated on a microtiter plate); (B) against mPsaA-Pn14TS; 
(C) against BSA-Pn14TS; (D) against S. pneumoniae serotype 14 capsular polysaccharide (CP). 
The serum samples data presented as geometric mean titer ± standard deviation of six mice 
per group. Statistical analysis was performed using one-way ANOVA with Kruskal-Wallis 
analysis for multiple comparisons. Statistical difference between the groups is *, p < 0.05; **, 
p < 0.01; ***, p < 0.001.  
To investigate whether the conjugates were able to induce the production of anti-CP Abs, CP 
from serotype 14 was coated on ELISA microtiter plates (Figure 4D).  As expected, no anti-CP 
Abs could be measured in the sera of mice immunized with PBS or mPsaA. The anti-CP 
response induced by the mPsaA-Pn14TS conjugate was significant after the first (P<0.05) and 
the second boost (P<0.001) (Figure 4D, green bars at Day 28 and Day 128). 4 out of 6 mice 
immunised with the mPsaA-Pn14TS conjugate raised anti-CP-titers superior or equal to 




measured in mice sera immunised with BSA-Pn14TS, but these titers were less consistent and 
accompanied by high variability from one mouse to another (Figure 4D, orange bar Day128). 
Mice immunised with the BSA-Pn14TS were administered twice as less carbohydrate antigen 
than those immunised with mPsaA-Pn14TS (1.5 vs 3.1 µg/dose, respectively) to keep the 
amount of protein dose equal. This might explain the apparent discrepancy between the 
immunogenicity of the two conjugates. To summarise, these results confirm that Pn14TS can 
be considered as an immune mimic of the S. pneumoniae serotype 14 CP (Safari et al., 2008; 
Kurbatova et al., 2017).  
4. Discussion 
The advent of glycoconjugate vaccines has been a breakthrough for the prophylactic 
treatment of infectious diseases caused by encapsulated bacteria including S. pneumoniae 
[36]. The pneumococcal glycoconjugate vaccine is safe and effective but faces serotype 
replacement phenomenon: Initially composed of 7 polysaccharides corresponding to 7 
different serotypes, it has been implemented to protect against 13 pneumococcal and soon 
15 serotypes. These have been selected by geographic prevalence and virulence but still, 
vaccination results in colonisation by non-vaccine serotypes.  While it is envisaged to increase 
the CP valency of the vaccine further – e.g., the licensed pneumococcal polysaccharide 
vaccine comprises 23 serotypes – to circumvent this drawback, researchers have moved on 
to the identification of novel surface exposed or secreted pneumococcal antigens [37]. On 
these lines, much attention has been paid to the identification of proteins which are i) targets 
of antibodies in the field, ii) highly conserved across the serotypes, iii) shared by all 
pneumococcal strains and iv) involved in virulence and colonisation, thereby limiting possible 




among others, pneumolysin, pneumococcal histidine triad protein D or pneumococcal surface 
protein A (PspA) is now under clinical investigation. However, to maximise the efficacy, such 
formulations will undoubtedly be composed not of one but several antigens. This has been 
suggested to be crucial for vaccines that aim to generate broad mucosal protection against 
this highly heterogeneous pathogen [38]. We believe that these novel vaccine targets would 
advantageously be combined with the current, effective glycoconjugate vaccines. They can 
be added merely as extra components or used as carriers [16,18,39–43]. It has even been 
shown for PspA that its conjugation to CP 23F induced higher survival than PspA alone in an 
infection challenge providing the basis for, at least, an additive if not a synergistic protective 
effect [40]. Herein, we have elected to investigate PsaA in a dual role of immunogen and 
carrier. The role of PsaA in inducing protective immunity against systemic infection or once 
bacteria have colonised the lungs has been controversial [12,13,44] but its beneficial role in 
reducing colonization cannot be disputed noticeably when co-administered with PCV7 
[12,18,45]. Besides, PsaA had already been used as a carrier for purified bacterial 
polysaccharide to prepare pneumococcal [16] and even hybrid Hib/pneumococcus [17] 
glycoconjugate vaccines. However, its use to access to semi-synthetic glycoconjugate vaccines 
which have recently appeared as a credible alternative to traditional glycoconjugates [46] 
remained uninvestigated before this study. Production and characterisation of conjugate 
whereby mPsaA is conjugated to a synthetic CP serotype 14 mimicking tetrasaccharide 
Pn14TS was the first objective of the study. Recombinant native mPsaA has thus been 
produced in high yield and purify using NiNTA affinity column followed by complete histidine 
tag removal, aware that an optimised production process, in the absence of a tag, has been 
developed for possible scale-up [34]. Most importantly, conjugation and further purification 




by circular dichroism analysis suggesting that potential conformational B-epitopes are 
conserved. 
The immunization efficiency of the conjugate mPsaA-Pn14TS adjuvanted with -GalCer was 
next examined in mice in comparison with mPsaA and a model conjugate BSA-Pn14TS. The 
conjugate elicited anti-mPsaA antibodies but at a lesser extent than unconjugated mPsaA. 
This situation is not found for the reported glycoconjugates which make use of either PsaA 
[16] or PspA [40,41] as carrier proteins which, differ by the nature of the conjugated antigens 
(polysaccharide vs tetrasaccharide). Since mice sera raised against mPsaA bind to mPsaA-
Pn14TS when coated on the microtiter plates at a high level, these observations are more 
likely due to B epitope competition than to masking of the mPsaA B epitope by Pn14TS after 
conjugation. In summary, these observations suggest that the mode of presentation of PsaA 
to the immune system as well as its chemical-physical structure might strongly influence the 
fate of the immune response. This indicates that special care should be given to the design of 
future mPsaA-based glycoconjugates.  
On the other hand, both mPsaA-based and BSA-based conjugates elicited anti-CP14 
antibodies mainly after the 2nd boost for BSA-Pn14TS. However, these data cannot be 
compared as the mice were immunized with a distinct amount of tetrasaccharide whether 
they received the mPsaA (3.1 µg/dose) or the BSA (1.5 µg/dose) conjugates to keep the 
amount of administered protein constant. Dose and sugar to protein ratio effects were 
beyond the scope of the study, which is focused on the design of a mPsaA conjugate 
prototype. Titers were nevertheless in the same range (1:1000 to 1:8000) to those observed 
for reported Pn14TS conjugates using carriers whose use is approved in humans such as 





In summary, the first semi-synthetic glycoconjugate vaccine solely composed of 
pneumococcal antigens, i.e., of a synthetic tetrasaccharide mimicking the capsule of serotype 
14 coupled to PsaA has been reported. The latter has been selected as it should contribute to 
control pneumococcal colonisation and ensure herd immunity. The conjugate has been 
prepared in high yield and purity and proved to be stable during long-term storage. The 
conjugate was able to induce the production of IgGs against both synthetic oligosaccharide 
and protein moieties. This study suggests further modifications in term of glycoconjugate 
design (e.g. using tyrosine-directed conjugation for finely tuning the anti-mPsaA/anti-
tetrasaccharide humoral response) [47] and route of administration (i.e. mucosal for an 
optimal adjuvantation of -GalCer)  [48] for its future improvement.  
Mucosal surfaces are the common entry points for the Streptococcus pneumoniae. Therefore, 
the change of the administration route from parenteral Immunization to a mucosal route is 
expected to enhance the production of mucosal IgA antibodies. This may significantly 
contribute to protection against mucosal infections by acting as the first line of defence. 
Combination of T-cell dependent immunogenicity of glycoconjugate vaccines with mucosal 
immunization could be an attractive strategy for preventing pneumococcal infections. 
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Subunit vaccines are the promising candidates for immunization against infectious diseases. 
However, the development of effective subunit vaccines formulation requires a combination 
of potent adjuvants, a suitable delivery system and an efficient route of delivery. In this 
chapter, we prepared semisynthetic glycoconjugate (GC) loaded chitosan nanoparticles to 
enhance the immune response generated against the glycoconjugate. The glycoconjugate 
was encapsulated into the chitosan nanoparticles (GC-CNPs) by simple ionic gelation method 
and the resultant nanoparticles had the size of ~150 nm with a zeta potential of ~30 mV. The 
nanoparticles had an encapsulation efficiency of 70% and in the presence of cryoprotectant, 
they could be lyophilized and reconstituted without altering their size. The colloidal stability 
studies were performed in simulated nasal mucosal medium and the results showed that 
nanoparticles were stable for a period of 24h. A comparative study was performed in mice, 
to evaluate the potential of nano-encapsulation on immune response generated against the 
glycoconjugates. The in vivo studies showed that the mice injected with the GC-CNPs (S.C), in 
combination with α-GalCer as an adjuvant has displayed 100 folds higher IgG response and 
10 folds higher IgM response over the groups treated with GC (S.C). However, the same GC-
CNPs did not show potential IgG response when administered via intranasal route. Overall, 
the study demonstrates the potential use of nanoparticulate systems to deliver semisynthetic 
glycoconjugate antigens effectively.  
Keywords: Pneumococcal surface adhesin A, Chitosan, Nanoparticles, Glycoconjugate 








1. INTRODUCTION  
Streptococcus pneumoniae is the leading cause of mortality in children under the age of 5 
years. In the year 2017, S. pneumoniae was responsible for 1.2 million deaths globally and 
300,000 deaths were due to pneumococcal pneumonia [1,2]. There are more than 96 
serotypes of S. pneumoniae based on the diversity of capsular polysaccharides [3]. The 
marketed vaccines employed in the prevention of pneumococcal infection are based on these 
capsular polysaccharides. Pneumococcal polysaccharide vaccines (PPSV23) and 
pneumococcal conjugate vaccines (PCV7 and PCV13) are commonly used marketed vaccines. 
The introduction of conjugate vaccines has significantly reduced the global burden of 
pneumococcal infections across many communities [4]. Still, conjugate vaccines offer 
protection against limited serotypes whose polysaccharide components are incorporated in 
the vaccines. Due to this, immunizing with the existing vaccines fail to protect against S. 
pneumoniae infections caused by serotypes not included in the formulations. Polysaccharide 
or conjugate vaccine requires complex manufacturing, purification and dose optimization 
steps, and introduction of further serotypes in the formulations will result in an escalation of 
the vaccine costs. To circumvent these limitations, vaccines based on pneumococcal proteins 
have been investigated. The proteins like pneumococcal surface adhesin A (PsaA) [5–7], 
pneumococcal surface protein A (PspA) [8], pneumolysin (Ply) [9], and pneumococcal 
histidine traid D (PhtD) [10] have been extensively studied as the potential vaccines against 
pneumococcal infections as they are expected to offer broad protection against all the 
pneumococcal serotypes [11].  
In our earlier study, the combination of protein and sugar valences have been proposed to 
induce an additional or synergistic effect. In this line, we have successfully synthesized a 




carrier. PsaA was covalently linked to a synthetic tetrasaccharide mimic of capsular 
polysaccharide (CP) from pneumococcal serotype 14 (Pn14TS) to obtain a glycoconjugate 
(Pn14TS-mPsaA/GC) [12]. Pn14TS is a synthetic tetrasaccharide derived from the capsular 
polysaccharide of S. pneumoniae serotype 14, that was able to evoke the opsonophagocytic 
response [13]. PsaA is a highly conserved, 37-kDa protein that is commonly present in all the 
96 serotypes of S. pneumoniae [14]. PsaA is a member of the ATP- binding cassette (ABC) 
protein that transports manganese. Additionally, PsaA is a surface-exposed protein that is 
reported to play a significant role in the adhesion and colonization of S. pneumoniae [14,15]. 
This makes the PsaA an ideal candidate for vaccination against pneumococcal infections 
[16,17].  
While most subunit vaccines alone are poor immunogens and fail to generate T and B cell 
responses, glycoconjugate vaccines can induce better immune protection on their own. 
Nevertheless, their co-administration with an adjuvant can further heighten the immune 
response. Several adjuvants like aluminium salts, cholera toxin (CT) [18,19], α-galactosyl 
ceramide (α-GalCer) [20] have been explored for this purpose. However, strong adjuvant 
activity is often associated with increased toxicity and adverse effects. As an alternative 
strategy, the use of particulate carriers offer multiple benefits as a vaccine delivery system: i) 
they can act as an adjuvant; ii) they enhance the stability of antigens; iii) they reduce the need 
of administering multiple doses; iv) they are suitable for needle-free vaccine delivery via 
mucosal routes [21–23]. Several particulate systems like polymeric nanoparticles [24], 
metallic nanoparticles [25], liposomes [26] and microparticles [27] have been explored for the 
delivery of pneumococcal antigens. Nanoencapsulation helps the antigens to cross the 
epithelial barrier and presents them to the immune cells [21]. In most of the cases, the subunit 




an adjuvant [28]. The increasing use of particulate systems in the delivery of the antigens has 
led to the deeper understandings in cellular and molecular mechanisms by which vaccines 
stimulate the immune adaptive response. 
Earlier studies have demonstrated chitosan nanoparticles as an adequate carrier for the 
delivery of protein subunit vaccines [29]. Chitosan is a biocompatible, biodegradable and a 
mucoadhesive polymer with adjuvant properties [30]. The preparation of chitosan 
nanoparticles (CNPs) involves a solvent-free and simple ionic gelation method and this makes 
it attractive for the encapsulation of delicate macromolecules such as protein-based antigens. 
In this study, GC was encapsulated into CNPs (GC-CNPs) and the characterization of GC-CNPs 
was performed. A comparative study on the immunogenicity of GC and GC-CNPs was 
performed to identify the importance of nanoencapsulation in enhancing the immunogenicity 
of the glycoconjugates. In summary, we demonstrate the use of chitosan nanoparticles for 
the delivery of semisynthetic glycoconjugate antigens.  
2. Methods 
2.1. Preparation and characterization of CNPs 
Chitosan nanoparticles were prepared by ionic gelation technique that was previously 
developed by our group [29]. First, the chitosan (2 mg/mL) and poloxamer (20 mg/mL) 
solutions were prepared under magnetic stirring using ultrapure water. Then 0.5 mL each of 
chitosan and poloxamer solutions were mixed in a reaction vial to form a 0.1% and 1% (w/v) 
mixture of chitosan and poloxamer, respectively. Next, 0.5 mL of a TPP solution (0.4 mg/mL) 
was added at once to the mixture of chitosan and poloxamer under magnetic stirring (700 
rpm). After 30 min of the reaction, the nanoparticles were concentrated by centrifugation at 




in the bottom was carefully collected and resuspended in ultrapure water. For GC loaded 
CNPs, the TPP solution (0.5 mL of 0.4 mg/mL) containing GC (50 μg) was added to 1 mL of 
0.1% w/v chitosan in 1% poloxamer kept under magnetic stirring at 700 rpm. 
The particle size and polydispersity index of the nanoparticles were measured by dynamic 
light scattering (DLS) and the zeta potential was calculated from the electrophoretic mobility 
values obtained by laser Doppler anemometry using a Zetasizer Nano-ZS90 (Malvern 
Instruments; Malvern, UK). All the measurements were performed at 25 °C with a detection 
angle of 173° in distilled water unless otherwise indicated. The nanoparticle concentration 
and stability in cell culture medium was evaluated by nanoparticle tracking analysis using 
NanoSight NS500 (Malvern instruments; Malvern, UK). 
The surface morphology of the GC-CNPs was examined by field emission scanning electron 
microscopy (FESEM, ZEISS FESEM ULTRA Plus, Germany). For FESEM studies, 10 µl of the GC-
CNPs suspension (10,000 times diluted) was placed on the silicon wafer and left to dry 
overnight in the desiccator. Prior to the analysis, the samples were sputter-coated with 
iridium (10 nm thickness).  
The blank and GC-CNPs (0.5% & 1% w/v) were lyophilized in the presence of 5% and 10 % 
(w/v) trehalose as a cryoprotectant in the Eppendorf tubes. The samples were frozen 
overnight at -20 °C and then transferred to the freeze-dryer Genesis 25 ES, VirTis Model-
Wizard 2.0 (SP Industries, USA). The primary drying step lasted for 35 h during which the 
temperature was gradually increased from -40 to -20 °C. This was followed by a secondary 
drying step in which the temperature was increased to RT from 0 °C. After the freeze-drying, 
the nanoparticles were resuspended in the ultrapure water and were analysed for their 
particle size and PDI. A similar freeze-drying process was used to determine the formulation 




2.2. Encapsulation of GC into CNPs and release studies 
The encapsulation efficiency (EE) of GC in CNPs was determined by calculating the amount of 
free GC present in the collected supernatant after the centrifugation. The amount of free GC 
was determined using the micro BCA assay kit (Thermo Fischer scientific) by measuring the 
absorbance at 562 nm. The quantification was performed using the linear standard curve 
produced with the solutions of GC solubilized in the supernatant of CNPs in the concentration 
range of 0.5 - 10 μg/mL. The % EE was calculated as follows: % EE = A – B/A × 100, where A is 
the total GC and B is the free GC in the supernatant. 
To perform the in-vitro release studies, GC-CNPs were incubated in the SNF (pH 6.5) at 37 °C 
kept under constant agitation in a shaking incubator at 300 rpm. At different time points (0, 
1, 2, 4, 8 and 24 h) the supernatant was collected by centrifugation. The micro BCA protein 
assay kit determined the amount of the GC released at different time points. 
2.3. Fluorescent labelling of chitosan 
The Cy5 labelled GC-CNPs were prepared to visualize the GC-CNPs during the in vitro studies. 
Briefly, chitosan (50 mg; 0.3 mmol monomer units; 1 eq) was placed in a reaction vial and 
dissolved in deionized water (5mL). Cyanine (Cy5) (1 mg; 0.015 mmol; 0.050 eq), in dimethyl 
sulfoxide (DMSO) (0.3mL) was added to the chitosan solution under continuous stirring. After 
sealing, the vial was stirred for 16 h at RT, protected from light. After the reaction, the labelled 
chitosan was purified using PD10 columns (Centri Pure P10; Zetadex Gel Filtration columns). 
The yield of the reaction was measured afterwards by weighing the freeze-dried product in 
the eppendorf and subtracting the weights. The labelling of the GC-CNPS was simply 
performed by substituting 2% of chitosan with the Cy5-labelled chitosan (Cy5-chitosan) during 





2.4. Colloidal stability of chitosan 
The colloidal stability of the GC-CNPs was studied by monitoring the particle size and the 
mean count rate (MCR) in the simulated nasal fluid (SNF) containing 0.1% mucin (Type III 
mucosa from Sigma Aldrich) using DLS. The SNF with different concentrations of mucin (0.001, 
0.01 & 0.1 % w/v) was used to mimic the nasal environment for the intra-nasal delivery. In 
brief, 200 μL of 1mg/mL GC-CNPs were mixed with 800 µl of mucin in SNF, while nanoparticles 
suspended in water and SNF at same concentrations are used as controls. The GC-CNPs in the 
different media are shaken at 100 rpm at 37 °C using a constant-temperature shaker, at 
different time points (0, 0.5, 1, 2, 4 and 24h) the size and mean count rate of samples are 
measured using DLS. To study the stability of GC-CNPs in cell culture medium, the GC-CNPs at 
the concentration of 0.5 mg/mL were incubated in RPMI + 10% FCS (R10 media) for 4h. Later, 
the change in the nanoparticles was measured using NTA as mentioned in section 2.1.  
2.5. In vivo studies Immunization studies in mice 
Specific pathogen-free C57BL/6 mice (6 weeks-old, female) were purchased from Janvier (Le 
Genest-St-Isle, France). Mice were maintained in a biosafety level 2 facility in the Animal 
Resource Centre at the Lille Pasteur Institute for at least two weeks prior to usage, to allow 
appropriate acclimation. Mice were fed a standard rodent chow (SAFE A04) (SAFE, Augy, 
France) and water ad libitum. The diet contains ~11.8% fibre including ~10% water-insoluble 
fibre (3.6% cellulose) and 1.8% water-soluble fibre. All the animal experiments were 
performed at Lille Pasteur institute according to the ethical guidelines (agreement number AF 
16/20090 and 00357.03). 
Groups of 6 female C57BL/6 mice were injected subcutaneously (S.C.) with GC or GC-CNPs, (1 
µg carbohydrate antigen/5 μg protein/dose). All mice were administered with 250 ng of α-




immunised S.C. on day 0 and boosted at day 14 with either PBS, GC or GC-CNP. Second, in a 
subsequent study 7 groups of mice were immunized with GC-CNPs (S.C), blank CNPs (S.C), 
Prevnar 13 (S.C), GC (I.N), GC-CNPs (I.N), blank CNPs (I.N), and GC + blank CNPs (I.N), thrice at 
day 0, 14 and 28). Mice were bled one week after every immunization. Sera were stored at 
−80 °C until the quantification of Ab response by ELISA. 
2.6. Measurement of humoral response  
The Ab responses induced upon immunization were assessed by using enzyme-linked 
immunosorbent assay (ELISA) as described previously, with slight modifications [1]. In brief, 
the samples with different serial dilutions were loaded into individual 96 wells microtiter 
Nunc Maxisorp (ThermoFisher Scientific) where the plates were coated with mPsaA (0.1 
μg/well) or Pn14TS (0.2 μg/ well) and plates overnight at 4 °C. The goat anti-mouse IgA, IgM 
and IgG(H+L)- HRP-labelled conjugate (CliniSciences) used as secondary Ab at a dilution of 
1/6000, was used as secondary antibodies. The reactions were read in an Infinite M1000 
spectrophotometer (TECAN). Similarly, anti-mouse IgG1, IgG2a, IgG2b and IgG3 were used to 
determine the predominant IgG subclass expressed. To determine the anti-CP14 response the 
purified capsular polysaccharide (CP14) (Alliance Bio Expertise, France) was coated in the 
wells. While the killed pneumococcal serotype 14 (Sp14) were coated in the plates to 
determine the anti-Sp 14 antibody response. The Ab titer was defined as the dilution of 






2.7. Influenza A virus (IAV) infection 
The S. pneumoniae (serotype 14) strain used in this study was a gift from Dr M. de Jonge 
(Nijmegen University, The Netherlands). The mouse-adapted H3N2 IAV strain 
Scotland/20/1974 was described in [31]. For infection with IAV, 50 µl of phosphate-buffered 
saline containing (or not, in a mock sample) 30 plaque-forming units (p.f.u.) of the H3N2 IAV 
strain Scotland/20/1974 were intranasally administered to anesthetized mice. This dose 
corresponds to a sub-lethal dose, which is necessary to investigate secondary bacterial 
infection. For secondary pneumococcal infection post-influenza, mice were challenged (I.N) 
at 7 dpi with S. pneumoniae (1x106 c.f.u.). The survival of the mice was monitored for 20 days 
[32]. 
2.8. Statistical Analysis 
All values are presented as geometric mean ± standard deviation. The statistical analysis was 
performed using Graphpad Prism 7 software. The statistical significance of the observed 
differences was assessed by Mann Whitney U test and Kruskal Wallis analysis by Dunns 
multiple comparisons. A probability value of P < 0.05 was considered statistically significant. 
3. Results 
3.1. Nanoparticle preparation and characterization  
The schematic representation of the CNPs formation is shown in Figure 1. DLS analysis of CNPs 
suspensions revealed the formation of nanoparticles with an average diameter of 142 ±18 nm 
and zeta potential of +27 ±3 mV. The PDI of the GC-CNPs was lower than 0.2, indicating the 
homogeneity of the nanoparticle population. The incorporation of poloxamers in the 
formulation and the use of glycerol bed during nanoparticle separation is attributed for its 
ability to maintain the stability of the nanoparticles [33] and improving the in vivo efficiency 





Figure 1: Schematic representation of chitosan nanoparticle preparation by ionic gelation method (A); 
Particle size and zeta potential of blank CNPs and GC-CNPs analysed by Malvern zeta sizer (B); Physico-
chemical properties of the prepared nanoparticles (C). 
The nanoparticle tracking analysis (NTA) displayed that the blank CNPs and GC-CNPs had 
similar average particle size around 150 nm (Figure 2A), close values to those obtained 
previously by DLS. The results from scanning electron microscopy presented in Figure 2B 
confirm that the CNPs and GC-CNPs have narrow size distribution. The SEM micrographs show 





Figure 2: Particle size determination by nanoparticle tracking analysis (NTA) and field emission 
scanning electron microscopy (FESEM) of the blank CNPs and GC-CNPS; A) The figure represents the 
particle size distribution and the nanoparticle concentration of blank and GC-CNPs, determined by 
NTA; B) The surface morphology of blank CNPs and GC-CNPs determined by FESEM and shows the 
CNPs had spherical shape; C) The particle size distribution from the FESEM images calculated using 
image J software and plotted by graph pad prism. 
The diameter of a hundred particles from the micrographs of both the blank CNPs and GC-
CNPs was measured using the Image J software. The size distribution of the measured 
particles is plotted as shown in Figure 2C. The average particle size was 147 ±19 nm and 145 
±28 nm for the blank CNP and GC-CNPs respectively. No significant difference in the 
distribution pattern of the NPs was observed, even though the GC-CNPs had a slightly higher 




labelled by conjugating Cy5 to chitosan. The particle size analysis shows that the Cy5-GC-CNPs 
had an average diameter of 150 ±9 nm and zeta potential of 30 ±2 mV. The use of the Cy5 
labelled chitosan exhibited a slight increase in the size of the CNPs. The formulation contained 
approximately ~8-15 thousand Cy5 molecules per particle as calculated from particle 
numbers obtained by NTA. 
3.2. Encapsulation efficiency and antigen release studies 
Encapsulation efficiency (EE) of GC in the CNPs was found to be 70 ±3% that corresponds to 
35 µg of protein per milligram of NPs, while the EE of mPsaA was < 20%. When compared to 
PsaA, the GC contains the tetrasaccharide and the acetyl thioacetate molecules associated 
with it. The higher encapsulation of GC into the nanoparticles, when compared to PsaA, might 
be attributed to its tetrasaccharide chains. The prepared GC-CNPs contained approximately 
6,000 GCs per particle as calculated with particle numbers measured by nanoparticle tracking 
analysis (~1.9 x 1010 particles per mg of GC-CNPs). The nanoparticles freeze-dried in the 
absence of cryoprotectant were dispersible in water but showed an increase in the particle 
size. Both the blank and GC-CNPs that were freeze-dried in the presence of 5% and 10% 
trehalose as a cryoprotectant were easily re-dispersible after 1 week of storage at 4° C. This 
helps in the storage of nano vaccines in the powder form.  
 





The amount of the GC released at different time points from the CNPs was quantified against 
the supernatant of the blank CNPs. Approximately 18% of antigen was released after 1 h of 
incubation in SNF. Afterwards, there was no significant increase in the percentage of the 
antigen released. At the end of 24 h, the percentage of antigen released was 24 ±9%, as seen 
in Figure 3.  
3.3. Stability of chitosan nanoparticles in simulated nasal fluid 
The stability of GC-CNPs in the mucosal medium was studied for a period of 24 h. The results 
obtained from the interaction of chitosan nanoparticles with mucin in SNF are represented in 
different plots as shown in Figure 4A & 4B.  
 
Figure 4: Colloidal stability of GC-CNPs in the mucosal and cell culture medium. Particle size (A) and 
mean count rate (B) characterization of the GC-CNPs measured at different time points during 24 
hours, to evaluate their stability in mucosal medium (SNF + 0.1% mucin); The particle size distribution 
measured by NTA to compare the stability of GC-CNPs while in water (C) and after incubation in RPMI 





Particle sizes in SNF containing 0.1% mucin were measured around 320 nm thereafter t=0 i. 
e. twice as much as the mean particle sizes observed when NPs are dispersed in water (Figure 
4A & 4B). While the nanoparticles incubated in SNF, the particle size increased with time, and 
the count rate of the particles reduced drastically. The results show that even though the 
nanoparticles are not stable in SNF, their stability in this medium increased in the presence of 
mucin. The reason for the initial increase in the size of nanoparticles with 0.1% mucin in SNF, 
even though they were stable thereafter, might be due to the mucoadhesive property of the 
chitosan nanoparticles. The higher viscosity of the mucosal medium can also reduce the 
Brownian motion of the GC-CNPs due to which the particles appear larger and this 
phenomenon cannot be ruled out with this method. Taken together the results obtained 
suggest that the chitosan nanoparticles might have enough stability in the nasal mucosa. The 
colloidal stability of the nanoparticles was evaluated by measuring their size and PDI in the 
R10 cell culture medium and was found to be concentration dependent. The data obtained 
by NTA confirms that the GC-CNPs showed no signs of aggregation in the R10 media at the 
concentrations below 500 μg/mL (Figure 4C & 4D). 
 
3.4. In vivo studies 
3.4.1. The effect of nanoencapsulation on GC immunogenicity 
 In the first series of experiments groups of 6 mice were immunized S.C. twice at two weeks 
interval with GC, GC-CNP or PBS adjuvanted with α-GalCer to test the effect of encapsulation 
on GC immunogenicity. ELISA determined the levels of the IgG and IgM antibody response 
raised by the different formulations. 
To investigate whether the GC and GC-CNPs were able to induce the production of anti-mPsaA 




alone nor GC-CNP induced an anti-mPsaA IgM response after the second immunization (data 
not shown).  Contrasting to this result, both GC and GC-CNPs were able to induce anti-mPsaA 
IgGs in mice. Notably, this anti-mPsaA IgG response at least, 100-fold higher in the GC-CNPs 
treated mice in comparison to the GC treated mice (P<0.0005) (Figure 5A).  
 
Figure 5: The antibody response in the mice immunised with PBS, GC and GC-CNPs one week after the 
final immunization. The immunization was performed twice at day 0 and 14 and the serum antibody 
response in the mice was determined at day 21. The obtained results are represented as anti-PsaA IgG 
response (A), anti-CP14 IgM response (B) and anti-CP14 IgG response (C). Statistical difference 
between the groups is *, P < 0.01; **, P < 0.001; ***, P < 0.0005. Data represent mean ± SD (n=6). 
 
To investigate whether the GC and GC-CNPs were able to induce the production of anti-CP14 
Abs, CP from serotype 14 was coated on ELISA microtiter plates. A low anti-CP14 IgM response 
was observed in both groups with high variability and no significant difference. However, the 
increase in anti-CP14 IgG in the mice treated with GC-CNPs was 10 folds higher than the mice 
treated with GC alone (Figure 5B). The results show that the encapsulation of the GC in CNPs 
enhance the IgG response against both the protein and the capsular polysaccharide. Finally, 
we tested whether the IgG induced in the sera of mice immunized with GC-CNP were able to 
bind to the bacteria. To this aim killed S. pneumoniae bacteria were used as coated antigen. 





Figure 6: The subclass of anti-IgG antibody response in the mice immunised with GC-CNPs one week 
after the final immunization. The immunization was performed twice at day 0 and 14 and the serum 
antibody response in the mice was determined at day 21. The obtained results are represented as 
anti-mPsaA IgG subclass response (A), anti-CP IgG subclass response (B).  Statistical difference 
between the groups is *, P < 0.05; **, P < 0.01; ***, P< 0.001.  Data represent mean ± SD (n=6). 
 
In addition, studies were performed to determine which subclass of the IgG was 
predominantly expressed in the groups immunized with GC-CNPs. The serum samples of mice 
immunized with GC-CNPs displayed a high level of Abs of the IgG1 subclass and at a much 
lower extent of the IgG2b against both PsaA and CP14 (Figure 6). There was no activation of 
other IgG subclasses in particular of the IgG2a one. However, the IgG2b was the second 
predominant IgG subclass that was in the mice immunized with GC-CNPs.  
 
Figure 7: Survival of vaccinated mice challenged intranasally by administering 30 CFU of H3N2 followed 
by 1x106 of S. pneumoniae serotype 14. The survival of the mice was monitored for 20 days. The 
differences between survival rates of 6 mice per group were analysed by Kaplan–Meier survival curve. 




The invasive pneumococcal challenge (Figure 7) in the mice displayed 50% of survival on day 
20, in the group immunized S.C with GC-CNPs while the group immunized with an equivalent 
amount of GC showed only 17% survival. Interestingly, there was 100% survival until day 13 
in the mice treated with GC-CNPs. Whereas, in the groups treated with GC the survival 
reduced to 50% in day 10. Overall, the results demonstrated that the mice immunized with 
GC-CNPs exhibited higher protection against the invasive pneumococcal challenge.  
3.4.2. The role of administration route on the immunogenicity of GC 
In the second set of experiments, we aimed at determining the humoral IgG and IgM response 
induced in mice by the GC-CNP depending on their route of administration, either S.C. or I.N. 
The serum samples of different groups of mice immunized with GC (I.N), GC-CNPs (I.N), GC + 
blank CNPs (I.N), blank CNPs (I.N), GC-CNPs (S.C), blank CNPs (S.C) and Prevnar 13 (S.C) 
adjuvanted with -GalCer. The serum analysis shows no anti-mPsaA IgM response in any 
groups (data not shown). Sera of mice immunized with blank CNPs by either route, as well as 
that of mice immunized with Prevnar 13 (which does not contain PsaA as an immunogen) do 
not show any anti-mPsaA IgG response. 
 
Figure 8: The antibody response in the mice immunised with  GC (I.N), GC-CNPs (I.N), GC + blank CNPs 
(I.N), blank CNPs (I.N), GC-CNPs (S.C), blank CNPs (S.C) and Prevnar 13 (S.C). The results are displayed 
as anti-mPsaA IgG response (A), anti-CP IgG response (B), and anti-CP IgM response (C). The serum 
samples data are presented as geometric mean titer ± standard deviation of six mice per group. 




High anti-mPsaA IgG response was raised against GC-CNPs via S.C. administration, confirming 
the results observed during the first series of immunization. The anti-PsaA IgG response was 
similar to GC-CNPs (S.C) when GC was administered intranasally. However, the group treated 
with a physical mixture of GC & blank CNPs showed a marked decrease in the anti-PsaA IgG 
(about 2 folds) compared to the groups treated with GC (I.N) and GC-CNPs (S.C) while the 
response was absent in GC-CNPs (I.N.) (Figure 8A). The results obtained from quantifying the 
anti-PsaA IgG in the groups immunized I.N clearly show that the anti-PsaA IgG response is 
highest in the group immunized with GC and a reduction in activity is seen when physically 
mixing the GC with CNPs prior to immunization.  Further reduction in the activity was 
observed on encapsulation of the GC in the CNPs. This indicates the influence of the CNPs in 
reducing the immune response against the GC while injected I.N. However, the same GC-CNPs 
when injected S.C increased anti-PsaA IgG several folds compared to GC (S.C). 
Considering the anti-CP14 IgG response, both the GC (I.N) and the GC-CNPs (S.C) were able to 
induce an anti-CP14 IgG response (Figure 8B). While, the GC-CNPs (S.C) showed significantly 
higher anti-CP14 IgG response against other groups (GC-CNPs (I.N), blank CNPs (I.N), and GC 
+ blank CNPs (I.N)) except GC (I.N). The group treated with Prevnar 13 showed very low anti-
CP14 IgG response (P<0.01). To study the production of anti-CP14 Abs in the mice immunized 
with different formulations, CP from serotype 14 was coated on ELISA microtiter plates. The 
anti-CP14 IgM response was very low in all the groups, except in the group immunized with 





4. Discussion  
Chitosan nanoparticles (CNPs) have earlier been investigated as a carrier for numerous 
vaccines [36–38], including pneumococcal protein vaccines [24] and have been tested as an 
adjuvant in mixture with PCV13 [39]. To the best of our knowledge, chitosan or any other 
polymeric nanoparticles have never been used as a carrier for the delivery of pneumococcal 
conjugate vaccines. The knowledge on the influence of the nanocarriers on the 
immunogenicity of the glycoconjugate is still missing. The current study provides significant 
data to understand the influence of the CNPs in altering/enhancing the immunogenicity of 
the glycoconjugates.  
CNPs have a proven track record in the delivery of therapeutic proteins and vaccines via 
mucosal route [40–42]. In addition, the CNPs have demonstrated to possess adjuvant activity 
in S.C immunization and thus, also appear as promising carriers for systemic administration 
[43]. CNPs carry the advantage of mild and solvent-free preparation, that is ideal for 
preserving protein integrity during the encapsulation step. The stability study to access the 
nanoparticle behaviour in the mucosal and cell culture media and to proceed with the further 
experimentation showed that the nanoparticles remained suspended for 24h. Even though 
there was a slight increase in the size of the nanoparticles in the mucosal medium, there was 
no reduction in the particle count. The slight increase in the particle size might be the result 
of higher viscosity of the mucosal medium that reduces the brownian moment of the 
nanoparticles. The incorporation of poloxamers in the formulation maintains the stability 
[33]. The nanoparticles freeze-dried in the presence of cryoprotectant did not show any 
increase in the hydrodynamic diameter of the nanoparticles after re-dispersing. This helps in 
long term storage of the nanoparticles in the powder form. In addition, the presence of the 




study, approximately 35 µg of GC was associated with per mg of CNPs. GC-CNPs released < 
30% of GC over 24h. The reason for this might be due to the strong association of the GC to 
the CNPs. The initial burst release might either correspond to the un-associated GC or the GC 
that is adsorbed on the surface of the CNPs. A similar phenomenon is seen in the literature 
where the CNPs were strongly associated with the antigen [45,46].  
Our study aimed to evaluate the role of nanoencapsulation in enhancing the immunogenicity 
against the GC. The groups immunized with GC-CNPs (S.C) displayed 10 and 100 folds greater 
anti-CP14 and anti-PsaA, respectively, IgG response in comparison to the GC (S.C). Strikingly, 
the IgG response induced by the GC-CNPs in mice was also higher than that previously 
observed for GC administered at a six times higher dose [12]. This is in agreement with 
published results where the encapsulation of antigen in the chitosan nanoparticles led to a 
ten-fold antigen dose reduction without affecting the level of the immune response [48]. In 
the first series of experiments, the functionality of Abs induced in mice was assessed using 
IAV infection challenge. The mice immunized with the GC-CNPs displayed greater protection 
over its counterparts immunized with GC. However, α-GalCer stimulates a non-specific 
immune response in control groups which protects against Flu and then Sp infection [47]. The 
-GalCer, an adjuvant used in this study is a glycosphingolipid that can potentially activate 
the NKT cells [48] and been explored as an adjuvant in both systemic and mucosal 
immunizations [49–51]. The adjuvant effect of chitosan is usually enhanced in the presence 
of an additional adjuvant. 
The generated IgG antibodies in the group treated with GC-CNPs were predominantly IgG1 
subclass. In the literature, it is seen that IgG1 subclass of antibodies are mainly induced by 
bacterial proteins, while the IgG2 antibodies are induced by capsular polysaccharides [52]. 




CP, while no IgG2a or IgG3 response was observed. Similar results were observed by Bal et 
al., when antigen-loaded trimethyl chitosan nanoparticles were injected intradermally [53]. 
The mice treated with GC-CNPs also displayed CP14 specific IgG1 response this is classically 
ascribed to the conjugation of the carbohydrate hapten herein Pn14TS to the carrier protein 
herein mPsaA. Interestingly, IgG2b against the CP14 was second prevalent subtype. The 
results are in agreement with the studies performed by Majela et al., [54] where the mice 
immunized with self-assembled PsaA particles produced predominantly IgG1 and IgG2b as a 
second predominant response. The generation of anti IgG1 Abs against both PsaA and CP can 
be attributed to the activation of phagocytosis by the macrophages [54]. The generation of 
IgG1 subclass antibodies corresponds to the Th2 (humoral) immune response and the IgG2b 
subclass is identified as a part of Th1 (cell-mediated) immune response [54,55]. The results 
are in agreement with the hypothesis that a vaccine based on PsaA can elicit both humoral 
and cellular immune response [56]. 
The second set of immunizations were performed to understand if the GC-CNPs can generate 
a greater immune response via I.N over S.C immunization. In this study, the GC-CNPs failed to 
produce anti-PsaA IgGs when administered through I.N (Figure 8A).  Whereas the same CNPs, 
when administered via S.C route, produced 100 folds higher anti-PsaA IgG response. This 
clearly displays that GC-CNPs were able to induce an anti-PsaA IgG response via S.C but not 
via I.N. It is well established that systemic routes of immunization are more efficient than 
intranasal one since they do not face to the mucosal barriers. Generally, the nanoparticles 
administered via mucosal routes tend to undergo mucosal clearance and hence the dose 
should be increased for mucosal immunization. In agreement with these observations, 




compared to the same CNPs administered I.N [57]. Herein it is surprising that GC was superior 
as an immunogen than GC-CNPs when administered I.N. On the contrary, the results show 
that the presence of CNPs is reducing the immune response produced against the GC when 
administered intranasally. The results displayed in the figure 8A, clearly demonstrate that the 
anti-PsaA IgG response is decreasing when the GC is co-administered with CNPs as a physical 
mixture via I.N. The anti-PsaA IgG response further reduced when the GC-CNPs were 
administered via I.N. It is surprising that the mice immunized with Prevenar 13 as control did 
not exhibit any IgG response against the CP14, while the GC administered via IN and GC-CNPs 
administered via S.C. produced IgG response. The studies on the quantification of IgA 
antibodies from the bronchial fluids of immunized mice show no IgA response (data not 
shown). However, the final study on the opsonophagocytosis from the serum of the 
immunized mice is underway. These results would be critical in concluding the role of 
nanoencapsulation of GC and the immunization route. 
Xu et al (2015) demonstrated that encapsulating the PsaA in chitosan nanoparticles and 
immunizing mice intranasally enhanced the IgG response against the PsaA and protected 
against pneumococcal infection challenges [58]. The results obtained from our study 
contradict these findings. In our study where the equal number of animals were used, the 
unencapsulated glycoconjugate (GC) displayed significantly higher IgG response when 
compared to the GC-CNPs. However, the number of injections made by Xu et al., were two 
times more (6 vs 3 injections) and the amount of protein (15 µg vs 5 µg/dose) was three times 
more than our study. Moreover, the mean particle sizes (695 nm vs 145 nm) as well as the 
composition of the CNPs (no poloxamer added in the literature protocol), were different. This 
finding brings the need to investigate further the influence of both nature and structure of 




response against the encapsulated GC. Considering the latter parameter, we cannot, of 
course, be sure that mucosal clearance is the only reason for reduction in IgG response in the 
groups treated with GC-CNPs via I.N. route. We do not know, how, GC interacts with CNPs 
when simply co-administered within a formulation and, beyond, whether CNPs facilitate the 
mucosal clearance of the glycoconjugate.  To date, there is no literature supporting this 
phenomenon while there are several studies that demonstrated the chitosan or CNPs as 
potential immunostimulants [59–62].  
Conclusions 
In this study, we reported chitosan nanoparticles as a potential carrier for semisynthetic 
glycoconjugate antigen. The nanoparticles were rationally prepared to encapsulate, control 
the release of antigen and maintain the stability in the mucosal medium. Moreover, the 
nanoparticles could be easily freeze-dried and reconstituted. The results obtained from the 
immunization studies suggest that the CNPs can enhance the immune response of GC when 
administered S.C. while the same CNPs were not effective via I.N administration. Overall, this 
study revealed that CNPs could enhance the immunological properties of both pneumococcal 
protein and carbohydrate components of glycoconjugate vaccine, encouraging the further 
study of the formulation as nanoparticulate vaccine delivery systems for preventing the 
infections against S. pneumoniae. 
5. Acknowledgements 
This work was supported by the grant from European Commission, Education, Audiovisual 
and Culture Executive Agency (EACEA), under the Erasmus Mundus programme, “NanoFar: 
European Doctorate in Nanomedicine and Pharmaceutical Innovation” (Project: 2015-01-C4). 





[1] Institute for Health Metrics and Evaluation (IHME), Findings from the Global Burden of 
Disease Study 2017, Seattle, 2018. 
http://www.healthdata.org/sites/default/files/files/policy_report/2019/GBD_2017_Booklet.
pdf (accessed September 23, 2019). 
[2] Streptococcus pneumoniae : Vaccines for AMR, (n.d.). https://vaccinesforamr.org/review-of-
pathogens/pathogen-profiles/streptococcus-pneumoniae/#impacte8a5-9923a88f-af42 
(accessed September 23, 2019). 
[3] K.A. Geno, G.L. Gilbert, J.Y. Song, I.C. Skovsted, K.P. Klugman, C. Jones, H.B. Konradsen, M.H. 
Nahm, Pneumococcal Capsules and Their Types: Past, Present, and Future, Clin. Microbiol. 
Rev. 28 (2015) 871–899. doi:10.1128/CMR.00024-15. 
[4] A. Torres, P. Bonanni, W. Hryniewicz, M. Moutschen, R.R. Reinert, T. Welte, Pneumococcal 
vaccination: what have we learnt so far and what can we expect in the future?, Eur. J. Clin. 
Microbiol. Infect. Dis. 34 (2014) 19–31. doi:10.1007/s10096-014-2208-6. 
[5] G. Rajam, J.M. Anderton, G.M. Carlone, J.S. Sampson, E.W. Ades, Pneumococcal Surface 
Adhesin A (PsaA): A Review, Crit. Rev. Microbiol. 34 (2008) 131–142. 
doi:10.1080/10408410802275352. 
[6] T.A. Olafsdottir, K. Lingnau, E. Nagy, I. Jonsdottir, Novel protein-based pneumococcal vaccines 
administered with the Th1-promoting adjuvant IC31 induce protective immunity against 
pneumococcal disease in neonatal mice, Infect. Immun. 80 (2012) 461–468. 
doi:10.1128/IAI.05801-11. 
[7] S. Rapola, V. Jäntti, R. Haikala, R. Syrjänen, G.M. Carlone, J.S. Sampson, D.E. Briles, J.C. Paton, 
A.K. Takala, T.M. Kilpi, H. Käyhty, Natural Development of Antibodies to Pneumococcal 
Surface Protein A, Pneumococcal Surface Adhesin A, and Pneumolysin in Relation to 
Pneumococcal Carriage and Acute Otitis Media, J. Infect. Dis. 182 (2000) 1146–1152. 
doi:10.1086/315822. 
[8] F.C.L. Csordas, C.T. Perciani, M. Darrieux, V.M. Gonçalves, J. Cabrera-Crespo, M. Takagi, M.E. 
Sbrogio-Almeida, L.C.C. Leite, M.M. Tanizaki, Protection induced by pneumococcal surface 
protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular 
polysaccharide, Vaccine. 26 (2008) 2925–2929. doi:10.1016/J.VACCINE.2008.03.038. 
[9] Q. Zhang, S. Choo, A. Finn, Immune Responses to Novel Pneumococcal Proteins Pneumolysin, 
PspA, PsaA, and CbpA in Adenoidal B Cells from Children, Infect. Immun. 70 (2002) 5363–
5369. doi:10.1128/IAI.70.10.5363-5369.2002. 
[10] K. Pauksens, A.C. Nilsson, M. Caubet, T.G. Pascal, P. Van Belle, J.T. Poolman, P.G. 
Vandepapelière, V. Verlant, P.E. Vink, Randomized controlled study of the safety and 
immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified 
pneumolysin with alum or adjuvant system AS02V in elderly adults., Clin. Vaccine Immunol. 
21 (2014) 651–60. doi:10.1128/CVI.00807-13. 
[11] A.D. Ogunniyi, J.C. Paton, Vaccine Potential of Pneumococcal Proteins, Streptococcus 
Pneumoniae. (2015) 59–78. doi:10.1016/B978-0-12-410530-0.00004-1. 
[12] M. Prasanna, D. Soulard, E. Camberlein, N. Ruffier, A. Lambert, F. Trottein, N. Csaba, C. 
Grandjean, Semisynthetic glycoconjugate based on dual role protein/PsaA as a pneumococcal 




[13] D. Safari, H.A.T. Dekker, J.A.F. Joosten, D. Michalik, A.C. De Souza, R. Adamo, M. Lahmann, A. 
Sundgren, S. Oscarson, J.P. Kamerling, H. Snippe, Identification of the Smallest Structure 
Capable of Evoking Opsonophagocytic Antibodies against Streptococcus pneumoniae Type 14 
ᰔ, 76 (2008) 4615–4623. doi:10.1128/IAI.00472‐08. 
[14] K.E. Morrison, D. Lake, J. Crook, G.M. Carlone, E. Ades, R. Facklam, J.S. Sampson, 
Confirmation of psaA in all 90 serotypes of Streptococcus pneumoniae by PCR and potential 
of this assay for identification and diagnosis, J. Clin. Microbiol. 38 (2000) 434–437. 
[15] J.S. Sampson, Z. Furlow, A.M. Whitney, D. Williams, R. Facklam, G.M. Carlone, Limited 
diversity of Streptococcus pneumoniae psaA among pneumococcal vaccine serotypes, Infect. 
Immun. 65 (1997) 1967–1971. 
[16] P. Schmid, S. Selak, M. Keller, B. Luhan, Z. Magyarics, S. Seidel, P. Schlick, C. Reinisch, K. 
Lingnau, E. Nagy, B. Grubeck-Loebenstein, Th17/Th1 biased immunity to the pneumococcal 
proteins PcsB, StkP and PsaA in adults of different age, Vaccine. 29 (2011) 3982–3989. 
doi:10.1016/j.vaccine.2011.03.081. 
[17] C. Entwisle, S. Hill, Y. Pang, M. Joachim, A. McIlgorm, C. Colaco, D. Goldblatt, P. De Gorguette 
D’Argoeuves, C. Bailey, Safety and immunogenicity of a novel multiple antigen pneumococcal 
vaccine in adults: A Phase 1 randomised clinical trial, Vaccine. 35 (2017) 7181–7186. 
doi:10.1016/j.vaccine.2017.10.076. 
[18] X. Shen, T. Lagergård, Y. Yang, M. Lindblad, M. Fredriksson, G. Wallerström, J. Holmgren, 
Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal 
immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B 
subunit conjugate, Vaccine. 19 (2001) 3360–3368. doi:10.1016/S0264-410X(00)00532-6. 
[19] J.-Y. Seo, S.Y. Seong, B.-Y. Ahn, I.C. Kwon, H. Chung, S.Y. Jeong, Cross-protective immunity of 
mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in 
microspheres., Infect. Immun. 70 (2002) 1143–9. doi:10.1128/iai.70.3.1143-1149.2002. 
[20] A. Donadei, C. Balocchi, M.R. Romano, L. Panza, R. Adamo, F. Berti, D.T. O’Hagan, S. Gallorini, 
B.C. Baudner, Optimizing adjuvants for intradermal delivery of MenC glycoconjugate vaccine, 
Vaccine. 35 (2017) 3930–3937. doi:10.1016/j.vaccine.2017.06.018. 
[21] T. Storni, M.K. Thomas, G. Senti, P. Johansen, Immunity in response to particulate antigen-
delivery systems, 57 (2005) 333–355. doi:10.1016/j.addr.2004.09.008. 
[22] B. Bernocchi, R. Carpentier, D. Betbeder, Nasal nanovaccines, Int. J. Pharm. 530 (2017) 128–
138. doi:10.1016/j.ijpharm.2017.07.012. 
[23] N. Csaba, M. Garcia-Fuentes, M.J. Alonso, Nanoparticles for nasal vaccination, Adv. Drug 
Deliv. Rev. 61 (2009) 140–157. doi:10.1016/j.addr.2008.09.005. 
[24] J.H. Xu, W.J. Dai, B. Chen, X.Y. Fan, Mucosal Immunization with PsaA Protein, Using Chitosan 
as a Delivery System, Increases Protection Against Acute Otitis Media and Invasive Infection 
by Streptococcus pneumoniae, Scand. J. Immunol. 81 (2015) 177–185. doi:10.1111/sji.12267. 
[25] D. Safari, M. Marradi, F. Chiodo, H.A. Th Dekker, Y. Shan, R. Adamo, S. Oscarson, G.T. Rijkers, 
M. Lahmann, J.P. Kamerling, S. Penadés, H. Snippe, Gold nanoparticles as carriers for a 
synthetic Streptococcus pneumoniae type 14 conjugate vaccine., Nanomedicine (Lond). 7 
(2012) 651–662. doi:10.2217/nnm.11.151. 
[26] R. Tada, H. Suzuki, S. Takahashi, Y. Negishi, H. Kiyono, J. Kunisawa, Y. Aramaki, Nasal 
vaccination with pneumococcal surface protein A in combination with cationic liposomes 




Streptococcus pneumoniae infections in mice, Int. Immunopharmacol. 61 (2018) 385–393. 
doi:10.1016/J.INTIMP.2018.06.027. 
[27] N.-H. Cho, S.-Y. Seong, K.-H. Chun, Y.-H. Kim, I. Chan Kwon, B.-Y. Ahn, S.Y. Jeong, Novel 
mucosal immunization with polysaccharide–protein conjugates entrapped in alginate 
microspheres, J. Control. Release. 53 (1998) 215–224. doi:10.1016/S0168-3659(97)00255-1. 
[28] J. Mosafer, A. Badiee, Z. Mohammadamini, A. Komeilinezhad, M. Tafaghodi, Immunization 
against PR8 influenza virus with chitosan-coated ISCOMATRIX nanoparticles, Artif. Cells, 
Nanomedicine, Biotechnol. 46 (2018) 587–593. doi:10.1080/21691401.2018.1464460. 
[29] P. Calvo, C. Remuñan‐López, J.L. Vila‐Jato, M.J. Alonso, Chitosan and Chitosan/Ethylene 
Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and 
Vaccines, Pharm. Res. 14 (1997) 1431–1436. doi:10.1023/A:1012128907225. 
[30] N. Riteau, A. Sher, Chitosan: An Adjuvant with an Unanticipated STING, Immunity. 44 (2016) 
522–524. doi:10.1016/J.IMMUNI.2016.03.002. 
[31] C. Paget, S. Ivanov, J. Fontaine, F. Blanc, M. Pichavant, J. Renneson, E. Bialecki, J. Pothlichet, 
C. Vendeville, G. Barba-Spaeth, G. Barba-Speath, M.-R. Huerre, C. Faveeuw, M. Si-Tahar, F. 
Trottein, Potential role of invariant NKT cells in the control of pulmonary inflammation and 
CD8+ T cell response during acute influenza A virus H3N2 pneumonia., J. Immunol. 186 (2011) 
5590–602. doi:10.4049/jimmunol.1002348. 
[32] K. Kosai, M. Seki, A. Tanaka, Y. Morinaga, Y. Imamura, K. Izumikawa, H. Kakeya, Y. Yamamoto, 
K. Yanagihara, K. Tomono, S. Kohno, Increase of apoptosis in a murine model for severe 
pneumococcal pneumonia during influenza A virus infection., Jpn. J. Infect. Dis. 64 (2011) 
451–7. http://www.ncbi.nlm.nih.gov/pubmed/22116322 (accessed October 17, 2019). 
[33] M.J. Santander-Ortega, A.B. Jódar-Reyes, N. Csaba, D. Bastos-González, J.L. Ortega-Vinuesa, 
Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation 
mechanisms, J. Colloid Interface Sci. 302 (2006) 522–529. doi:10.1016/J.JCIS.2006.07.031. 
[34] M.L. Kang, H.-L. Jiang, S.G. Kang, D.D. Guo, D.Y. Lee, C.-S. Cho, H.S. Yoo, Pluronic® F127 
enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of 
Bordetella bronchiseptica antigens containing dermonecrotoxin, Vaccine. 25 (2007) 4602–
4610. doi:10.1016/J.VACCINE.2007.03.038. 
[35] C.M. Coeshott, S.L. Smithson, E. Verderber, A. Samaniego, J.M. Blonder, G.J. Rosenthal, M.A.J. 
Westerink, Pluronic® F127-based systemic vaccine delivery systems, Vaccine. 22 (2004) 2396–
2405. doi:10.1016/J.VACCINE.2003.11.064. 
[36] M. Amidi, S.G. Romeijn, J.C. Verhoef, H.E. Junginger, L. Bungener, A. Huckriede, D.J.A. 
Crommelin, W. Jiskoot, N -Trimethyl chitosan ( TMC ) nanoparticles loaded with influenza 
subunit antigen for intranasal vaccination : Biological properties and immunogenicity in a 
mouse model, 25 (2007) 144–153. doi:10.1016/j.vaccine.2006.06.086. 
[37] N. Csaba, M. Köping-Höggård, M.J. Alonso, Ionically crosslinked chitosan/tripolyphosphate 
nanoparticles for oligonucleotide and plasmid DNA delivery, Int. J. Pharm. 382 (2009) 205–
214. doi:10.1016/J.IJPHARM.2009.07.028. 
[38] J. Xu, W. Dai, Z. Wang, B. Chen, Z. Li, X. Fan, Intranasal vaccination with chitosan-DNA 
nanoparticles expressing pneumococcal surface antigen A protects mice against 
nasopharyngeal colonization by Streptococcus pneumoniae, Clin. Vaccine Immunol. 18 (2011) 
75–81. doi:10.1128/CVI.00263-10. 




Nanoparticles as Adjuvant Codelivery on the Immunoglobulin G Subclass Distribution in a 
Mouse Model, J. Immunol. Res. 2017 (2017) 1–5. doi:10.1155/2017/9125048. 
[40] D. Pawar, K.S. Jaganathan, Mucoadhesive glycol chitosan nanoparticles for intranasal delivery 
of hepatitis B vaccine : enhancement of mucosal and systemic immune response 
Mucoadhesive glycol chitosan nanoparticles for intranasal delivery of hepatitis B vaccine : 
enhancement of muco, 7544 (2016). doi:10.3109/10717544.2014.908427. 
[41] W. Xu, Y. Shen, Z. Jiang, Y. Wang, Intranasal delivery of chitosan – DNA vaccine generates 
mucosal SIgA and anti-CVB3 protection, 22 (2004) 3603–3612. 
doi:10.1016/j.vaccine.2004.03.033. 
[42] R. Fernández‐Urrusuno, P. Calvo, C. Remuñán‐López, J.L. Vila‐Jato, M. José Alonso, 
Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles, Pharm. Res. 16 
(1999) 1576–1581. doi:10.1023/A:1018908705446. 
[43] T. Neimert-Andersson, A.C. Hällgren, M. Andersson, J. Langebäck, L. Zettergren, J. Nilsen-
Nygaard, K.I. Draget, M. van Hage, A. Lindberg, G. Gafvelin, H. Grönlund, Improved immune 
responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae 
type b glycoconjugate vaccine, Vaccine. 29 (2011) 8965–8973. 
doi:10.1016/j.vaccine.2011.09.041. 
[44] S.L. Nail, S. Jiang, S. Chongprasert, S.A. Knopp, Fundamentals of Freeze-Drying, in: Springer, 
Boston, MA, 2002: pp. 281–360. doi:10.1007/978-1-4615-0549-5_6. 
[45] S. Gordon, A. Saupe, W. McBurney, T. Rades, S. Hook, Comparison of chitosan nanoparticles 
and chitosan hydrogels for vaccine delivery, J. Pharm. Pharmacol. 60 (2008) 1591–1600. 
doi:10.1211/jpp.60.12.0004. 
[46] C. Bulmer, A. Margaritis, A. Xenocostas, Production and characterization of novel chitosan 
nanoparticles for controlled release of rHu-Erythropoietin, Biochem. Eng. J. 68 (2012) 61–69. 
doi:10.1016/J.BEJ.2012.07.007. 
[47] T. Nakamura, D. Yamazaki, J. Yamauchi, H. Harashima, The nanoparticulation by octaarginine-
modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic 
administration, J. Control. Release. 171 (2013) 216–224. doi:10.1016/j.jconrel.2013.07.004. 
[48] L.J. Carreño, S.S. Kharkwal, S.A. Porcelli, Optimizing NKT cell ligands as vaccine adjuvants, 
Immunotherapy. 6 (2014) 309–320. doi:10.2217/imt.13.175. 
[49] S.-Y. Ko, H.-J. Ko, W.-S. Chang, S.-H. Park, M.-N. Kweon, C.-Y. Kang, α-Galactosylceramide Can 
Act As a Nasal Vaccine Adjuvant Inducing Protective Immune Responses against Viral 
Infection and Tumor, J. Immunol. 175 (2005) 3309–3317. doi:10.4049/jimmunol.175.5.3309. 
[50] C.J.H. Davitt, S. Longet, A. Albutti, V. Aversa, S. Nordqvist, B. Hackett, C.P. McEntee, M. Rosa, 
I.S. Coulter, M. Lebens, J. Tobias, J. Holmgren, E.C. Lavelle, Alpha-galactosylceramide 
enhances mucosal immunity to oral whole-cell cholera vaccines, Mucosal Immunol. 12 (2019) 
1055–1064. doi:10.1038/s41385-019-0159-z. 
[51] G. Lu, A. Zhou, M. Meng, L. Wang, Y. Han, J. Guo, H. Zhou, H. Cong, Q. Zhao, X.Q. Zhu, S. He, 
Alpha-galactosylceramide enhances protective immunity induced by DNA vaccine of the 
SAG5D gene of Toxoplasma gondii, BMC Infect. Dis. 14 (2014). doi:10.1186/s12879-014-0706-
x. 
[52] C. Papadea, I.J. Check, Human Immunoglobulin G and Immunoglobulin G Subclasses: 





[53] S.M. Bal, B. Slütter, R. Verheul, J.A. Bouwstra, W. Jiskoot, Adjuvanted, antigen loaded N-
trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-
dependent immunogenicity in mice, Eur. J. Pharm. Sci. 45 (2012) 475–481. 
doi:10.1016/J.EJPS.2011.10.003. 
[54] M. González-Miro, L. Rodríguez-Noda, M. Fariñas-Medina, D. García-Rivera, V. Vérez-
Bencomo, B.H.A. Rehm, Self-assembled particulate PsaA as vaccine against Streptococcus 
pneumoniae infection., Heliyon. 3 (2017) e00291. doi:10.1016/j.heliyon.2017.e00291. 
[55] C.F.M. Vadesilho, D.M. Ferreira, A.T. Moreno, C. Chavez-Olortegui, R.A. Machado de Avila, 
M.L.S. Oliveira, P.L. Ho, E.N. Miyaji, Characterization of the antibody response elicited by 
immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA 
vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus 
pneumoniae, Microb. Pathog. 53 (2012) 243–249. doi:10.1016/J.MICPATH.2012.08.007. 
[56] R. Palaniappan, S. Singh, U.P. Singh, S.K.K. Sakthivel, E.W. Ades, D.E. Briles, S.K. Hollingshead, 
J.C. Paton, J.S. Sampson, J.W. Lillard, Jr., Differential PsaA-, PspA-, PspC-, and PdB-specific 
immune responses in a mouse model of pneumococcal carriage., Infect. Immun. 73 (2005) 
1006–13. doi:10.1128/IAI.73.2.1006-1013.2005. 
[57] S.M. Bal, B. Slütter, R. Verheul, J.A. Bouwstra, W. Jiskoot, Adjuvanted, antigen loaded N-
trimethyl chitosan nanoparticles for nasal and intradermal vaccination: Adjuvant- and site-
dependent immunogenicity in mice, Eur. J. Pharm. Sci. 45 (2012) 475–481. 
doi:10.1016/j.ejps.2011.10.003. 
[58] J.-H. Xu, W.-J. Dai, B. Chen, X.-Y. Fan, Mucosal Immunization with PsaA Protein, Using 
Chitosan as a Delivery System, Increases Protection Against Acute Otitis Media and Invasive 
Infection by Streptococcus pneumoniae, Scand. J. Immunol. 81 (2015) 177–185. 
doi:10.1111/sji.12267. 
[59] R. Scherließ, S. Buske, K. Young, B. Weber, T. Rades, S. Hook, In vivo evaluation of chitosan as 
an adjuvant in subcutaneous vaccine formulations, Vaccine. 31 (2013) 4812–4819. 
doi:10.1016/J.VACCINE.2013.07.081. 
[60] P. Watts, A. Smith, M. Hinchcliffe, ChiSys® as a Chitosan-Based Delivery Platform for Nasal 
Vaccination, in: Mucosal Deliv. Biopharm., Springer US, Boston, MA, 2014: pp. 499–516. 
doi:10.1007/978-1-4614-9524-6_23. 
[61] D.A. Zaharoff, C.J. Rogers, K.W. Hance, J. Schlom, J.W. Greiner, Chitosan solution enhances 
both humoral and cell-mediated immune responses to subcutaneous vaccination, Vaccine. 25 
(2007) 2085–2094. doi:10.1016/J.VACCINE.2006.11.034. 
[62] Z.-S. Wen, Y.-L. Xu, X.-T. Zou, Z.-R. Xu, Chitosan nanoparticles act as an adjuvant to promote 
























This work was performed in collaboration with Department of Biochemistry and Molecular 









Interaction of glycoconjugate loaded chitosan nanoparticles with human 
dendritic cells  
Abstract  
Nanoparticle delivery systems have been extensively studied for vaccination, as they can 
enhance the immunogenicity of antigens by protecting them from degradation and increasing 
their uptake by antigen presenting cells. Despite their potential utilisation, their clinical 
application is limited due to the lack of knowledge on the interaction of the nanoparticles 
with the immune system. This study was focused on understanding the presentation of 
glycoconjugate (GC) loaded chitosan nanoparticles (CNPs) by human monocyte-derived 
dendritic cells (MoDCs). For this purpose, GC loaded chitosan nanoparticles (GC-CNPs) were 
investigated for their compatibility with immune cells, uptake and immuno-stimulatory 
properties. The glycoconjugate (Pn14TS-PsaA/GC) encapsulated in the CNPs was earlier 
synthesised and characterized in our laboratory. The nanoparticles were compatible with DCs. 
Flow cytometry and confocal microscopy analysis confirmed that DCs internalized GC-CNPs 
within 2h. GC-CNPs promoted DC maturation and enhanced expression of the co-stimulatory 
molecules CD80, CD83 and CD86. Furthermore, significant activation of CD8+ T cells was 
observed in the DCs treated with the CNPs. The GC-CNPs treated DCs showed an increased 
proinflammatory cytokine (TNF-α) response in comparison to the GC alone. In conclusion, the 
encapsulation of the GC in CNPs showed the enhanced uptake and displayed better 
immunostimulatory properties in comparison to the naked GC. 
Keywords: Chitosan, Nanoparticles, Glycoconjugate, Dendritic cells, Pneumococcal surface 












1. Introduction  
The central hallmark for effective vaccination is to prime the adaptive immune response. This 
requires the activation of naive B and T lymphocytes into effectors cells that translate into 
protective immunity. Dendritic cells (DCs) are the primary antigen presenting cells (APCs) that 
play a key role in the orchestration of the humoral and cell-mediated immunity [1,2]. As APCs, 
DCs act as the connection between innate and adaptive arms of the immune system [2,3]. For 
the presentation of the antigens by DCs, it is crucial that the DCs undergo maturation and 
express high levels of MHC-II and other co-stimulatory molecules like CD80 and CD86. Having 
the capacity to capture and process the exogenous antigens, DCs can effectively stimulate 
naive T cells against them. 
The quest for safer vaccines has increased the demand for the subunit vaccines that are 
composed of purified bacterial or viral components. Most of these newly developed sub-unit 
vaccines are weakly immunogenic [4,5]. Their poor immunogenicity is attributed to the small 
size and the lack of pathogen-associated molecular patterns that are essential for antigen 
recognition. In order to trigger the immune response, the subunit vaccines are co-
administered with the adjuvants or delivered via particulate systems. The major hurdle of 
developing an effective and successful vaccine is to design antigen delivery systems showing 
broad protective immune responses.  
The nanoparticle-based delivery systems offer several advantages due to their 
physicochemical characteristics like particle size, surface charge, and immunostimulatory 
properties [6,7]. They tend to mimic the pathogens with their size, shape and often by 




and control the release of the antigen [10,11]. In recent years, the use of biocompatible and 
biodegradable polymers has been investigated as adjuvants and antigen carriers. Polymers 
like chitosan, alginate, protamine, dextran, hyaluronic acid, and poly(lactic-co-glycolic acid) 
(PLGA) have been investigated for protein/peptide [12] or DNA-based vaccines [13]. Amongst 
them, chitosan is a nontoxic, biocompatible, biodegradable and mucoadhesive natural 
polymer, that is considered as an excellent biomaterial for the design of antigen carriers [14]. 
As an immune adjuvant, chitosan is known to enhance humoral and cellular immunity [15]. 
Despite their positive attributes, limitations such as burst release, poor mechanical properties 
and stability in biological media pose a stiff challenge to their universal acceptability as a drug 
carrier [16]. However, the previously mentioned positive attributes of the chitosan 
nanoparticles dominate its shortcomings. Therefore, these properties fostered researchers to 
adopt chitosan nanoparticles (CNPs) as a carrier for vaccine delivery.  
In our previous studies, we produced a synthetic mimic of S. pneumoniae type 14 capsular 
polysaccharide (Pn14TS) and conjugated it to pneumococcal surface adhesin A (PsaA), using 
thiol maleimide coupling chemistry to obtain a semisynthetic glycoconjugate. The 
immunization studies in mice have shown that synthesized glycoconjugate (Pn14TS-PsaA/GC) 
was able to induce the production of IgGs against both the synthetic oligosaccharide and the 
protein moieties [17]. In the present study, the GC loaded CNPs were prepared by the ionic 
gelation method [12], and a systematic study was performed to understand the influence of 
the CNPs in presenting the GC to the APCs. For this purpose, PsaA, GC, blank CNPs and GC 
loaded CNPs (GC-CNPs), were compared in a systematic study. This included the in vitro 
evaluation of antigen uptake and their localization in the DCs and upregulation of the 




antigen carrier, the studies on DC stimulation and DC-mediated T lymphocyte stimulation 
were performed. 
2. Materials and Methods 
2.1. Materials 
Pneumococcal surface adhesin A (PsaA) and GC were produced and synthesised respectively 
at UFIP, University of Nantes [17]. The cytokines IL-4, GM-CSF, INF-γ were procured from 
Miltenyi Biotech. PBS (pH 7.2), RPMI 1640, PSG 100X and fetal bovine serum (FBS) were 
obtained from Gibco, Life technologies. Ficoll Histopaque 1077, paraformaldehyde, DAPI, 
Triton X-100 and pentasodium tripolyphosphate were procured from Sigma Aldrich. The 
pharmaceutical grade water-soluble chitosan with an acetylation degree of 80% was 
purchased from HMC+ biopolymers. Kolliphor P 188 was obtained as a gift sample from BASF. 
All the antibodies used for FACS analysis were either obtained from Miltenyi Biotech or Sigma 
Aldrich. Pierce Chromogenic Endotoxin Quant Kit (A39552) was procured from Thermo 
Fischer Scientific. The Cy5-NHS was purchased from Lumiprobe. The gel filtration columns 
(centripure PD10 columns) were obtained from EMP Biotech. All the other chemicals and 
reagents used were analytical grade.  
2.2. Preparation of antigen loaded chitosan nanoparticles 
Chitosan nanoparticles (CNPs) were prepared by the ionotropic gelation of chitosan with 
tripolyphosphate (TPP), according to the method previously reported by our group [12]. In 
brief, glycoconjugate-loaded chitosan nanoparticles (GC-CNPs) were fabricated by adding 500 
μL of TPP (0.4 mg/mL) to 1 mL of chitosan (0.1% w/v) in 1% poloxamer 188 containing 50 μg 
of GC and kept under magnetic stirring (1000 rpm) for 1h. The polymer to antigen ratio was 




centrifugation at 12,000 g for 12 min. Supernatants were discarded, and particles were 
resuspended in ultrapure water.  
The hydrodynamic diameter and polydispersity index (PDI) of the particles were determined 
by dynamic light scattering (DLS) and the zeta potential was measures by laser doppler 
anemometry using a Zetasizer Nano-ZS90 (Malvern Instruments; Malvern, UK). All the 
measurements were performed at 25 °C with a detection angle of 173° in distilled water, 
unless otherwise indicated. 
2.3. Preparation of Cy5 labelled nanoparticles 
For in vitro studies the CNPs were fluorescently labelled with Cy5. For this, during the 
preparation of the CNPs, 2% of chitosan was replaced with the Cy5-labelled chitosan (Cy5-
chitosan). The detailed synthesis of Cy5-chitosan is mentioned in the previous chapter 
(Chapter 2; Section 2.3). 
2.4. Endotoxin testing  
The quantification of endotoxins in the samples used for DC cell studies was performed using 
the Pierce Chromogenic Endotoxin Quant Kit (A39552). Briefly, 2 micrograms of antigen (PsaA 
or GC) or 50 micrograms of chemicals (Chitosan, Kolliphor-188 or TPP) were suspended in 
water and tested for the presence of endotoxin according to the manufacturer’s instructions 
[18]. The calibration curve (0.1–8 EU/mL) was constructed using a stock solution of 10 EU/mL. 
To avoid external endotoxin interference, all the dilutions were prepared in endotoxin-free 
water, which was also used as blank. All the tubes and tips used to perform this quantification 





2.5. Donor selection and blood collection 
Buffy-coats used in the experiments were obtained from anonymous donors and were kindly 
donated by the Agency for the Donation of Organs and Blood (ADOS, Santiago de Compostela) 
with the approval of the Director of the Agency and the Clinical Research Ethics Committee 
of Galicia (2014/543). Freshly obtained buffy coats were used within 24h. Heparinized blood 
samples were obtained from healthy volunteers among the staff of Faculty of Pharmacy, 
University of Santiago de Compostela, and CiMUS. Before the collection, informed consent 
was obtained from the volunteers in accordance with the guidelines of the Ethical Committee 
of Clinical Research of Galicia.  
2.6. Dendritic Cell (DC) and Peripheral blood lymphocytes (PBLs) generation 
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient centrifugation 
method. Adherent monocytes were isolated by incubating PBMCs in culture plates (2h, 37 °C) 
in R2 culture media (RPMI-1640 completed with 2% of FBS). After the incubation period, non-
adherent cells were washed thrice with PBS and adherent monocytes were cultured for six 
days in R10 media (RPMI-1640 completed with 10% FBS) supplemented with GM-CSF and IL-
4 (100 ng/mL each). After three days, half of the media was replaced with fresh R10 
supplemented with equal amounts of cytokines. The resultant immature DCs (iDCs) were 
scraped and collected from the culture plates on day 6. These iDCs were used for further 
experimentation. 
Mature DCs (mDCs) were obtained by incubation of iDCs with bacterial lipopolysaccharide 
(LPS) (10 ng/mL) and interferon-γ (IFN-γ) (100 U/mL) for 48h. The peripheral blood 




washing the non-adherent cells after incubating the PBMCs for 2h at 37 °C and these non-
adherent PBLs were stored in liquid nitrogen until further use. 
2.7. Cytocompatibility Studies 
The cytocompatibility assay of GC-CNPs in the DCs was performed by MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay. 
The generated iDCs (1 x 105 cells/mL) were incubated with different concentrations of the 
CNPs (25, 50, 100, 200, 400 and 900 μg/mL) for 24h. The untreated iDCs were used as a 
positive control. After 24h incubation with the CNPs, the cells were washed with PBS and 
were incubated with fresh R10 media for another period of 24h, and 20 μL of MTS reagent 
was added to each well after 20h and incubated for another 4h. The intensity of colour was 
quantified by measuring the absorbance at 490 nm using a spectrophotometer. The results 
were plotted as percentage (%) viability v/s the nanoparticle concentration. The percentage 
viability is a difference of metabolically active cells in the untreated group and the groups 
treated with the nanoparticles. 
The cytocompatibility of blank CNPs and GC-CNPs was also studied using 7-amino actinomycin 
D (7-AAD). Briefly, following the incubation of iDCs with blank CNPs or GC-CNPs (25, 50, 100, 
200, 400 and 900 μg/mL) for 24h, cells were harvested, washed twice with PBS and stained 
with 7 AAD (1 μL per tube (0.05 μg/μL)), for 30 min at 4 °C. After washing 3 times with PBS 
containing 2% BSA, the cells were analysed by flow cytometry (BD FACS Calibur™ cytometer). 
Data were analysed using Flowing software (Cell Imaging Core, Turku Centre for 
Biotechnology, Finland). Data are shown as the percentage of cells viable after incubating 






2.8. The study on internalization of nanoparticles by DCs  
To evaluate the time-dependent uptake of CNPs by human MoDCs, iDCs (5x105 per well) were 
plated into a 24-well plate with 0.5 mL of R10 media. Immediately, Cy5-labelled GC-CNPs (Cy5-
GC-CNPs) were added at a concentration of 50 μg/mL. At different time intervals (0, 0.5, 1, 2 
and 4h of incubation), cells were collected for uptake analysis. The collected cells were 
washed immediately with PBS and fixed in a flow cytometry tube using 200 μL of PBS 
containing 1% paraformaldehyde (1% PFA). As a control, the MoDCs treated with an equal 
amount of CNPs at 4 °C was used. The samples were diluted with 500 μL of PBS, and the 
suspension was analysed by flow cytometry (BD FACS Calibur™ cytometer). The surface 
morphology of the macrophages incubated with the nanoparticles (50 μg/mL, for 0.5 h, at 37 
°C) was performed using FESEM, (ZEISS FESEM ULTRA Plus, Germany).  
In addition, uptake studies were performed in the cells (5 x 105 cells per well) pre-treated with 
chlorpromazine (CLO), cytochalasin D (Cit-D), dimethyl amiloride (DHA) in R10 medium for 1h 
at 37 °C. Next, the Cy5-GC-CNPs (50 µg/mL) were added to iDCs and incubated for 4h at 37 
°C. Afterwards, the iDCs were collected by pipetting, washed twice (300 x g, 7 min, 4 °C) with 
PBS and fixed using 4% PFA (15 min, RT). The uptake of the nanoparticles in the DCs treated 
with inhibitors was determined using flow cytometry and compared against uptake in the 
untreated iDCs. 
For CSLM analysis, the DCs (5x105 per well) were plated into a 24-well plate with 0.5 mL of 
R10 media and incubated for 30 min. Following that the DCs were incubated with the Cy5 
labelled GC-CNPs for 1h. After the incubation time, the DCs were washed with PBS and seeded 




min. Afterwards, the cells were fixed with 4% PFA for 15 min. The DCs were permeabilized/ 
fixed using 100 μL of BD Citofix / Citoperm™ (15 min, RT, in the dark) and were washed twice 
with PBS. The cells were stained using DAPI and phalloidin-488 and fixed on the glass slide 
using mounting medium (Vectashield® Antifade Mounting Medium, Vector Labs, USA). The 
image acquisition was made using CLSM (Leica SP5, Mannheim, Germany). Excitation 
wavelengths were 670 nm for Cy5 and 488 nm for Alexa 488.   
2.9. Study on effect of GC-CNPs on DC maturation by phenotypic analysis 
For the phenotypic analysis, the iDCs were seeded on 24 well plates at a density of 5 x 105 
cells per well 0.5 mL of R10 media. The DCs were incubated for 48 h at 37 °C in R10 with blank 
or GC-CNPs using LPS (10 ng/mL) as a positive control. After 48 h of incubation, the generated 
DCs were collected, washed twice (300 x g, 7 min, 4 °C) with PBS containing 0.1% BSA. DCs 
were resuspended in 200 μL of PBS with 1% FCS (1% PBS), of this 100 μL of the DCs were 
incubated with 50x diluted anti-CD83-PE, anti-CD86-APC and anti-CD1a, another 100 μL with 
50× diluted anti-CD80-PE, anti-HLA-APC and anti-CD1a-FITC (in all cases, for 30 min, in dark, 
on ice). CD1a was included as a DC marker to verify correct monocyte differentiation. After 
the 30-minute staining period, the cells were harvested, washed thrice with 1% PBS and 
resuspended in 500 μL of PBS. The DCs were quantified for the expression of CD80, CD83, 
CD86 and HLA using flow cytometry (BD FACS Calibur ™ flow cytometer; BD Biosciences, 
Madrid). The cytometry data were analysed using the Flowing software program (Cell Imaging 
Core, Turku Centre for Biotechnology, Finland). The forward versus side scattering was used 
for gating the live cells and the CD1a positive cells were picked for the quantification of co-
stimulatory markers. The expression of cytokines from the CNPs treated DCs were compared 




2.10. T cell stimulation by GC-CNPs 
Heparinized whole blood was taken from 4 healthy human volunteers and the peripheral 
blood mononuclear cells (PBMCs) were collected by Ficoll Histopaque density gradient 
centrifugation and washed twice with ice-cold PBS. Collected PBMCs were seeded in 24 well 
plates at a density of 1.0 × 106 per well using 0.5 mL of R10 media. The PBMCs were treated 
with different components of formulation (Pn14TS, PsaA, GC, Blank CNPs and GC-CNPs). The 
DCs treated with Staphylococcus Enterotoxin-B (SEB), LPS were used as positive controls and 
the untreated DCs were used as control and incubated for 48h at 37 °C. After 48h incubation, 
brefeldin (5 μg/mL) was added to block the cytokine secretion and incubated at 37 °C 
overnight. The following day, the cells were harvested, washed with 1% PBS. Further, the cells 
were stained with 5 μL CD3-FITC, washed twice with 1% PBS and were fixed using 1% PFA for 
15 min at RT. The cells were centrifuged and permeabilized with BD Citofix / Citoperm™ (15 
min, RT, in the dark), and the cells were resuspended in 100 μL of Citofix / Citoperm™. The 
staining was performed by adding 5 μL of TNF-α-PE for each tube (30 min, on ice, in the dark). 
The cells were washed twice using Citofix / Citoperm™ and resuspended in 0.5 mL of PBS and 
analysed by using flow cytometry (BD FACS Calibur™ flow cytometer; BD Biosciences, 
Madrid). 
2.11. Activation of allogenic T cells by antigen primed DCs 
The immature DCs (iDCs) and the non-adherent cells (peripheral blood lymphocytes, PBLs) 
were obtained according to the methods mentioned (Section 2.6). Mature DCs (mDCs) were 
obtained by incubation of iDCs with bacterial lipopolysaccharide (LPS) (10 ng/mL) and 
interferon-γ (IFN-γ) (100 U/mL) for 48h. The capacity of iDCs pre-incubated with the PsaA, 




allogenic culture was determined by flow cytometry. Briefly, after incubation of iDCs with the 
CNPs (50 μg/mL) and PsaA (2 μg/mL) for 24h, cells were harvested, washed with PBS and 
plated with allogenic T cells (non-adherent PBLs) at a 1: 10 ratio (DC: T) for 7-10 days. After 
the activation and proliferation period, cells were harvested, washed and stained with 5 μL of 
CD8-FITC and CD28-PE or CD4-APC and CD25-PE antibodies and analysed by using flow 
cytometry (BD FACS Calibur™ flow cytometer; BD Biosciences, Madrid). 
2.12. Statistical Analysis 
The statistical analysis was performed using GraphPad prism 7 software. The 2way ANOVA 
Bonferroni’s multiple comparison test, one-way ANOVA with Kruskal-Wallis analysis by 
Dunn’s multiple comparison test and one-way ANOVA with Bonferroni’s multiple comparison 
test were used to calculate statistical significance. 
3. Results and Discussion 
3.1. Nanoparticles preparation and characterization 
The aqueous dispersion of CNPs had an average diameter of 140 ± 4 nm and the zeta potential 
of 32.3 ±0.2 mV. The PDI of the GC-CNPs was shown to be less than 0.2, indicating the 
homogeneity of the nanoparticles. Next, encapsulation efficiency of the protein GC loaded in 
the CNPs was analysed and was found to be 70 ±3%. To track the uptake of CNPs, the 
nanoparticles were prepared by using Cy5-labelled chitosan. The particle size analysis showed 
the Cy5-GC-CNPs had an average diameter of 150 ±9 nm and zeta potential of 30 ±2 mV. All 
the components used in the preparation of CNPs were assayed for the detection of endotoxin 
activity using the end-point chromogenic Limulus Amoebocyte assay (LAL test). Endotoxin 
content was lower than 0.5 EU/μg in all the cases (Figure 1), which are far below the maximum 




colloidal stability of the nanoparticles was evaluated by measuring their size and PDI in the 
R10 medium and was found to be concentration dependent. The aggregation of the CNPs was 
observed when the concentrations were above 500 μg/mL in R10 media after 24h. Below this 
concentration, the NPs showed no signs of aggregation (data not shown).   
 
 
Figure 1. Endotoxin analysis of CNPs formulation components. A) The calibration curve used to 
quantify the endotoxin level in the formulation components. B) Endotoxin quantification in the 
different CNPs components. As can be seen, all of them shows levels below 0.5 EU/g.  
 
3.2. In vitro evaluation of dendritic cells viability in the presence of chitosan 
nanoparticles 
To study the influence of the GC-CNPs concentration on the metabolic activity and/or survival 
of iDC an MTS assay was performed. As seen in Figure 2A, the GC-CNPs displayed the dose-
dependent reduction in the metabolic activity of iDCs. Over 80% of the iDCs were 
metabolically active when treated with GC-CNPs in the concentration range of 25 to 100 
μg/mL. Whereas, the metabolic activity was reduced to 60% in the concentrations of 200 to 
400 μg/mL and significantly reduced down to 40% when treated with 900 μg/mL of GC-CNPs. 
The results suggest that the GC-CNPs at a concentration of 25 to 100 μg/mL were in the 
acceptable non-toxic range. The toxicity seen at the higher concentrations might be due to 
the possibility of the nanoparticle aggregation at higher concentrations after 12h. However, 




of 0.1 mg/mL or lower. In this regard, the GC-CNPs at a concentration of 50 μg/mL was 
adopted for further studies. 
 
Figure 2. Chitosan Nanoparticles (CNPs) cytotoxicity on immature dendritic cells (iDCs). A) MTS 
staining assay; B) 7-AAD assay was performed for both GC-CNPs (blue lines) and blank CNPs (red lines) 
and C) Representative histograms obtained from flow cytometric analysis after 7-AAD staining. Results 
are presented as mean± SD from 4 donors.  
In a likely manner, the cytocompatibility of the nanoparticles with DCs was studied using 7 
AAD assay.  7 AAD is a fluorescent DNA dye that can pass the plasma membrane of the cell 
which is apoptotic or dead. The dose-dependent mortality of the DCs was observed in Figure 
2B. The GC-CNPs at the concentration range of 25 to 200 μg/mL displays over 90% survival 
and 80% at 400 μg/mL. At the highest concentration of 900 μg/mL, the DCs displayed 75% 
survival (see also Figure 2C for representative histograms). However, the mortality of the DCs 




of cytocompatibility and considered to be least toxic to DCs at the concentrations below 200 
μg/mL. 
3.3. The GC-CNPs are effectively internalized by the DCs 
The uptake of GC-CNPs in DCs was studied as the function of incubation time at different 
temperatures of incubation. As can be seen in Figure 3A, the pattern of GC-CNPs (50 μg/mL) 
internalization in DCs at 37 °C shows greater uptake with the increase in incubation time. 
However, only 10% increase in the GC-CNPs uptake was observed between 2h and 4h of 
incubation at 37 °C. While the DCs incubated at 4 °C as a control (treated with 50 µg/mL of 
GC-CNPs), did not show any significant uptake of GC-CNPs even after 4h, showing a specific 





Figure 3: The internalization of the Cy5-GC-CNPs are studied in MoDCs. As shown in (A) Time-
dependent uptake of Cy5‐labeled GC-CNPs (50 μg/mL) at 4 °C and 37 °C analyzed by flow cytometry. 
(B) Comparison of untreated DCs with Cy5-GC-CNPs (50 μg/mL for 2 h at 37 °C) treated DCs, is 
represented as dot plot and histogram. Results are presented as mean± SD from 3 donors. Statistical 
difference between the groups is *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.   
Further to this, the CLSM was used to examine the localization of GC-CNPs in DCs. For the 
intracellular localization the nanoparticles were probed with Cy5. In the Figure 4A the co-
localization of Cy5-GC-CNPs (red) and the nucleus stain (blue) confirms the uptake of 
nanoparticles by the DCs. The z-stack of the images in Figure 4A confirms the internalization 
of the nanoparticles by DCs. Further, cytoskeleton labelling (phalloidin-488, green) of the DCs 
were performed to see if the nanoparticles were associated with the cell membrane or 




nanoparticles were mostly inside the DCs with very slight or no adsorption to the surface of 
DCs. 
 
Figure 4: Internalization of the Cy5-GC-CNPs in DCs. Confocal microscopy images of the DCs incubated 
without or with Cy5-GC-CNPs. (A) DCs with DAPI staining and (B) DCs with cytoskeleton staining using 
phalloidin-488 (F-actin) and nucleus staining using DAPI. Red channel: Cy5-GC-CNPs; blue channel: cell 





In the Figure 5B, from the micrographs obtained from FEG-SEM, we can visualize the uptake 
of GC-CNPs by the DCs. This was observed after 0.5h of co-incubation of the GC-CNPs with 
the DCs. During the sample preparation for imaging, the monocytes undergo a series of 
washings to retain only the GC-CNPs firmly attached to the cell membrane and this helps in 
visualization of the nanoparticles that are being internalized by the DCs and not the 
nanoparticles that are adsorbed to the cell surface. The red arrow marks in the Figure 5B 
indicate the nanoparticles that are being internalized by DCs. In addition, the film that can be 
observed on the nanoparticles might be the cell membrane that is ruffling around the 
nanoparticle for their internalization. However, these studies are preliminary and further 
studies are in progress to understand this in detail. 
 
 
Figure 5: Assessment of GC-CNPs uptake by monocytes using FEG-SEM. A) untreated monocytes B) 
Monocytes treated with GC-CNPs. The GC-CNPs are pointed with the red arrow marks. 
Next, we investigated the pathways by which the GC-CNPs were internalized. To perform this, 




chlorpromazine (Clathrin-mediated endocytosis, CLO), cytochalasin D (actin-mediated 
phagocytosis, Cit-D) and dimethyl amiloride (micropinocytosis, DHA). The uptake of the 
nanoparticles was not affected by the presence of CLO or DHA, while the GC-CNPs uptake was 
slightly reduced in the presence of Cit-D as seen in Figure 6A, which indicates phagocytosis as 
a possible mechanism of uptake. Next, we further tried to block the uptake by a combination 
of different inhibitors (DHA+CLO, DHA+Cit-D, CLO+Cit-D and DHA+CLO+Cit-D). The DCs pre-
treated with the DHA+Cit-D and CLO+Cit-D showed a slight reduction in the uptake of GC-
CNPs. This indicates the phagocytosis as the critical mechanism of nanoparticle uptake. 
However, the results obtained are not statistically significant. Altogether, results show that 
the GC-CNPs are probably internalized by multiple uptake pathways and blocking one of them 
might force the DCs to internalize the GC-CNPs by alternative routes. However, the detailed 
study on the uptake mechanism should be performed using the inhibitors like dextran sulfate, 





Figure 6: Effect of endocytic inhibitors on the internalization of GC-CNPs in the MoDCs. MoDCs were 
either untreated or pre-treated with chlorpromazine (10 µg/mL, clathrin-mediated endocytosis), 
cytochalasin D (10 µg/mL, phagocytosis), or amiloride (50 µM, micropinocytosis) and were incubated 
with GC-CNPs (50 µg/mL, 4h). Results are presented as mean± SD from 4 donors.  
3.4. Chitosan nanoparticles enhance expression of the co-stimulatory molecules CD80 
and CD86 on DCs 
The study on the expression of co-stimulatory markers was undertaken to elucidate the effect 
of GC-CNPs on DC maturation. The co-stimulatory marker CD86 designates to be a marker of 
primary DC maturation, while CD80 only increases in mature DC. Many studies have shown 
that antigen delivery to DCs upregulates expression of both CD80 and CD86 that are known 
to induce T cell receptor signalling and promote T cell activation [20]. The CD83 is most 
characteristic of cell surface markers for fully matured DCs, whose role is regulating the 





Figure 7: GC-CNPs induce moDC activation and maturation. The bars in the different colors indicate 
GC (Blue), Blank CNPs (Red), GC-CNPs (green) and the control with LPS+ INF-γ treatment (Purple). The 
data represent the mean ±SD of the results obtained from the 4 donors.  
As illustrated in Figure 7, iDCs treated with blank CNPs and GC-CNPs showed an enhanced 
expression of CD80, CD83 and CD86 markers, although this upregulation does not reach 
statistical significance probably due to the variability seen among the different donors. 
Moreover, there was no marked increase in the HLA expression with the same treatments 
probably due to the high expression level seen already in untreated iDCs.  
The stimulation of DCs with different concentrations of nanoparticles showed that the 




was highest at 100 µg/mL concentration. The CD80 upregulation was observed only at 100 
µg/mL and not at the lower concentrations. The CD83 upregulation was observed when 
treated with nanoparticles and was independent of their concentration. The DCs treated with 
blank CNPs and GC-CNPs displayed a similar profile of activation marker expression, but the 
upregulation was always higher in the case of GC-CNPs. This suggests that the presence of GC 
in the CNPs potentiate the stimulation of the CD80, CD83 and CD86 by the DCs. The DCs 
treated with the GC alone, showed similar CD83, lower CD86 and no CD80 upregulation when 
compared to the GC-CNPs treated DCs. Finally, a clear upregulation of all co-stimulatory 
molecules is seen when iDCs were treated with LPS and INF-γ (Figure 7, violet columns) and 
higher for both CD83 and CD86 when compared to CNP-treated DCs but not for CD80. 
These results can emphasize the role of CNPs as an adjuvant in DC stimulation. Chitosan is 
known for its role in macrophage activation, and upregulation of the cytokines. There were 
low levels of endotoxin detected in our formulations (see Figure 1) and the results obtained 
are not due to the endotoxin activation. Overall, the results suggest that the nanoparticles 
alone or in combination with GC can upregulate the co-stimulatory markers in comparison to 
the GC alone, suggesting the adjuvant property of the CNPs.  
3.5. DCs matured by the CNPs stimulate T cells 
Next the role of different components of the CNPs in the stimulation of both peripheral 
lymphocytes and monocytes was determined by the quantification of TNF-α secreted by 
these cell types. SEB was used as a positive control for T lymphocyte stimulation, whereas LPS 
was used as a positive control for monocyte stimulation (Figure 8). When PBMCs were 
incubated with CNPs or their components no significant activation of T lymphocytes 




was seen in the case of peripheral monocytes. Treatment with blank CNPs stimulate more 
TNF-α production by monocytes compared to the untreated iDCs, but to a lesser extent when 
compared to the GC-CNP treated PBMCs. iDCs incubated with GC-CNP synthesise more TNF-
 compared to their individual antigenic components (Pn14TS and mPsaA; Figure 8, 
monocytes). However, it is interesting to notice that the GC alone induce the secretion of 
TNF- by monocytes to a level similar seen using LPS. This increase in the TNF- by monocytes 
might be associated with the conjugation of tetrasaccharide to the carrier protein. The ability 
of the CNPs (either blank and GC-CNPs) to induce TNF-α secretion mainly by monocytes 
indicates the capacity of these nanoparticles to activate APCs (as suggested above for DCs) 
and their precursors (i.e. monocytes) to trigger a significantly higher activation of the adaptive 
immune system (i.e. T lymphocytes) and induce protective activity against the pathogens. 
 
Figure 8: The graphs indicate the percentage of TNF-α positive cells after treatment with SEB, LPS, 
Pn14TS, PsaA, GC, Blank CNPs and GC-CNPs. A) Lymphocytes and B) Monocytes. Results are 
presented as mean ± SD from 4 donors. Statistical difference between the groups is *, P < 0.05; **, P 
< 0.01; ***, P < 0.001; ****, P < 0.0001. 
To determine the role of CNPs and PsaA on the allo-stimulatory activity of DCs, iDCs were pre-
treated with either PsaA, Blank CNPs and a mixture of PsaA and Blank CNPs and incubated 




controls, respectively. The expression of either CD25 or CD28 was used to determine the 
activation of both CD4+ and CD8+ allogeneic T lymphocytes.  
 
 
Figure 9: CNPs treated DCs induce the proliferation of T cells in mixed lymphocyte reaction. A). The 
number of CD4 & CD25 positives, B) and the CD8 & CD28 positives, were analysed. Results are 
presented as mean ± SD from 4 donors. Statistical difference between the groups is *, P < 0.05; **, 
P < 0.01; ***, P < 0.001; ****, P < 0.0001. 
As can be seen in Figure 9A, there is a significant increase in the CD25 positive CD4+ allogenic 
T cells when DCs were pre-treated with blank CNPs, compared to the CD25 expression when 
using DCs pre-treated with either LPS or the antigen PsaA (Figure 9A). Moreover, an increase 
in the level of CD4+ T cell activation is also seen when DCs used to stimulate T cells were pre-
treated with the mixture of blank CNPs and PsaA, although this activation did not reach 
statistical significance when compared to either LPS- or PsaA-treated DCs. Since DCs treated 
with PsaA alone did not promote the activation of CD4+ T cells, it is tempting to speculate 
that the CNP by itself is capable of activating iDCs. 
On the other hand, when the activation of CD8+ T lymphocytes was examined (Figure 9B) a 




blank CNPs or a mixture of blank CNPs and PsaA. The up regulation of CD28 is significantly 
higher in CD8+ T lymphocytes stimulated by those DCs compared to that seen in CD8+ T 
lymphocytes stimulated with DCs pre-treated with either LPS or PsaA alone (Figure 9B; blue). 
This sharp stimulation is also seen when the number of CD8+ T lymphocytes is examined, 
because a higher percentage of this lymphocytes is seen in cultures where DCs pre-treated 
with CNPs are used, compared to those seen in cultures using either LPS or PsaA-treated DCs 
(Figure 9B; red).  
4. Discussion 
 Dendritic cells are considered as important targets for the vaccine delivery due to their 
central role in inducing the immune responses. The particulate systems can deliver the 
antigen to DCs and act as excellent tools for achieving immune activation. In this study, we 
used chitosan nanoparticles of ~150 nm to deliver the antigen and activate the DCs. The 
literature suggests that the nanoparticles of this size are optimal for the uptake by DCs. The 
nanoparticles used in our studies, both blank and antigen loaded nanoparticles produced low 
levels of toxicity and were free from any endotoxin contamination. The cell viability was more 
than 80% at concentrations below 100 μg/mL. This was confirmed by both MTS and 7 AAD 
assays. Performing both MTS and 7 AAD assays helps to know the number of cells that are 
metabolically active vs non-apoptotic. Similar study was performed by Das et al., to determine 
the survival of DCs in the presence of chitosan nanoparticles. They reported that percentage 
DC survival when incubated with 100 μg/mL chitosan nanoparticles was ~40% viability, while 
in our case, viability was > 80% at the same concentration [22]. However, the chitosan 




possible that the higher zeta potential of the nanoparticles might have resulted in the 
increased toxicity.  
The results obtained from the confocal microscopy suggests the GC-CNPs are localized in the 
cytoplasm. This is essential for the processing and presentation of the antigens by the DCs [7]. 
In addition, we performed nanoparticle uptake studies by blocking different uptake pathways 
like phagocytosis, micropinocytosis and clathrin-mediated endocytosis to understand the 
major pathway by which nanoparticles are internalized. Although the results obtained from 
the uptake studies are not statistically significant when compared to the controls (DCs 
without inhibitor treatments) and do not indicate any single dominant mechanism by which 
the GC-CNPs were internalised, they suggest that phagocytosis could be the possible 
mechanism by which most of the GC-CNPs were captured by iDCs. The studies performed by 
He et al., have also shown that the nanoparticles in this size range can be phagocytosed and 
processed by the APCs [23]. In addition, studies performed by Roser et al., suggest that the 
positive charge of the nanoparticles might influence phagocytosis mediated uptake [24]. 
Overall, our studies suggest that the nanoparticles were internalised by different uptake 
pathways, in particular phagocytosis. 
In the body, the DCs are present in an immature state, which in the presence of foreign bodies 
undergo a maturation process. As a result of this activation process, the DCs undergo 
physiological changes, which include among others the upregulation of different 
costimulatory markers, including CD80, CD83 and CD86 [25]. The ability of antigens to induce 
the DC activation is pivotal in inducing the adaptive immunity. We found that the GC-CNPs 
were able to promote the expression of the costimulatory markers like CD80, CD83 and CD86.  




costimulatory markers like CD80, MHC II and CD86, while the antigen loaded CNPs enhanced 
the production of these costimulatory markers in comparison to the antigen alone or blank 
CNPs [26]. In contrary, Molina et al., demonstrated CD80 and CD83 upregulation with blank 
CNPs. They demonstrated the use of CNPs to differentiate human monocytes into immature 
dendritic cells [27]. The DCs treated with ovalbumin loaded PLGA nanoparticles have also 
shown the upregulation in these costimulatory markers [28,29]. In our studies, we have used 
the poloxamer 188 as a stabilizing agent during the nanoparticle preparation and Zupancic et 
al., reported that Pluronic® F127 (poloxamer 407) used as a stabilizing agent in the nano-
formulations has shown inhibitory effect on the stimulation of CD80 and CD86 markers [28]. 
Interestingly, Thiele et al., has reported that upregulation of CD83 is associated with the 
nanoparticle uptake by phagocytosis [30], which supports our results that shows the GC-CNPs 
uptake by phagocytosis. Most of the times endotoxin contamination in the formulation might 
result in the false positive results. However, it is important to note that the chitosan 
nanoparticles used in the study were free from endotoxin contamination. 
TNF-α is a cytokine secreted by the macrophages, monocytes and activated lymphocytes that 
act as an inflammatory marker in protecting against infectious pathogens. TNF-α produced by 
the macrophages can activate the T cells and can be the product of the activated T cells. As a 
product of effector CD4 and CD8 T cells, TNF-α is best known for its protective activity against 
several pathogens. The results obtained from our studies showed that the PBMCs primed with 
the GC-CNPs were able to induce the secretion of TNF-α. However, it is interesting to observe 
that the DCs treated with PsaA alone did not exhibit the TNF-α stimulation in the monocytes, 
while its counterpart GC resulted in significant TNF-α stimulation. The higher TNF-α 
stimulation in the GC may be the result of conjugating the Pn14TS to the PsaA. There are 




[31]. However, we could not find any literature that suggests that conjugating the 
polysaccharide antigen to carrier protein could enhance the TNF-α stimulation against the 
protein itself. In contrary, we found that both outer membrane protein complex (OMPC) and 
the OMPC conjugated to HiB polysaccharide have shown the TNF-α stimulation in the bone 
marrow derived DCs [32]. In any case, the possibility of the higher TNF-α stimulation in the 
GC treated cells, due to the traces of endotoxins in the GC cannot be ruled out. Studies from 
Silva et al., have shown that, for activation and differentiation of T cells the NPs uptake, 
processing and presentation by DCs is essential [11]. In addition, the stimulation of antigen 
specific CD4+ and CD8+ T lymphocytes is essential for efficient adaptive immunity. In our 
study, we have accessed the ability of the DCs primed with GC-CNPs and GC to activate the T 
cells. The DCs primed with the GC-CNPs induced the stimulation of both CD4+ and CD8+ T 
lymphocytes. In contrary, the DCs primed with the GC exhibited CD4+ T lymphocytes only. 
Zupancic et al., reported that DCs treated with ovalbumin loaded PLGA nanoparticles showed 
the activation of both CD4+ and CD8+ T lymphocytes [28]. The results obtained from our study 
clearly indicate the role of CNPs in the upregulation of CD25. The expression of the activation 
markers like CD25 is an indication of the activation of adaptive immunity. The presence of the 
CD28 signals demonstrates the ability of the CNPs to stimulate the naive T lymphocytes [33]. 
Our results suggest that the CNPs, in combination with the PsaA, can stimulate adaptive 
immune responses.  
Conclusions: 
The study shows that encapsulation of GC in the CNPs enhances the expression of co-
stimulatory markers when compared to the naked GC or blank CNPs. In addition, priming the 




T lymphocytes, in particular, the latter. Overall, the results suggest that chitosan 
nanoparticles can act as an efficient delivery system for glycoconjugate vaccines targeting the 
dendritic cells.  
5. Acknowledgements:  
I would like to acknowledge Cristina Calvino Sanpedro for initially teaching me how to work 





6. References:  
[1] R.M. Steinman, Dendritic cells: Understanding immunogenicity, Eur. J. Immunol. 37 (2007). 
doi:10.1002/eji.200737400. 
[2] J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.J. Liu, B. Pulendran, K. Palucka, J. 
Banchereau, F. Briere, F. Briere, C. Caux, C. Caux, J. Davoust, J. Davoust, S. Lebecque, S. 
Lebecque, Y.J. Liu, Y.J. Liu, B. Pulendran, B. Pulendran, K. Palucka, K. Palucka, Immunobiology 
of Dendritic Cells, Immunology. 18 (2000) 767–811. doi:10.1146/annurev.immunol.18.1.767. 
[3] K. Palucka, J. Banchereau, Linking innate and adaptive immunity, Nat. Med. 5 (1999) 868–
870. doi:10.1038/11303. 
[4] A. Vartak, S.J. Sucheck, Recent advances in subunit vaccine carriers, Vaccines. 4 (2016). 
doi:10.3390/vaccines4020012. 
[5] L.A. Brito, D.T. O’Hagan, Designing and building the next generation of improved vaccine 
adjuvants, J. Control. Release. (2014). doi:10.1016/j.jconrel.2014.06.027. 
[6] M.F. Bachmann, G.T. Jennings, Vaccine delivery: A matter of size, geometry, kinetics and 
molecular patterns, Nat. Rev. Immunol. 10 (2010) 787–796. doi:10.1038/nri2868. 
[7] C. Foged, B. Brodin, S. Frokjaer, A. Sundblad, Particle size and surface charge affect particle 
uptake by human dendritic cells in an in vitro model, Int. J. Pharm. 298 (2005) 315–322. 
doi:10.1016/J.IJPHARM.2005.03.035. 
[8] T.G. Dacoba, A. Olivera, D. Torres, J. Crecente-Campo, M.J. Alonso, Modulating the immune 
system through nanotechnology, Semin. Immunol. 34 (2017) 78–102. 
doi:10.1016/j.smim.2017.09.007. 
[9] M. Zaman, S. Chandrudu, I. Toth, Strategies for intranasal delivery of vaccines, Drug Deliv. 
Transl. Res. 3 (2013) 100–109. doi:10.1007/s13346-012-0085-z. 
[10] R.P. Gala, M. D’Souza, S.M. Zughaier, Evaluation of various adjuvant nanoparticulate 
formulations for meningococcal capsular polysaccharide-based vaccine, Vaccine. 34 (2016) 
3260–3267. doi:10.1016/J.VACCINE.2016.05.010. 
[11] A.L. Silva, R.A. Rosalia, E. Varypataki, S. Sibuea, F. Ossendorp, W. Jiskoot, Poly-(lactic-co-
glycolic-acid)-based particulate vaccines: Particle uptake by dendritic cells is a key parameter 
for immune activation, Vaccine. 33 (2015) 847–854. doi:10.1016/J.VACCINE.2014.12.059. 
[12] P. Calvo, C. Remuñan‐López, J.L. Vila‐Jato, M.J. Alonso, Chitosan and Chitosan/Ethylene 
Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and 
Vaccines, Pharm. Res. 14 (1997) 1431–1436. doi:10.1023/A:1012128907225. 
[13] N. Csaba, M. Köping-Höggård, M.J. Alonso, Ionically crosslinked chitosan/tripolyphosphate 
nanoparticles for oligonucleotide and plasmid DNA delivery, Int. J. Pharm. 382 (2009) 205–
214. doi:10.1016/J.IJPHARM.2009.07.028. 
[14] H.B.T. Moran, J.L. Turley, M. Andersson, E.C. Lavelle, Immunomodulatory properties of 
chitosan polymers, Biomaterials. 184 (2018) 1–9. doi:10.1016/J.BIOMATERIALS.2018.08.054. 
[15] D.A. Zaharoff, C.J. Rogers, K.W. Hance, J. Schlom, J.W. Greiner, Chitosan solution enhances 
both humoral and cell-mediated immune responses to subcutaneous vaccination, Vaccine. 25 
(2007) 2085–2094. doi:10.1016/J.VACCINE.2006.11.034. 




Physicochemical characterization of chitosan nanoparticles: electrokinetic and stability 
behavior, J. Colloid Interface Sci. 283 (2005) 344–351. doi:10.1016/J.JCIS.2004.08.186. 
[17] M. Prasanna, D. Soulard, E. Camberlein, N. Ruffier, A. Lambert, F. Trottein, N. Csaba, C. 
Grandjean, Semisynthetic glycoconjugate based on dual role protein/PsaA as a pneumococcal 
vaccine, Eur. J. Pharm. Sci. 129 (2019) 31–41. doi:10.1016/J.EJPS.2018.12.013. 
[18] Instructions Pierce LAL Chromogenic Endotoxin Quantitation Kit, Thermo Sci. (n.d.). 
https://assets.thermofisher.com/TFS-
Assets/LSG/manuals/MAN0016039_2162445_Pierce_LAL_Chromo_Endotox_Quant_UG.pdf 
(accessed June 17, 2019). 
[19] L.A. Brito, M. Singh, Acceptable Levels of Endotoxin in Vaccine Formulations During Preclinical 
Research, J Pharm Sci. 100 (2010) 34–37. doi:10.1002/jps.22267. 
[20] G.M.Z. Al-Ashmawy, Dendritic Cell Subsets, Maturation and Function, in: Dendritic Cells, 
InTech, 2018. doi:10.5772/intechopen.79926. 
[21] M. Breloer, B. Fleischer, CD83 regulates lymphocyte maturation, activation and homeostasis., 
Trends Immunol. 29 (2008) 186–94. doi:10.1016/j.it.2008.01.009. 
[22] I. Das, A. Padhi, S. Mukherjee, D.P. Dash, S. Kar, A. Sonawane, Biocompatible chitosan 
nanoparticles as an efficient delivery vehicle for Mycobacterium tuberculosis lipids to induce 
potent cytokines and antibody response through activation of γδ T cells in mice., 
Nanotechnology. 28 (2017) 165101. doi:10.1088/1361-6528/aa60fd. 
[23] C. He, Y. Hu, L. Yin, C. Tang, C. Yin, Effects of particle size and surface charge on cellular 
uptake and biodistribution of polymeric nanoparticles, Biomaterials. 31 (2010) 3657–3666. 
doi:10.1016/J.BIOMATERIALS.2010.01.065. 
[24] M. Roser, D. Fischer, T. Kissel, Surface-modified biodegradable albumin nano- and 
microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats, 
Eur. J. Pharm. Biopharm. 46 (1998) 255–263. doi:10.1016/S0939-6411(98)00038-1. 
[25] K. Palucka, J. Banchereau, I. Mellman, Designing vaccines based on biology of human 
dendritic cell subsets., Immunity. 33 (2010) 464–78. doi:10.1016/j.immuni.2010.10.007. 
[26] H.D. Han, Y. Byeon, J.H. Jang, H.N. Jeon, G.H. Kim, M.G. Kim, C.G. Pack, T.H. Kang, I.D. Jung, 
Y.T. Lim, Y.J. Lee, J.W. Lee, B.C. Shin, H.J. Ahn, A.K. Sood, Y.M. Park, In vivo stepwise 
immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer 
immunotherapy, Sci. Rep. 6 (2016). doi:10.1038/srep38348. 
[27] M.A. Franco-Molina, E.E. Coronado-Cerda, E. López-Pacheco, D.G. Zarate-Triviño, S.A. 
Galindo-Rodríguez, M. del Carmén Salazar-Rodríguez, Y. Ramos-Zayas, R. Tamez-Guerra, C. 
Rodríguez-Padilla, Chitosan Nanoparticles Plus KLH Adjuvant as an Alternative for Human 
Dendritic Cell Differentiation, Curr. Nanosci. >15 (2018) 532–540. 
doi:10.2174/1573413714666181008110627. 
[28] E. Zupančič, C. Curato, M. Paisana, C. Rodrigues, Z. Porat, A.S. Viana, C.A.M. Afonso, J. Pinto, 
R. Gaspar, J.N. Moreira, R. Satchi-Fainaro, S. Jung, H.F. Florindo, Rational design of 
nanoparticles towards targeting antigen-presenting cells and improved T cell priming, J. 
Control. Release. 258 (2017) 182–195. doi:10.1016/J.JCONREL.2017.05.014. 
[29] V.B. Joshi, S.M. Geary, A.K. Salem, Biodegradable Particles as Vaccine Delivery Systems: Size 
Matters, AAPS J. 15 (2013) 85–94. doi:10.1208/s12248-012-9418-6. 




Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does 
phagocytosis activity of dendritic cells measure up with macrophages?, J. Control. Release. 76 
(2001) 59–71. doi:10.1016/S0168-3659(01)00412-6. 
[31] R. Planès, M. Serrero, K. Leghmari, L. BenMohamed, E. Bahraoui, HIV-1 Envelope 
Glycoproteins Induce the Production of TNF-α and IL-10 in Human Monocytes by Activating 
Calcium Pathway, Sci. Rep. 8 (2018). doi:10.1038/s41598-018-35478-1. 
[32] E. Latz, J. Franko, D.T. Golenbock, J.R. Schreiber,  Haemophilus influenzae Type b-Outer 
Membrane Protein Complex Glycoconjugate Vaccine Induces Cytokine Production by 
Engaging Human Toll-Like Receptor 2 (TLR2) and Requires the Presence of TLR2 for Optimal 
Immunogenicity , J. Immunol. 172 (2004) 2431–2438. doi:10.4049/jimmunol.172.4.2431. 
[33] F.A. Harding, J.G. McArthur, J.A. Gross, D.H. Raulet, J.P. Allison, CD28-mediated signalling co-
stimulates murine T cells and prevents induction of anergy in T-cell clones, Nature. 356 




























Currently available vaccines for pneumonia, either PPSV or PCV are based on polysaccharide 
antigens from the S. pneumoniae and does not protect against all pneumococcal serotypes. 
As the capsular polysaccharide composition is different among serotypes, researchers should 
incorporate polysaccharide antigens from all pathogenic serotypes. Due to their high number, 
this is a complex and costly approach. Several reports describe the incorporation of 
pneumococcal proteins antigens for the immunization against all pneumococcal serotypes. In 
this line, we started working on semisynthetic glycoconjugate antigen based on the 
pneumococcal proteins that are commonly present in all the pneumococcal serotypes [1]. 
Glycoconjugate development: As a first objective, we focused on developing a semi-synthetic 
glycoconjugate antigen that can act as a better alternative to the marketed glycoconjugate 
vaccine. Accordingly, we developed a glycoconjugate that was composed of a pneumococcal 
protein antigen, Pneumococcal surface adhesin A (PsaA) and a synthetic tetrasaccharide 
(Pn14TS) that mimic the capsular polysaccharide of pneumococcal serotype 14 [2]. The PsaA 
has been selected because of its immunogenic nature and its previous use as carrier protein. 
PsaA used in the study was recombinantly produced in E. coli using the methods already 
mentioned in the literature [3]. To aid in the purification, the PsaA equipped of a poly-
histidine tag was produced, although its production in absence of tag had been reported in 
the literature. We however inserted a sequence specific for the TEV protease between the 
histidine tag and the PsaA sequence. Later the poly-histidine tag was cleaved, and the 
resulting protein purified using affinity chromatography. The removal of the poly-histidine tag 
was confirmed by western blot analysis using anti-histidine tag antibodies. The whole 




by thiol-maleimide coupling gave rise to a glycoconjugate (GC) that retained its secondary 
structure on long term storage in a lyophilized form. The prepared GC was successful in 
maintaining its functionality even after lyophilization, while other carrier proteins like 
diphtheria toxoid and tetanus toxoid or their combination products are freeze sensitive and 
should always be maintained between 2-8 °C [4–6]. The results from the circular dichroism 
give the indication that the conformational B-epitopes are conserved during the conjugation 
process. The immunization efficiency of the glycoconjugate (GC/ Pn14TS-mPsaA) adjuvanted 
with α-GalCer was compared with mPsaA and model conjugate (Pn14TS-BSA). The studies 
displayed that mPsaA (S.C.) generated higher anti mPsaA antibodies compared to mPsaA-
Pn14TS/ GC (S.C.). The reason for this result might be due to the masking of the B epitopes of 
mPsaA after conjugating with the Pn14TS or a competition between the protein and 
polysaccharide B epitopes or a different processing for the protein and the polysaccharide 
given the route of administration. The overall observations from the study suggest that the 
synthesized glycoconjugate was effective in generating IgG antibodies against both its protein 
(mPsaA) and tetrasaccharide counterparts.  
Formulation development: Despite the effectiveness of the synthesized GC when 
administered (S.C.) in the free-from, it is well known that the use of nanocarriers could 
enhance the immune response generated against the GC. This brings to the second objective 
of this thesis to design the suitable nanocarriers for the delivery of glycoconjugate antigens. 
Generally, pneumococcal infections are caused by nasopharyngeal colonization and it is 
reported that mucosal immunization can generate effective systemic and mucosal immune 
responses. Bearing this in mind, we have evaluated chitosan nanoparticles (CNPs) as carriers 




The use of such CNPs offers various benefits due to their biocompatible, biodegradable and 
mucoadhesive properties. The developed CNPs had a size of ~150 nm and positive zeta 
potential. Every milligram of these nanoparticles was able to encapsulate approximately 35 
μg of a glycoconjugate, while the encapsulation of PsaA alone was three times lower. Besides, 
the GC-CNPs were easily freeze-dried and could be re-dispersed in water without changes in 
their size and zeta potential. Further studies on this are required to see if these nanovaccines 
could be stored for longer-term without refrigeration, which would help to eliminate the 
requirement of the cold chain when transporting to remote locations in countries with limited 
logistic capacity and reducing the overall cost of vaccination. While the nasal delivery of 
antigens using the mucoadhesive nanoparticles provide significant advantage over 
unencapsulated antigen, this advantage is limited by the particle aggregation and the mucus 
adhesion. However, in our studies the nanoparticles displayed slight increase in the particle 
size but did not show any signs of aggregation when incubated with simulated nasal mucosal 
fluid. 
Release kinetics of the antigen plays important role in presenting the antigens to the immune 
system. If the antigen release from the nanoparticles is too fast antigens will be presented to 
the APCs in the soluble form and if the release is too slow there will be not enough antigen 
for their presentation to APCs. In our study, obtained CNPs were able to release <30% of GC 
over 24h, of which the majority was released within the first hours. Two mechanisms can 
explain the initial burst release of antigen from the nanoparticles: either by the release of 
antigen adsorbed on the nanoparticle surface or the escape of the antigen from the pores of 
the nanoparticles. This indicates that the initial burst release might correspond to the drug 
adsorbed on the surface of the CNPs or the non-associated GC. There are previously reported 




from the formulations serves as an advantage for the depot formulations. This sustained 
release of the antigens increases the antigen exposure to the DCs and prolong the antigen 
presentation.  
In vitro studies: We furthermore evaluated the interaction of nanoparticles with antigen-
presenting cells (APCs) in generating an effective immune response. To understand, if the GC-
CNPs were effective in interacting and activating immune cells, a series of studies with MoDCs 
were performed. The GC-CNPs showed concentration-dependent toxicity when incubated 
with these cells. At concentrations below 100 μg/mL, the nanoparticles were highly 
biocompatible, and they displayed > 80% of survival as shown with both MTT (metabolic 
activity) and 7-AAD assay (apoptosis). The percentage of metabolically active cells at 100 
μg/mL are higher than in reported literature were the same concentrations displayed lower 
than 50% survival [9]. In our studies, both CNPs and GC-CNPs treatments displayed similar 
DCs survival. The nanoparticle uptake is pivotal in activation of the DCs that play a substantial 
role in inducing the adaptive immunity. The internalization studies were performed in the 
presence of inhibitors that block different uptake pathways (CLO, Cit-D and DHA) and the 
results did not indicate any dominant mechanism of uptake. Even though the results were not 
statistically significant, they suggested phagocytosis as a possible uptake mechanism. These 
results are supported by the literature that shows the chitosan nanoparticles with ~150 nm 
size range and having zeta potential > 15 mV are internalized by phagocytosis [10]. Confocal 
microscopy and flow cytometry have confirmed the internalization of the GC-CNPs by the DCs 
in less than 2h. The GC-CNPs were able to upregulate the production of costimulatory markers 
(CD80, CD83 and CD86) in the DCs, which indicates their activation. The GC loaded CNPs were 
successful in the activation of DCs. However, the upregulation of these co-stimulatory 




with phagocytosis, which strengthens our hypothesis of phagocytosis as a dominant 
mechanism of GC-CNPs uptake [13]. Besides, in further experiments, the DCs pulsed with GC-
CNPs were able to stimulate T cells and induce the production of TNF-α. The TNF-α is well 
known as a product of effector CD4 and CD8 T cells and for its protective activity against 
several pathogens. In our study, we also observed that the DCs pre-treated with a mixture of 
blank CNPs and PsaA produced higher CD25 activation in CD4 allogenic T cells when compared 
with either LPS or PsaA alone.  However, this activation was even higher with the DCs pre-
treated with just blank CNPs. Similarly, the mixture of PsaA and blank CNPs significantly up 
regulated the CD28 in CD8 allogenic T cells and increased the proliferation of CD8 T cells, in 
comparison to the DCs treated with either LPS or PsaA. This leads to the belief that the CNPs 
by itself can activate the DCs. Also, researchers have used CNPs to differentiate human 
monocytes into immature dendritic cells [11]. Overall, the results suggest that the 
combination of CNPs and mPsaA, can stimulate adaptive immune responses.  
In vivo studies: In this study, two sets of immunizations were performed in mice with the 
following aims. 1) To evaluate the role of nanoencapsulation in enhancing the 
immunogenicity against the GCs; 2) To understand if GC-CNPs can generate higher immune 
response via mucosal administration as compared to subcutaneous immunization.  
The GC-CNPs immunized via S.C. route produced 10 folds and 100 folds anti-CP and anti PsaA 
IgG response, respectively, when compared with the mice treated S.C. with GC alone. 
Moreover, the group immunized with GC-CNPs displayed the generation of IgG1 subclass 
predominantly and IgG2b as a second prevalent subtype against the capsular polysaccharides. 
While only IgG1 subclass of antibodies was produced against PsaA.  Studies from Majela et 




and slightly lower IgG2b antibodies [14]. Also, the group immunized with GC-CNPs displayed 
higher protection against the systemic pneumococcal challenge, when compared to 
untreated and groups treated with GC alone. It is important to note that, all the formulations 
were co-administered along with the adjuvant α-GalCer that can potentially activate NKT cells 
[15].  
The second series of immunizations were performed to compare the immune response 
generated by GC-CNPs/ GC administered S.C. and I.N. Interestingly, the GC alone I.N. 
administered produced equivalent anti-PsaA IgG response to that of GC-CNPs S.C. 
administered. The results suggest that GCs via I.N. were effective in generating the higher 
immune response when compared to the GC via S.C.  However, it is surprising that GC-CNPs 
administered via I.N. produced 100 folds lower anti-PsaA IgG when compared to the GC alone 
administered via I.N. or GC-CNPs administered via S.C. The generated anti PsaA IgG response 
is in the order of GC-CNPs (S.C.) = GC (I.N) > GC+ CNPs (I.N.) > GC-CNPs (I.N.). This shows that 
the presence of CNPs via I.N. is reducing the anti PsaA IgG response generated against the 
GCs. Additionally, both GC via I.N. and GC-CNPs via S.C. generated anti CP IgG response, while 
the groups immunized with Prevenar 13 or GC-CNPs (I.N.) failed to do so.  This contradicts our 
hypothesis that the CNPs as a carrier for I.N. delivery of GC would enhance the immune 
response against the GCs. The possible reason for this phenomenon might be the mucosal 
clearance of the CNPs. This leads to the conclusion that in our study CNPs were not effective 
via I.N. An alternative explanation for the higher immunogenicity of GC over GC-CNP when 
I.N. administered could refer to intrinsic adhesive properties of PsaA, responsible for 
nasopharynx epithelial cell colonization. However, the further optimization of the formulation 




In summary, this thesis describes the design of nanoparticles encapsulating the semisynthetic 
glycoconjugate as a vaccine against pneumococcal infections. Even though, the CNPs were 
not effective in generating the immune response via I.N. route, they showed promising results 
via S.C. immunization and offer an opportunity for the future development of improved 
pneumococcal vaccines.  
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In this thesis, we developed a semisynthetic glycoconjugate antigen against pneumococcal 
infections. We also evaluated chitosan nanoparticles as carriers for the delivery of the 
synthesized glycoconjugate antigen. The results obtained from the studies led to the following 
conclusions.  
 
1) The PsaA was successfully produced in E. coli using recombinant DNA technology. A 
semisynthetic glycoconjugate vaccine solely composed of pneumococcal antigens, i.e., 
of a synthetic tetrasaccharide mimicking the capsule of serotype 14 coupled to PsaA 
was synthesized. The conjugate was able to induce the IgGs antibodies against both 
synthetic oligosaccharide and protein moieties in the immunized mice. 
 
2) Chitosan nanoparticles produced by ionic gelation method had an average size of 150 
nm, a narrow size distribution, positive surface charge and over 70% association 
efficiency of the glycoconjugate. Chitosan nanoparticles exhibited good colloidal 
stability upon incubation in simulated nasal fluid containing mucin. 
 
 
3) The studies with monocyte derived dendritic cells indicated that chitosan 
nanoparticles were compatible with DCs. The interaction of CNPs with the dendritic 
cells was time dependent and were internalized by multiple uptake pathways. In 
addition, priming the DCs with CNPs significantly enhanced the proliferation and 
stimulation of both CD4 and CD8 T lymphocytes, indicating that the CNPs can generate 
both cellular and humoral immune responses. 
 
4) The GC-CNPs produced specific anti PsaA and anti CP IgG responses that were 100 
folds and 10 folds higher than GC when administered via S.C. while the same GC-CNPs 
did not show similar effects via I.N administration.  
Overall, our findings suggest that chitosan nanoparticles as carriers could enhance the 
systemic immune response against the glycoconjugates. Future work will mainly focus on 

















Super-resolution imaging of nanoparticle uptake by dendritic cells 
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Although nanoparticles are widely investigated for the intracellular delivery of the vaccines 
and the therapeutic molecules, their clinical transition has not progressed as rapidly as 
preclinical results. Also, most of these investigated nanomedicines fail during the clinical trials 
[1]. One of the reasons for this is lack of rational design of the nanoparticles and lack of 
understanding on their interaction with cells [2]. Several experimental challenges need to be 
addressed to move the nanoparticles from bench to the bedside.  Primarily, it is essential to 
have an adequate understanding of the interaction of the nanoparticles with the cells. 
The study of the nanoparticle cell interactions is one of the biggest challenges with the 
nanomedicines that are currently investigated. The amount of the nanoparticles that are 
internalised or adsorbed on the surface of the cells determine the efficiency of the 
nanomedicines. However, the nanoparticle cell interactions are under-investigated due to the 
lack of user-friendly methods. Generally, the interaction of the nanoparticles with the cellular 
structures are visualized using either electron microscopy (EM) or confocal laser scanning 
microscopy (CLSM). In addition, the quantitative analysis to study the interaction of the 
nanoparticles with the cells can be performed using mass spectrometric techniques like ICP-
MS.  However, this can be only used for metallic nanoparticles and requires pre-treatment 
using chemical etching methods [3]. Electron microscopy offers excellent resolution and 
enables in visualizing the nanoparticles and the subcellular structures in detail, but it is limited 
to the fixed cells and involves complex sample preparation. On the other hand, CLSM allows 
the 3D multicolour imaging of the live cells but is restricted due to the limited resolution of 
250 nm. This resolution does not allow the visualization of individual nanoparticles. Super-




techniques and act as a bridge between confocal and electron microscopy. Super-resolution 
microscopy offers the great advantage of multicolour imaging from optical microscopy and 
the resolution of electron microscopy [4]. Super-resolution techniques enable the analysis at 
single-cell level and allow the intracellular localization of the nanoparticles. A wide variety of 
super-resolution techniques like stochastic optical reconstruction microscopy (STORM) [5], 
stimulated emission depletion (STED) [6], structured illumination microscopy (SIM) [7] and 
photoactivation localization microscopy (PALM) [8] is used for the identification of the cellular 
structures in the biological sciences. STORM imaging provides the accurate localization of the 
nanoparticles based on the stochastically blinking fluorophores and can offer the resolution 
of 20 nm [5]. This higher resolution of the STORM imaging enables visualization at the 
molecular level.  
Overall, the main objective of this work has been using STORM based imaging technique for 
intracellular localization of the nanoparticles in the dendritic cells. 
2. Methods 
2.1. Human dendritic cell and DC 2.4 cell line preparation 
The iDCs were obtained from buffy coats according to the method mentioned in Chapter 3 
(2.6 section). DC2.4 cells were cultured in RPMI 1640 medium which was supplemented 
with 10% fetal bovine serum and penicillin/streptomycin antibiotics.  
2.2. Internalization of Cy5-GC-CNPs in MoDCs  
To track the nanoparticles after internalization by dendritic cells, the nanoparticles and the 
dendritic cells were labelled with two different dyes. The nanoparticles were labelled with 




cyanine-based dyes for STORM imaging. DCs (5x105 per well) were plated into a 24 well plate 
with 0.5 mL of R10 media. Following that cells were incubated with the Cy5 labelled GC-CNPs 
(50 µg/ million cells) for different time periods (0.5, 1, 2, 4 and 24h). After the incubation time, 
the DCs were washed with PBS. Afterwards, the cells were fixed with 4 % PFA for 15 min. To 
understand the position of the nanoparticles inside cells, the plasma membrane of the MoDCs 
was stained with Alexa 488-labelled WGA at 0.2 μg/mL  (Wheat Germ Agglutinin, a lectin 
known to bind to N-acetyl-D-glucosamine and sialic acid on the cell membrane) and the 
nucleus was stained using DAPI. The staining was performed in Lab-Tek 8 well plates for 10 
min, and the DCs were washed twice with PBS after incubation. The cells were suspended in 
20-30 µl of STORM buffer (160 µL of PBS + 20 µL of 50% glucose + 20 µL of β-mercaptoethanol 
+ 2 µL of Glucose oxidase) just before imaging.  
2.3. Internalization of GC-CNPs in DC2.4 cell lines after different time periods of 
incubation 
The DC2.4 cells (25,000 per well) were seeded on Lab-Tek plates with 0.2 mL of R10 media. 
Following that cells were incubated with the Cy5 labelled GC-CNPs (0.5 µg of NPs) for different 
time periods (0.5, 1, 2, 4 and 24h). After the incubation time, the DCs were washed with PBS. 
Afterwards, the cells were fixed with 4% PFA for 15 min. For imaging, the cells were stained 
using DAPI and wheat germ agglutinin (WGA, at 0.2 µg/mL) for 10 min, and the DCs were 
washed twice with PBS after incubation. The cells were suspended in 20-30 µl of STORM 
buffer. 
2.4. The fate of GC-CNPs in DC2.4 cell lines after incubating for 1h  
The DC2.4 cells (25,000 per well) were plated into a Lab-Tek plate with 0.2 mL of R10 media. 




incubated at 37 °C for 1h. After the incubation time, the DCs were washed with PBS and then 
replaced with R10 medium and incubated at 37 °C. At different time points (1, 4 and 24h), the 
cells were fixed with 4% PFA for 15 min. For imaging, the cells were stained using DAPI and 
wheat germ agglutinin (WGA, at 0.2 µg/mL). The cells were suspended in Lab-Tek using 20-30 
µl of STORM buffer for imaging. 
2.5. Endosomal uptake of GC-CNPs in DC2.4 cell lines 
The DC2.4 cells (25,000 per well) were plated into a Lab-Tek plate with 0.2 mL of R10 media. 
Following that cells were incubated with the Cy5 labelled GC-CNPs (2.5 µg of NPs) for 1 h. 
After the incubation time, the DCs were washed with PBS and then replaced with R10 medium 
and incubated. At 4 h, the cells were fixed with 4% PFA for 15 min. For imaging, the cells were 
stained using DAPI and anti-lamp2 antibody (Lamp2-488, at 0.1 µg/mL). The cells were 
suspended in Lab-Tek using 20-30 µl of STORM buffer for imaging. 
3. Results and Discussion 
3.1. Internalization of Cy5-GC-CNPs in MoDCs 
The images in Figure 1 shows the internalization of the GC-CNPs increased with time. Each 
red dot in Figure 1 represents a nanoparticle that is present in the plane (0.5 µm thick) of the 
MoDC. Even though there is a gradual increase in the NPs uptake with the time until 4h, it 
was not maximum. However, a significantly higher NPs inside the cells were observed after 
24h (Figure 2) and the NPs were inside the cells. The uptake of the chitosan nanoparticles was 
strictly temperature dependent. The nanoparticles were rapidly internalized at 37 °C. While 
the DCs incubated at 4 °C displayed only a small number of NPs in the cells and were mostly 
present on the surface of the DCs. These results are in agreement with our previously 




chitosan nanoparticles by the DCs might be attributed to the cationic property of the chitosan. 
Similarly, the studies performed by veronica et al., have shown that PLGA nanoparticles 
coated with chitosan had higher internalization compared to the uncoated nanoparticles after 
4h of incubation [9]. 
 
Figure 1- Internalization of Cy5-GC-CNPs (50 µg/ million cells) by MoDCs at different time 
points (0.5, 1, 2 and 4h). The cell membrane is stained with wheat germ agglutinin-488 (WGA-
488; green colour), the nucleus stained with DAPI (blue colour) and the nanoparticles are 





Figure 2- Internalization of the Cy5-GC-CNPs (50 µg/ million cells) by MoDCs at 24h (at 37° C 
and 4° C). The cell membrane is stained with wheat germ agglutinin-488 (WGA-488; green 
colour), the nucleus stained with DAPI (blue colour) and the nanoparticles are labelled with 
Cy5 (red colour). 
3.2. Time-dependent internalization of GC-CNPs in DC2.4 cell lines  
Figure 3 clearly displays that NPs internalization increases with time. With the increase in 
time, the NPs concentration increased both on the surface and the centre of the cells, which 
indicates the NPs were continuously internalized throughout the incubation time and not just 
during the initial hours of incubation. The images from the mid-section of the cells show the 
NPs concentration in the cytoplasm increases with the time, and the NPs were present around 
the nucleus and were not observed inside. The results obtained from these studies are 





Figure 3- Internalization of the Cy5-GC-CNPs by DC2.4 cell lines at different time points (0.5, 
1, 2, 4 and 24h), when incubated with NPs 0.5 µg/ 25,000 cells. The cell membrane is stained 
with wheat germ agglutinin-488 (WGA-488; green colour), the nucleus stained with DAPI 
(blue colour) and the nanoparticles are labelled with Cy5 (red colour). 
In addition, the study was performed to analyse the fate of nanoparticles that are internalized 
during 1 h of incubation with DC2.4 cells. To understand the localization of nanoparticles in 
DC2.4 cells, the imaging was done in 2 planes of 0.5 μm thickness, at the middle and the top 
of the cells. Figure 4 displays the change in NPs concentration with time, inside the cells. At 
the 1h of incubation, the NPs were mainly observed on the surface and very few were present 




on the surface. This shows the nanoparticles that were present on the cell surface were 
internalized completely. However, at 24h the NPs concentration inside the cells have 
considerably decreased, this suggests that the internalized NPs were processed after 24h. In 
this study, higher NPs concentration (2.5 μg instead of 0.5 μg; at 4h and 24h) was used to 
make sure that some fluorescence is seen after 24h (as we are only incubating the DCs with 
NPs for 1h). Overall, the study shows that the nanoparticles internalized by the cells were 







Figure 4: Internalization of Cy5-GC-CNPs by DC2.4 cell lines at different time points (1, 4 and 
24h), when pulsed (incubated for 1h with NPs and then washed) with two different 
concentrations NPs (0.5 and 2.5 µg/ 25,000 cells). The cell membrane is stained with wheat 
germ agglutinin-488 (WGA-488; green colour), the nucleus stained with DAPI (blue colour) 
and the nanoparticles are labelled with Cy5 (red colour). 
3.3. Endosomal uptake of GC-CNPs in DC2.4 cell lines at 4h. 
To study the endosomal uptake of the nanoparticles, both the nanoparticles and the 
endosomes were labelled with different dyes. The nanoparticles were labelled with Cy5 (red), 




see the internalization of nanoparticles in the DC2.4 cell line. However, it shows no endosomal 
uptake of the nanoparticles, as there is no co-localization of green and red fluorescence. In 
contrary, the literature shows that the nanoparticles coated with the chitosan were delivered 
to early or late endosomes, while the uncoated ones ended in the sub-cellular compartments 
of the DCs [9].  
 
Figure 5- Study to determine the endosomal uptake of the Cy5-GC-CNPs by DC2.4 cell lines 
after 4h incubation at 37 °C. When pulsed (incubated for 1h with NPs and then washed) with 
GC-CNPs (2.5 µg/ 25,000 cells). The endosomes were stained with anti-Lamp2-488 (Lamp2-
488; green colour), the nucleus stained with DAPI (blue colour) and the nanoparticles are 
labelled with Cy5 (red colour).  
Also, the literature suggests that the chitosan derivatives are mainly internalized by the 
mannose receptor mediated endocytosis [10]. However, the results obtained for our study is 
supported by the theory of endosomal escape of the chitosan nanoparticles due to proton 
sponge effect. However, these studies were performed only once without any replicates and 




processing of these particles. In addition, similar studies in the presence of different inhibitors 
should be performed to further confirm the pathways involved in the internalization of GC-
CNPs. 
Conclusions 
Overall, the STORM analysis was successfully used to investigate the interaction of the 
nanoparticles with dendritic cells. The STORM images clearly show that the nanoparticles 
were internalized by the dendritic cells, and the uptake was increasing with the time. The 
nanoparticles internalized during 1h were being processed and a significant reduction in the 
nanoparticle concentration inside the cells was observed at 24h.  
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AAD, Aminoactinomycin D 
APCs, antigen-presenting cells 
APC, Allophycocyanin 
BSA, bovine serum albumin 
CD, Cluster of Differentiation (CD4, CD8, CD25, CD28, CD80, CD83 and CD86) 
CD, Circular dichroism 
CLO, Chlorpromazine 
CLSM, Confocal laser scanning microscopy 
Cit-D, Cytochalasin-D 
CNPs, Chitosan nanoparticles 
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DCs, Dendritic cells 
DHA, 5-(N, N-Dimethyl)amiloride hydrochloride 
DMSO, Dimethyl sulfoxide 
DT, Diphtheria toxoid 
ELISA, Enzyme-linked immunosorbent assay 
EM, Electron microscopy 
EU, Endotoxin units 
FACS, Fluorescence activated cell sorting 
FBS, Fetal bovine serum 
FCS, Fetal calf serum 
FEG-SEM, Field emission gun Scanning electron microscopy 
FITC, Fluorescein Isothiocyanate 





GC-CNPs, Glycoconjugate encapsulated chitosan nanoparticles 
GM-CSF, Granulocyte-macrophage colony stimulating factor 
HLA, Human leukocyte antigen 
iDCs, Immature dendritic cells 
IgA, Immunoglobulin A 
IgG, Immunoglobulin G  
IgM, Immunoglobulin M 
IFN-γ, Interferon 
IL, Interleukin 
LAL, Limulus amebocyte lysate 
LC 50, Lethal concentration 50 
LPS, lipopolysaccharide 
mDCs, Mature dendritic cells 
MFI, Mean fluorescence intensity 
MHCII, Major histocompatibility class II 
MoDCs, Monocyte derived dendritic cells 
MPLA, Monophosphoryl lipid A 
MS, Mass spectrometry 




PALM, Photoactivation localization microscopy 
PBLs, Peripheral blood lymphocytes 
PBMCs, Peripheral blood mononuclear cells 




PGA, Poly glutamic acid 




PLGA, Poly (lactide-co-glycolic acid) 
pDNA, Plasmid DNA 
Pn14TS, Pneumococcal serotype 14 tetrasaccharide 
PPA, Pneumococcal protein antigens 
PPSV, Pneumococcal polysaccharide vaccine 
PsaA, Pneumococcal surface adhesin A 
PSG, Penicillin-Streptomycin-Glutamine 
RPMI, Roswell Park Memorial Institute medium 
R2, RPMI-1640 medium supplemented with FBS (2%) and PSG (1x)  
R10, RPMI-1640 medium supplemented with FBS (10%) and PSG (1x) 
RT, Room temperature 
SD, Standard deviation 
SEB, Staphylococcal enterotoxin B 
SIM, Structured illumination microscopy 
Spn, Streptococcus pneumoniae 
STED, Stimulation emission depletion 
STORM, Stochastic optical reconstruction microscopy 
TNF, Tumor necrosis factor 
TPP, Tripolyphosphate 
TS, Tetrasaccharide 
TT, Tetanus toxoid 













I. Animal Studies: 
1. Specific pathogen-free C57BL/6 mice (6 weeks-old, female) were purchased from 
Janvier (Le Genest-St-Isle, France).  
2. All the animal experiments were performed at Lille Pasteur institute according to the 




II. Primary cell line, Human monocyte derived dendritic cells 
1. Buffy-coats used to collect the dendritic cells were obtained from anonymous donors 
and were kindly donated by the Agency for the Donation of Organs and Blood (ADOS, 
Santiago de Compostela) with the approval of the Director of the Agency and the 
Clinical Research Ethics Committee of Galicia (2014/543). 
2. For heparinized blood from the healthy volunteers, an informed consent was 
obtained from the volunteers in accordance with the guidelines of the Ethical 
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